var title_f5_13_5328="Anatomy of ADH release";
var content_f5_13_5328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central pathways of ADH release",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram of the mammalian hypothalamus and pituitary gland showing pathways for the secretion of antidiuretic hormone (ADH). The hormone is formed in the supraoptic and paraventricular nuclei, transported in granules along their axons, and then secreted at three sites: the posterior pituitary gland, the portal capillaries of the median eminence, and the cerebrospinal fluid (CSF) of the third ventricle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Zimmerman, EA, Robinson, AG, Kidney Int 1976; 10:12. Reprinted by permission from Kidney International.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5328=[""].join("\n");
var outline_f5_13_5328=null;
var title_f5_13_5329="Pseudohyphae";
var content_f5_13_5329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida pseudohyphae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pseudohyphae (as opposed to true hyphae) are formed when buds elongate with differential rates of wall synthesis at various points along the cell wall. Elongation then stops, and the cell produces a new apical bud which elongates. This repeated process of budding and elongation can result in extensive filamentation. Side branches initiate as buds and develop in the same manner. In most cases, a constriction remains and can be seen at the origin of each bud.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wiley Schell, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5329=[""].join("\n");
var outline_f5_13_5329=null;
var title_f5_13_5330="Opisthorchiasis egg";
var content_f5_13_5330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Opisthorchiasis egg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 309px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE1AiYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6N8VeIk8PR6d/xLr7Ubi/uvskFvZ+VvZ/KklJJkdFACxN39Ky4vGGpSsyx+B/EhK9R52nj/26qTxt/wAh/wAC/wDYZk/9N95WJDHf3+s+Mr248V6rpFjpd4sIjtIbQxpELO3mZiZIHYndI569McVHM+bl8iklbU2z4q1Yf8yL4l/7/wCn/wDyVS/8JTq3/QieJP8Av/p3/wAlVxXwu16L4k6ZeXmg+N/GEItJhDLDd2umJIMqCrYW3YbTzjnPyniu9+HmoXWreAfDWpahJ5t5eaZbXE8m0LvkeJWY4AAGSTwBihtoRX/4SnVv+hE8Sf8Af/Tv/kqj/hKtWH/Mi+JP+/8Ap3/yVXTSHANVHnxz6dqcW2FjE/4SrVv+hF8S/wDf/T//AJKpf+Ep1f8A6ETxJ/3/ANO/+Sq34H3KGY9egqwCe4ou0DVjmP8AhKdX/wChE8Sf9/8ATv8A5Ko/4SnV/wDoRPEn/f8A07/5KrqaQmpc2gsct/wlOrf9CJ4k/wC/+nf/ACVTG8XamvXwN4k/7/6f/wDJVdM79aqXDZBOah1Wi4077mCfGWojr4H8Sf8Af7T/AP5KqGTx3dx/f8FeJB/21sP/AJKq/czlOprB1C9wvJ/Oo9vI29hEmk+JTR53+D/Egx/t2P8A8k1Vk+LMEbbX8J+JAfTdZf8AyTXL6lf7nOMYHNZETG4l8wnpT9tIPYxPRo/ieJRlPCHiQj/fsf8A5JqaP4iTSDKeDfEh/wC2lh/8k1yFm+1cZrStbvYPepeIkP2ETePxDnHXwZ4k/wC/lh/8k0f8LDm/6E3xJ/38sP8A5JrJM/ybiuAeBUb3G0f1pfWJB7CJuD4gXBGR4M8Sf9/LD/5Kpr/ESZFy3g3xIB/10sP/AJJrnLnVxbplmUDsCeSa5rWPEU9zlIm8tcEHtmj6xIPq8e53Evxct4mKv4U8RgjsGsj/AO3NQj4y2JYqPC3iTI65+xj/ANuK8omvGQEqxOP50hvY5UYuArEAEY6/SpeJn2KWGj3PWv8AhcVnuA/4RXxLk/8AXn/8kVC/xs02NmVvDPiPK9cfYz/K4ryBbnHIJIUnjNU5pW3sccGrVeTJdCJ7J/wvbR/+hb8Sf982n/yRS/8AC9dI/wChb8Sf982n/wAkV4kd2c8YFOT5selHt5C9hE9q/wCF66R/0LfiT/vm0/8AkinH456SOvhrxJ/3zaf/ACRXiuwhs044xnqKX1iQ/YRPZv8Aheuj/wDQt+JP++bT/wCSKlj+N2mSfc8M+JD+Fp/8kV4cWw1bOlKZDkEY96r28ifYxPY4/i9bSDKeFPEpH1sv/kirEfxREmNng/xMc9ObIf8AtzXA6Wu7GOK6vTrXgYX3pe3kUqETsLPxpZXHgO+8VtaX0FnZRXcs1vIsZnX7O0iyLhXKE5ibHzYPHIqnbeN765AMHgnxI4P/AE108f8At1XLRrt/Z58aL6ReIB/5MXdaBivrvxfpGj6frV9pNvLp95dyvZxwM7vHJaqgJmjcAYmfoB29K3cnol1OdRWrfQ6IeKdXPTwJ4k/7/wCnf/JVL/wlGr/9CJ4k/wC/+nf/ACVXmfhvxymuXeixReJfH9rb6xcy2lldXFppHlySx/fUhImdfqVAr0vwNNqH2vxRYalqdzqf9namtvBPcxxJJ5bWltLg+UiKcNK/O3OKv1IGJ4u1R5XjHgTxPuTGcyWAHPoftWD+FPPinVh/zIniT/v/AKd/8lV1NFK7A5YeKtWP/Mi+JP8Av/p//wAlVGPF+pGUxjwP4k3jnHn6f/8AJVdBqt7HYQCaaeCGMMAWlbAx7e9cNfXx1fUYVtb+3ju7e480GNv+WQPtwcisp1nF2NoUuZXNmfxfqVvA803gfxIkUalmYz6fwB1P/H1VXSPH1zrFr9o03wZ4inh3FdyzaeOR7G6zXSacZp7Bo79VkD5GccOp9RXIeEfDWpWN5cxzStb2ccpaFI2+UjPQegxQq19hezSumzZ/4SnVv+hF8Sf9/wDTv/kqj/hKdW/6ETxJ/wB/9O/+SqseGodYivL7+1HdoGb91udW5yclcdFI28HnOa25Sy8jkVbnZXI5dbHNHxZqo6+BfEn/AH/0/wD+SqafF+pj/mRvEn/f/T//AJKrdeX5hzg03zAqs+BkHkVn7ZmipGIfF+pg/wDIjeJeP+m2n/8AyVSHxlqIGT4H8S4/67af/wDJVbBlyivzsJxnFShgU4H40vbSH7JHP/8ACbX/AP0JHiX/AL+6f/8AJVA8bX//AEJHiT/v7p//AMlVtGPPsKaY8Zx0pe3kP2UTFPji9GM+CfEvPT97Yf8AyVTv+E2vycf8IR4l/wC/th/8lVqiEidHKlsdvWljt7xI7lp5o5jI26MKuNq9xVe1kJ04oy/+Ey1H/oR/Ev8A3+0//wCSqf8A8Jdqf/QjeJP+/wBp/wD8lVtxIHUEdPerCxgdqftZEuEUc2fF+pj/AJkbxL/3+0//AOSqUeLtT/6EbxL/AN/tP/8AkqulMXFG0haHVkLlicwfGOpDr4H8S/8Af7T/AP5Kph8a346+CPEv/f3T/wD5KrfdTuNZuo5VNyHDLWcq8kaxoxZiy/El4pCkng7xIGHUb7H/AOSaqv8AFmBGKt4T8SAj/asv/kmsrXPMN+GbnLAEgcYrC1NSGXKrtZsdPep+syL+rxOu/wCFvWp/5lTxL/5J/wDyRUi/FiF03r4S8SlfXNl/8k1xKGOCRSw2oxwAeTVxGijDLGDtYZKj1oeJl2F9Xj3OqPxZhBI/4RLxLke9l/8AJNOf4rRIMt4S8SAf71l/8k1y6uhO5T14Jx045qjcsUYBGJO7gHuKFiJvoHsIrqdifi9bDr4U8Sj8bL/5Io/4W9bf9Cp4k/Oy/wDkiuNMZyMqDu5+lE1uN3HH0p/WJB7CJ7f4e1WDXtA0zV7NZUttQtYruJZQA6pIgYBgCRnBGcE0Vi/Cf/klng3/ALAtl/6ISiuw5BnjfjX/AAL/ANhqT/033lcf4j0HWfFOg/EzQ/DtxaWt3f6xDBJNcsyqsJsLLzMbVJJK5GPc8113js7dc8Dn/qMyf+m+8qbU/BfhXUr17zVvDejX99NgyT3NjFJI+AAMsyknAAH0FZt2kWldHJ+BPhlqHgf4hS6lpWqLd+H7vTIrO6iutiTiWEBYmVYo1QqEAXnnkk5rqPhP/wAkt8Hf9gaz/wDRCVC3w58ErIMeD/DmCOh0yD/4mupsreC0tYLW0hit7aFFjiiiUKiIowFUDgAAYAFTKXMLlsPmBKmsa6UsxBOBW44+U1kyKu5lVwxzyKaqcqubUXqFvNkLGzEAdx1q1ply9wH8wAEHIA7VWghIkB7Vds4EhZyi438tWX1hNpdy6vJZlo1GxJ+lSVHJxVyOZFSRjn5Tk+9UbqTAPOKtT8N8rdayb/of61i2dcVoZN/ckZJJ/OuU1e8LBgDW5qOdpA6da5TUSSOCM/WkUYd5cMzbSeferVm3lxgZ69qy71sy570C7bjNKWoHRxXGxTzUsV3zyeK537ScE7qabvAHNKw7nZRX6FSCN+Rj6Vn6nqq2kIOcsTwM1hR3+BgNWbqTvPcR/NwoyKVrMbZbn1A3Lu0v3j0GeBWZdTbkOeuetRTyMOo56GqzyDaQeoqWUixEDMME+2f8aiKFTjBz6HtUMTnGF71bml8yPBOXAxmp1uBU2gkknAHGM0ZGAOp96VFywA7dvWneWVzkAD3qriaI2G4GnxrwMdRTxDgk/pUirhdxGR6UNgkQgM309qVkJTI71PtB6cAjvULg52g8UIT0Kxj+bJrY035F4HWqcVszMMZGOTXQeHNOa4n5X5RV30EldnRaHDkJkZzzzXc6XbnC+lcxE0Gn4WRX4GTgZxXcaOFmt4pozmNhkGpTvsUco4x+z/44HoniEf8Akzd1o6K+74oaMvcaLqGf+/8AZVRuBj4C+Ox6L4i/9KbusrUdL07XLmP+19NsdQEO7y/tUCS7M4zjcDjOB09BXZJ8rizkguZSRk+Dfgxr2jyeHFlTw/YT6ZqrahcavYTSNd3cRYn7OQYU+QggHLsOOnavVfB7Y8S+Ol/6jMX/AKb7OuP0vwV4Pdg0nhXw+fY6dCf/AGWu60DT9J0GyaDRtOstOtWcytFZwLErPgAsQoAJwAM+wqZVk9Bexa1Oi7VS1V5UtG+zuEkyPmPQDPJp0N5FLgKwyRmuS8bR6hPPMBc3kdssINvHZj5pJOcl/UdMClKouWwoQalqZfjR5XtdPuZZ2uYEkJdgnAPbj06iq3heygvLCJ1Ro2ikJGcfLk9Ppg10enW8b6UtnqHy3SRK00RHGSOf1zWWggtJXW0GFYjgcYGfeuVydrHYoxbuWNd1y8kEcWkRmPaokMkiZDL2wPQkEZ6itm21+ziWBZjtd1GcNuwT1rm7uaHKRxRYZOrKc4A7VDcaeqacbtAXBU7hjawB704y1IlD3dT0GHUIJyPKcMCeops8c0l0kqXGyJRgx7chj6k15XZT3drfCOB2VXw65J6jtivR9NumltlLfePWtedtambpqOsSa7APXFVo23na+SBViWQAgdaz7lVRtzE7cZ4POaVzRLQ1Lobo9z9EGflqNZA6EYwCM59KqW1yksW3JzgjBHanRtgAHsKQlHoWw2VGO1SxgMvIFVFfHHYd6sxsXACjAFNIljwvB/SnQqyeWoU+Vj/vk1Iic8VN5YIGScelaRRlKXQqW06vcPGI2zuyWIwMVcbAFIQI0+VenAFA+bBNVa2hDd9RRndzjFDdMCgL16nNC52/MMGm12EU5htznvXP6ncqrYNamtzmKFm7Vx1r519O7HcY16Ed/auSZ20lpdlbVDueWQYz2HrXNGQSFFkU7ifqa6TULcnYjERn+LJqvDaoEYIFIHUmszXqY6pG0iAjLZPO3J6U426tIFjbqOcj/CtKYLFcKQh6cipETzEG1EAXkE/eY01cTRWS2aBVCMWA7Yyp/KkWyaaZSUADKTuHt1qzHDdSIVhymHwTuwp+o+mavRW7wYjnUhf4RuyFOev6U9gsZS2qBSSfoTUaW+FDnlTz15rWuoPMV9nDKBgDqfpToLIG0QSxnJJbIbJ5p67k6HU/Cf8A5JZ4N/7Atl/6ISij4T/8ks8G/wDYFsv/AEQlFemecR+OhnXPAw/6jMn/AKb7yujWTjDY49q53xxzr3gbH/QZk/8ATfeV0YTisam5pHbUMlnz2AqReDTcDNOBxUpAx7AMpBqhHYJFK7qxO7nBq6GpCpLA9qmrKSjaKuEZOOiIduDU0Y4o2808CsYQs7hJ3HVFIOOlS01sY5rpkrolbmbcLzxWPfFipx6Vt3PHTmsjUOPlIwcZrnsdcXoctqOeciuS1NGyea67UVJJxXLaoNoIamkU2cjqLhW681mrcEMc5zWnqkXG4DFYT/KeKrQl3TL/ANr4xzimtcZGc1nEnPBpDLxilYOY0FuQB1qBr3MjHNUWfg81AWx0NKw72NGS4LZJ5quZC7epqsrE9TUsQ+YZ6VLjYfMXIW28gcj2qzDl8sygCoI1ZgNtWY14w3JqGUmN8nknaRTwh24zuHcVZRM5I7ConGMbVw31pIZCyKrAgkn+7UsKlslsLn1psaOWwVBzWna2RJJYZ7D2p2EVvIJIjQFh6ipfsW3C7c/WtexsWL4wB6mrhstu456H0pXsOxi2Vk7llA/E12nh2zZIgqjk9SOtZ9nGEIULknkkV1nh+LClQMFh37U3qgWjMudZ497CFnlcbEAGeTwP/r13vhTTms9MtoJ33Oic/X0ritQXR47qWDxK0sO35oWcPhh2Kleprc8ItcpaIYbiebTy2yJrkEPuPoTyV9CaqCtuRJ3ukZF4MfAjx7n08Rf+lV3WDb3EkbFmyRnFbt1n/hQ3jzccnHiLJ/7ebusMMOSQPSumt0MKHU2bO9VFyc7j79KvXmupBprsJwGHAz61zDTvxx2xVCedmlTfGN3Zsfdrnep0rRGVe6jeHUHntbu4WYkHCsR+npXeeGvHU72rJqzKs0TAKVGCVx1x61wMMCmfcMs6uTye2aS8QB84UuGx1HzZNNtPQlJ2uzt77xodQun8hcBTsz3NNkumitWlUrIzN8xY5xn0riI5DHGGHDKx/wAmtA3M0mnAIApQ7nPb8KlrsVFnR6brTNqkayAGLkNzw3NdmLjzgqCKQRZxu42njoa8itp3WaJyQCvWuu0rW2VBEZCygZXPc0pR7ApXNOxsZ5NT8y4nV9oO4Keh966iKVLVCu7AAriLXVrlpJXIJ5BwB156VtLNPdDM5VGbHANFn1DQvrfNcXTJDnA71rhI4oQXO5j1zWVZWsVum7g+rHtWN4g1xrVQoIBfhRntQ227IDeuJNrCROvcU5btZX9yP1rirHW2nmRDlGIPBH3h/jW7BMrqGQ/IDyx45q0K50UTEZ54PWtGBgE5rHtWIiypBGOO+au28p3Lu6HqDTWpEkbMWMcHipCOMVQsy2ZF5wrkAkdqurnHJraL0OWSsxkgwMZNQG42qQe3epLiUIpzXGarqLQSysCSG7DtUPfQ0hG61OyguFdAQeKmZsocVxGlajIAoJyG4rq7aQ7Bnpii7Wg5U7aoy9ZjeVSuPlxkmsfSo47WOUSHG75hIOq+1dNeKHXgDmsG4tyuSmA2c1lJG8XeJz+ox+fcNvUkHO2P+LHYn61e0uwXyFypVh97PQip4LLMpcjJPzE45zWtHC8ajcMr3I4xUtaWK5tTKlsw+V2cAdTVG6hVNuAd2OMV1QiX55Pmxjaoz+ZrIniWWUDZnb3pJD5rmU0b2RQGWNZCuVjk6HI5wfX6063tri4ZC7krEMdO3t6nite30qIgybQ75x83P6UxLC4upC0+Y4Twsannb7+5qlHW5LdiqMTRBYItqDjzD1ar8FsgAGB061aa28tQFXAHQelPjUAAnA9qYIZ8J/8Aklng3/sC2X/ohKKPhP8A8ks8G/8AYFsv/RCUV6B543xr/wAjB4F/7DMn/pvvK6U1zXjU48QeBc9P7Zk/9N95XSkrxWU9yojcHNOxx60vFKDUFXGjg5p6kYpGXINNUU720FuPzS0ClpJIQVDMBt3OSAKlzkdaimJCk7c4p6X1HHcqyAMuR1rMvUZ2wRjitCLccluPb0qC8GB6Vi2nszpS1sczfwjbxXJ6vDtUnH/167W8U5xgY+lYOp2wkQ5HNJaMtpdTgb20Mqs2AGHb1rmbqLDH2rtpI/Jvlic4RzVDW9KMc7CKNimM59R60R1bsKz2ZxrIefaq7grxzW6LMklSOlPbT8j7uadxWObfIGMU1Y2IOBXRPpRJ6VKmlgL0/Si4crOYKMB0/SrMEe7g8mtuWw7be3XFJbaXIX+UHntSbGkynHFI3AJFX/IdIwRk/hXQ6XoUvV0461uPo/7sb0GAOmKhsqxwEKZJ3kknOfanrCGkHbPStXXLM2oLAcH2xx6VQhYyEBVBBHBosBcsLVQ5JG7HtXR2NnuUEoKZo+lvJErg4cnpXX2OlMIhkYNQyzGGnoANqYI74q3HZLKhDYHGfrW+lkQhBA/GqU1t5N5EXyI26t2osF9DFstJkmvSkbcKMkCtvSiwnKbQMdfrW1HNp+nxSNbgbiCKz9IQvLJMwADnIqm03dErsa8aGePaScVegtVMaxucqGDD6io7bAAHWrqdquKM6kjzi7/5IP49+niL/wBKrusRhuHORzwK27v/AJIP48+niL/0qu6S5sXjdykPnQE4DL/SuirsjKgr3OZYtFMxbJXOQPSmBS7iUMqjOOTWjqGnSjJ5HHPFY8pktf3bAnA5PrXPKJ0JlSQKs23aX5yCeOaZO4/eb4sFucHmrRlJIx9/pz1FVrn5WDFTkddvQ1GoyFJtxAJAVeTx+lSRXKRkrtypOQccE+lVmikQEk4DdqURqhQdcDrVWRN2iyHXzE+TaCOVxmrMMyxq3K5OCoHBNU9qtwScn+dSeQFaPBJbrjsKSBm/pd9IWKjG7oOK67THR1j80jce1cJpx25eQYfPQ966TSpw0uVPKDJXHJH9aHYpdzpb95RFmKNmiXr05/DrXm99eSz3081yi/uzhQemK9InhMtl5luyorL972rzvWPD2pwXbzQRboEG7czcUoq/UHfoZHmF79drkSHkbTjbXXeGr17mN47mTe6nBI/SuPuVm3BktvLYcFjW54WgkjlknUEh8ZIHf1q1sR1PSNKLxLscbkPRh0rXhRCATwc1m6CrXA5yMfrW6lntHWnFMU5JaEkUgAAXmrAGRWZrNyuk6XLd+U8ojG4qnU07w9q0WsaZBdxI8QkXPlyDDL9a2W9mc8lpzIuywBwc1z+oaGlzICy9O4611GKaRVOHUUajRh2WkLEgBxx7VrCEKmKnAoNHJpcTm2UZYi3ArLit3e6AmUAAdjW3Jx0qAR7MuTwetYyibRnZGcqLHk8KQ1PEm+TCfMqnnFJcRllUMOGJOaljKw2u8j5QOwzUNGlx+1dpwOTWXNaFLnzWXaWwMA9arWviSG5vWtio3Lk7h3A9q0XnknkVY1DRsOT3FKzQ1cniiXyxzz7VOsak8DHNLDDtQI2QSOtToijkGqsZykQXMQKEVnuuB8wP1rWmAIwBVUxjnPek0VCWmpmfCf8A5JZ4N/7Atl/6ISij4T/8ks8G/wDYFsv/AEQlFd5xjPG4B1/wKD/0GpP/AE33ldQ8YK56GuY8ajd4g8Cj/qNSf+m+8rpiDjGeKyna+pSGnJFIDnpTs4GarPMrNhFLc9RUbblpXLQpV/SoYpA3GMGpVIzzQ43E1YQoxYneR7elEm5YW/iYCqr2oDOyzNuNWbZGWEB2Ln1NVzwvyxldi5Ix1TEU7Ikx14qUjIpiwqp4FSgYHFR8S1BtdCvImAeKp3CZHIrSbGKqyqDms+RR2NISMK7iHNYt/CStdRcRZBPH+NZt1bZU8VJvucDqun/aACvDocioJLm5Wz+zsgLDgNjmutnsGDEgVVewyckD2JFJ2vcvl01OEWzYy8pyeSaux2GOoro2sh5hwB+FWI7EHHFNiRy76eDk44pYtOY84+XufSuqksVx05ogtDDNk/cbhh60dAObfRQse95FweijrWlpOjIihmXLH1raa1Se5RYoiqg5Y+tbltZqqjI6UmPYy7PTQowFxVp9NyhwPzrYihAA4q4IQR060rNkuSW557rGgi5XaUDDvmsi28KlAAqZGe46CvVmtN3AAx9KglSK0kXzFIDcAAZzmmkxKV9EYejaSkaBSvTvW5HbBeMYFacMSAZAqTYvpRGPMrkSramY1uuc4qG4sllTayg59RWu0eSQAKj2HIyOnWqUBKqc5/ZMZf5skelW44BCgCADAxitNk3OzAcdqbDGjJI0gHy0KLehfPZEEKjHHNW1RjyMEVVhyI1OM4OcVdjdBkrkEjpVR0ZNR9jzS65+A3jv6eIv/Sm7rsr5AEQRoqxAjn+tcdd/8kH8efTxF/6VXdaV5cS3ETw+d5QDhgRxkdxVV/sk0FdstF4zdTwNErxp+ePWub8R6QpfzoWzEeuOSBV8z3CgX8ifuChVsDkL2JFTQzJMrGFg69WA5J+tc7utUdK7M83Mc/2h1WLn++a0bW1Kxss3OevtW9qWnhrpVQ8DkVWgtC0m0N85bDZNNu5NrGVJAhfYFHTgYrOuYUDgBSMdK7F9NQtjnex4P9ap3umeWVO3IoTHY52KDbyTk1N5J8pSIyzFsAjpWutvwfkyB7VpabbxsCNhH0o21BpMwZbJ0jBd2Zs9Dz+FWLWKaMtIw2+WcBkOefp6VuW9sGvhE4CozEqpOTXR2OkRhmbG4N/Ki7CyMbwVrhmhnhvQCkJwrYGQc4wRXVI1vdp5KkMhOcj1qG88N29zalIIkh3cMyfKT78dTUdhp/8AZDiKL5ohj7xyaqyepmpX0C88KWrus8UWWGMoeQ1WNP0m0YSLGpjIO0oRgjFbcUxz93KY4NY2torXMVzFfpalXAY9S4/u4ptJbEKUm7M1bazFogEY3H0zUF1dvZo77GkGcnHai6uZo7FZ41aQ7cgDhm/wqlqDT3NnASJopWkCOoTkgngkc49/Sm32FFXfvE41uxvLeRDIu4jG1h/SqXhSSeJ5Le4ttpViFdR8uO36Vla7o0EbiVIoiQ2W+bBHrirGhXN9EVhmO4j7pLZOO2TRdvVl8qtaJ2wNFVEmYGMuoG7jrU/mDcQCCw6jPSuhTujlcWiSkZgBmmluM1DK/UZpOQKNxxYGnYBUjHGKoq/z8mp1kyvXis+Y1cGiOZjDBAGhabJKsVx8oweaa+ySzHk4MbDPFLdXkdnA00x2xKMn2rJhnjk1eE2ZJgltyxIHB+brUS1KimY9zo80d20thFGsjnlsc47102kwMqDeAG74q2uMDAAPSpY2CsRjHemglLTQl8vgZ6ijYKa8wHeoxdoWwDVaGSjJj2XqRVeVMnmpzJnpjFVWnUyGNicj2qWXC5kfCf8A5JZ4N/7Atl/6ISij4T/8ks8G/wDYFsv/AEQlFdhgJ40/5GHwJ/2GZP8A03XldM4zXMeNf+Rg8C/9hmT/ANN95XSg5OKzluUkQzKWZYs9etWUiVFCqMYFVZ8q4f8AlUn2pVTJyW9KiNm3zFyTaViOZRHOmOpqU5xVeFXlmMsox6D0qy3I4qb9hvS1xY1AAJ61KeBxUaHAGetPzRGyWiIe4oNFFAqiRpFRFVBO5eDU/ekIBHNS0UnYozoo5XGPSqzxg5PatAx8k9qjZORis7G0ZmRLb5yOKryWoxitp4iaiMHOMVPLqa89zBlslIJIINFtb/vNjD7vPPpW20WDgjmgRANkAA/Sm72sUmlczXtA2OKVLNV5Yc1rCIelPMOMdqdiedIoxQIBwBVhIx2xUwj9Pzp6pz0/KlYTmNRO9WY1OOTTAPanAntVGMncl2gikMantmmqSevWpBkVSM9UKBilNJnikPIIq9NiQ6jg0hXI5JxTbeLyolQHpTmJ5x0pWH10I2AANZt35i3IRVcpJjOOgxnNXry7jsrRrifO1ccDkkk4A/WmWV0l6jlUeN0OGRxgipcbo1je3NbRD1UHA7fpUiJj6UqrTqEuhLZ5hef8kI8e/wDcxf8ApVd1FO0sxt0ceTMIwybzyxbox+gqW8/5IR49/wC5i/8ASq7rd1PSrfTbNrvDAxMGPOcr6DP8qde2ly6G9hllBqkFlsvWimkddgMS84PdvX6Vnpb232JP7MYLK+csx5fBweB6elddpNxFeRRz2+DFIPlI7VSg8NwWWpyXsVvFKZCd2AVIz1OOn6Vgomzkk7EUGjEwLM21n4UN3aof7HQXBfy8nPTtXUJBHFHlQdoO4A84NMgdJQzqv3X2kYq+UhVXYxxpwBDqqbh6jtVG608M3Qc+ldWUXftXuM1SuISWIRcnBI/CpcXuVGpc5v8AspArHbg+1TWtgsY4zn1rc8pWyQV27c++aUQgqDjFKzKUkZi6YgmWXAJH3TjkVpORDCpXjHXFSJGwUDqKmkg3r2NPlbIlJGda6tHeSPb280e5ODjk1oyxbl8t23lgQFzg1g2nh6Cx1OW6hLBpDlgTxmt4NmaNnGNo4YHr9a05UTLuiisFxDZPFbF4ZMYUKQST7Fv8Kv21miGOeaJWu9uC/BI9gaZqMCSQp56eaM8kcYH4Gm+ZeHUYlihi+xAEPIXO4EdsfXFXFW6ESk2i/NGssLI4BVhgg9xUEcH2ePbHkjJI3HJHsParLn5T9KYSQB3FVO1zOLKnkhlbcqdSfu9TXP6ddRxatcfaDsIz8rdSfT6V1YxtziuX8R6B/asitHM8ThgTIn3selZOOptCV7pmxC4vJPlVlUDrV4RIsjyAfOwAJ9cVnWNv9hgRDIzYHJNTw3RZypoTFKLeqLLngD1NVbjnIGeKsMCcDp71VmZ275FNhBECgltzNjvjFSiUDiq9x8i5z0FU/OcEnB+tQbWuadw8ckWyXBU8EGqKRxw30ZhAEWzaMDpVE3EkhIOfrWgku9ckAZwcelISRpwMNuT2ps06g5DD86olpPLJTgVWcSHO7qeaExcmtye4uhgnf1rNhlYXO8556UptZGbLnC9elWIIlB5+nFDdjRW2LcEzs3DD6VbWaOF2SUYLjgkdaz0UxnPb2q4jB+WUdc4Pai5Mlcz/AIT/APJLPBv/AGBbL/0QlFHwn/5JZ4N/7Atl/wCiEoruOEb41/5GHwL/ANhqT/033ldIw9K5rxsA2v8AgUHp/bUn/pvvK6gYrKpuVENo24PNRsigjgc1IWAByOabgk7j3rN2e5SYmaAeaCPmxSjrSAXPtRnmlAo700IcOnNL3pM8UhPcc1RI7PNIec0m7npimb9r4wT9KGxpDugxTD1pWcFgMEfWlxmpa6FCFeKjZefepwPypCOeKVgTK5jqJI2V23NkE8DHSrhXimOCF4FKxSn0EAC9uKVlyFJ6mlRG2ckZpQPm5OTVJaXJvqCKMU7YKcBTqaiS2RbaTbU1IaOULka9aVjimvIqfeYCiU4AJ5FA9x2Ce9AOaYSyttH3ccUuDjrRsFiSm5ypC8GgcLg00g7sjrTuJIrXtml/amK4wUbO5SMijT7SCxh8q3XCjv1JqxnLYJAzx9aCoQE54pPW3kCik211Fz709R61WicSIXRgQDg/WpWDPCyqxVmBAb096NimjzK9/wCSE+Pf+5i/9KruvRriFJrXLqM7OQRmvMUha2/Z68aQPK0zxReIEaRurkXF2Mn613OiaxFqcRKfeVjGw/xp1dlccE9Wuhr6dZx2lskcSgKOQAOmauYqjYzq8jxREv5WEc54BAq9mqja1yJXbEI44qOGLyg+OSxyaZJcojbc80+OUP0qeZNj5WkRPG3mZHyg9Wzz+FOEeAuzqvrUxAOM00j8qlxWyQ+YhaIHO1FGepAoMfGKkJI9KQmlYabIwPelViCR14zSHPajZnB7ihIobKN6hl/HNUryKZ9Y01ozKLZUk80KwCZIGMjvzmrxYqpLAkegpYyHX5QQPcUw1sNSLyicElSenX9Kq6hcytPHaWYxJjcT6YrSA4rNmDwap9o2FkKbePrTEnd+ZSu5dSiuYbZ3BE5CiQDhfWtaZLmORfJZXDH5i/G0e1Qyo9+6MyNFGnIOec+tSxRGEOJXkk3Hgk5xQxvoWEZvuPgHGcjvTVwrnjIoU5IIXaoHFNx8wJPGeaRKRJJEHB44qJbcAjaAKsA5PHIp1HKLma0I2X5aiMeOgqbJIzjikYZ6UNDTsZ93ECprPiTzHaNSAAOTn+Va86E5H61S+yRmTLD5vUHBrNm8XoQJboB8oP1qUIQuMVeSBVAxz2qRY+OlFhOaKAU7cfrQsDBwTyK0GiHHFOZflwKLC9oZN8CIuOPwrL+0eSvzkgk9R1rcu4tyMrdKwWsIzNksWx6mkaRs0TR3O9QSTg1b81do5NVUgUSY24GODnkVA6SBm649qLDXmXPhP/ySzwb/ANgWy/8ARCUUfCf/AJJZ4N/7Atl/6ISiu44Bvjb/AJGDwL/2GpP/AE33ldJnBrmvG/8AyH/Av/Yak/8ATfeV0xAIrKe5cRCpK5zyaehG0ZPNNGQuM0u2oTBgOWJpD1p2OKQ8jJOKVgEHNL9aTBBpwppAK33aEOV4oJwKhO7zMAHnkntTVhOyWpK/BX1qONgsjq3GehNOC4OcmgoG6jNK+t0PTYa5G9VU8ipT2pqoFHFPpA2NzzxTqRfvE4p1NITEFIyhuDS559qXtT0ERBCB1P0pyrtOMU/FJSa7DuKTikLCopY1YqWzweMGnNyBindbIEhS3eiR9qFvQZqMmhl3RketCeupVjOtQbiO5uJW6kqg9Ap/qQat2TmW2G/71VVEtviJoyYyzZI9/wD9dWbTCqxPAJqdU9e5VpW8gubhoCp25bpz3+lXAeATwTUSsG9DTZWZSNoB9aErMTVyZjmgDn3pigkZYkU7pjByKZLOX8WJJNcRBJjARkK6jkH8enHPvVnwnqz6xYSx3qp9qt5DDIyfdfH8Q9M1ralZWl/bmK8jDoeoPFR6bplppkHlWUSxoTuIHc+tFSUnJWX/AA3+d/1KpS5YShL5eTvq/mt18yeKFIhhBhc4p27BIIpHcIvOSc8Uz5mYt61Oi2Gkeb3f/JB/Hn08Rf8ApVd1oadoM8LzhpZbcyncpjGefQj1x/Ks66/5IN48z6eIv/Sm7r0O9SZbXzbPa80WWEbdH46fWtKmyFTla5T8I/ZhpS3FrKskc7cOD97b8g/HjmtK51C3gbbLIqn3NcT8NYTENbSBJltV1GSWJHGFQsAzAH/eJ49q6fTLK1vI3lulWWcEq4JztpK7VhabslnjWYiSNsqR2qzboVXvxVDT4lt9RlggctAvQE52n0rZAxSRcp6WGxk7dxbJ9KFfOSemcUpRc5xzTVG4kjGAetMz0YN16Ug5OKVieQetIhwuOhz1pD6C4GeDS9qjZ/mJCsR7CjJPSgdh+O+aB9aah45PNL0BoCw4MM9adwV9qgGAfbrWdqfiPRtKMi6lqdpbvGMujyjcPTjr+FNXYma2cdOKUjPSuB1X4n6ZaoxsdO1G7x913jFtG30aUrn8AaxP+FrajcsVsdGs92cAG6eYkev7uMj9aXNHuvvFq9lf8T1raT1pCVU4PWvJ5viH4nSST/iTWqovfybg8f8AfNZ158VdQiO24tLHzCRjZK8fH0ce9Q6kfssqMJveLS9Ge1rg9KGPFeceHPilpE4ii1gyWEr8B3XdF/32OB+NehxTQ3MKywSJLE4yrowII9jWlmlczur2QqEjI4pyDFCjFO6UkNsY4zxUDwjPTmrVBANKxSlYgVcDnmnCPc6uWbAHTPFSbacMAcU1ETYwjjFIMCpCM1G49qGgRBc4YEY/Gsi6hwQy9a2mGRzVa4iVh1NZtG9OVtDMjB2buc9qdJbN/CMk96tSBQhVcZqMSOeW+X5cYqTXcp/Cf/klng3/ALAtl/6ISij4T/8AJLPBv/YFsv8A0QlFdxwDfG3/ACMHgX/sNSf+m+8rphwc1zPjX/kYPAv/AGGZP/TfeV0w/nWVTcpbACRThQBSM4UfMcVCVxinpxSnnFMDDHHIpNwz1H50xWHEYwO9KKQCo7g7LdyTjihbinLli32JCBIo54PPFV7+3eeNFRwoDZYEZyPSmWE3nS3CL/q4GEQPqwHP86uHI96ppwZa5oNX3I0yIxkU5W9BSnvUMDMTyMDGcVnFcsdXsLcnzQaQ0L0zTEL05psLs4O5dvOMZzXF/FDxm/hPS4jYQx3OozuFjhZug7tivLrzVPiBrV89xa6q9nCRmG3jIic8f3GwTzSclHdlxpymtEfRAFLXlfws8eX99eS6F4r2pqcQzHORs80f3WHZv516oavR7ENNPUKKTpSd8mlcQhIpueaJMbuOtMBOaGy0h+KZLGWZGVyNpyQO9PzSr9aSAjDblyRgntVeZWeURjhT1xVuReOOtVLuIyfMrtHIBwQaT31KiyveQ3Fj++gcvCPvoeo9xVyCfzYxIoyCKx7r+0romAyKsB4YgcmtW0i8mFUHYYodlsPlaXvFqM5AI/8A1UPwvqTUWOR9akyO9F+hNtSO6KCBjJnb04Gabbq+zlw6AfKR1qYkEFT0pkarGuxc7fSjqNN2sEozg+9SMrHBVgBSYGOehpNnPBOKa0EeZXn/ACQjx7/3MX/pVd16FZRSxM5Z87jkZ7V57djHwH8eD28Rf+lV3XpYznAPTknsKufQUHZNCquCQMAHrjjJrLudCt2mMkUkkTN97YxGa1lGO+R61HMzAMysQAMEAZNRtuNN30IrOyjs41SL6knvU1yJTH/o7KJf9voaUKRtwSwI9KU9aAbuxSx2gNjdjnFORhswB0puM/WkYD3ouxWQ5yDls9B1qrbedcjzSQiH7i45I9TUu0vGy5wvSoYHmtVEJQyAfdb2o9SknstySPzBIUdjx0xUoGDSwgnLv949vSlbgmgTepGy/PuB/CndaOo4pF5B64HQkUBc5Xx34mbQ7eGC1Ki9ud21mXcIo1G55CO+B0HckCvP9N8LNAlzdXtxfS3lzIbhlVgZtzf3n4wenA4HTnFbPxSjht9fsbu5YhZrZreM5/iE0chH4oG+uMVrXsV6yxzpOFtZThpo9reWex44I561yV5Nu3Q6KMY7so2ujR2CpPaaPppnUBnkniMk34Z5z7k1bGvT27rHPdWsGeCkVqcKfc9qfbzk291DdCIXccm1zD8wIP3T1zg9c/4VDbTwaTM0Uhh8qXLSYJD5z+ea5zbmursw9Yu9S1LU4p7PWV2IchFjdEkx2zuwT7VtOmoXFhbi+bS7kow3xPEQZEPZtwOMcdqj1KO2u7tIxEJIpYywjwAAOg69cHuaydU0KaHT1ktpdjqcNApxgAnIJzSsnZMtPsX28P6NdtOt1o0VpLD9/wCxXCjjsSvvn0NZDaNrHh2can4P1E3FqBmW2zmNvZl7H3FM0C30+WNXgWURSS+RJG+S8Jzwyt6Dv9M4rp9Pg1OymknX7OEkZBMsKncOD82Dwc45x2NWpSpu8H/kRKMai99fPr9/9ehu+CPGVr4lheJkNrqUH/HxaOeU/wBoeqn1rqjnHFeK/ELTb3SPs3i3w/GsGoW/+uQHK4/iXHcV6t4X1eHXdBstSt2DRXMSyDHv1H4HIrtp1FUjzLTv5M4qlNwdmaRJHSl3cUj9aTIrQgdupd1REg1IAKaBoVXBbGeRTiM9aYBz9akqkIicD0qnKjEmrzLk9aQoKhouMrGQ8ZBzimkBky3ArTkiGMkVWFuwypwVY559aho2VRNGT8J/+SWeDf8AsC2X/ohKKPhP/wAks8G/9gWy/wDRCUV1nIN8bf8AIweBf+w1J/6b7yumz7iuZ8bf8h/wLk4/4nMn/pvvK6NjjafWsam5cSQZxVFUW6vJkkJwgGFye9XlbK1TuLZXlMikrIRjIOM1KaW449TOkuHhvZrSJycY2+2e1TjS7gruF0+/0IqK6t/skkc0YyQctWpb30EsQbzFB7gnFHMm9di5tpLlKem3su9re6GJU/Wrt5L5dnNIIzKyKWCDksR0FZMcputW8xRhAMfWtleMZpp2YpJacyKWixNb2VvHIu2VlMsv++3J/nWixqBAwkc561MoHrUQlKfNOe7b/wAl+VxVJc0nJ9RrNgik27emB9KVv9ao/GnyfKpNVa+5IgFZnifWrfw9odzqN19yFeFHV2PAUepJrTBwmTxxXk3iedvFfjZbVZiul6YxyxPy+YB87++3OB7n2qZyUI3Y4xc3ZGVoGly6rqMvivxSxfa3yxHkDv5aew7n1rs7y4iv7R72WG2uGiO7BbacA8jms64m+2pEbeAGyhHl28I6N07Dvjn8annffELaZDB+7Xadowx56/Q158m5PmZ3xioq0TnPipoCXOlLquiXEiPLtidR95CeUIbqOcD8a9M8DamNV8KaXctOs8zQIJXAxlwMNx9Qa5y0tYNT0m/0Z5DuubfdG/OVYHg/gwBrJ+F95JY61d2FyxRrktMYv4VmU7ZlH/AsMPZq6KNS2jMK0bv+v6/4Y9XFJkHoelDHBpnfNddzlSAjmmjFPxUbA5ApMpAT2pqyAsQOopemc1E0e6RXUkMO/rSbaV0Va5YDZJB6UpAOfWmIePSnA5pp3JsRMgyMZFPUU48GkGB1qR3FxjntTCcnFEpbA2+vPsKRc59aY13HqODmkA54PShz6U1M5pMCQDApQaaTjvRjtTEeZXnPwI8e/TxF/wClV3XpuCMg8rXmV3/yQfx59PEX/pVd16b3xitJ7ImIqkYwKGOwlh07igDFVNRztQNuEe4byPSs2y0ruxZU7zn0/SlbiqVqsa3R+ysxiK/MM8Z9qvkUxPQjkJwFBwPXNNhDfOTwpPy85NSsBjB/WmnPrQG4A7d36U4/cU5NA5XB6VDcAiML2z19BSbsgSuxlxf29tJtklRSR3NJDeQTnEcilvSkksrGWMtLAhx1OMk/jVa9e2cxR2qKZAw5UYK0L1H1skaQOBilP3e/ApgB20oOKAsc74t8L2vinRPs17MYpVlWaCQAHynU8cHr3GPevPLO61Dw5rMumaqZVaXOIUGY54/78OfQdYjyP4civY9qZ3bRn1qhr2i6d4isDZanEJI8hhjhlI6FT1BFZzhzbFxnyu/9f1/XdPiry2sZJbKXT54rbzYgYLyBPvHP3Tk9R6HmoAl1qDMbp4ppRlHdlCN6dFPP44qhqei6x4RMzyq2p6Ix3PIg/eJj+ORf72ON69f4h3otp4r+Q6hY6iSSoxIxDK4HRZQOh/2xwe9ck4uG50wkp27/ANbd/wBOtumzeWphlSW2MUkqqo/ec8D29KrQDVhtkljiuYHbfIIAAcd8ev0qvLqZaSFy3lSLxtXLoQRjd7ii1udTt7tJWikAI8zzdvyH2/2c1mvMt9yJ9KMusvcyRz2ZncxSJG5CyoBnBX+pqfS5p/Dk8ku+W4t7bcCkjFmiRmG0DjJx056ZxSXusQatqVrPI5i8lizDBG5gDgZ7DtVR4m1OOKSBjHYeYslxKz8yhW3+WgPJ5GSfaqV/tEbnca7G95HeQhQ1qYXMh7huMfoa5/4AyP8A8Ijc2xO6O2vZo4z/ALOc/wBai8Y+JX0Xwrfz3aMlzqBMdpAx+cpj7xA6VsfBrw/N4f8AA9nDdqUu5ybmZT1DPzg/hit8Kn7z9PwMa+iSO4cc00AjvmnOcH1xTep6YrqOdCg4z0ppbmloC80wF3GnK2etNpRjFMB68jNKetRZK9OlKzPgbQCc4OT0FNa6E2JMVH94+pHSpPrSc4NAkcx8J/8Aklng3/sC2X/ohKKPhP8A8ks8G/8AYFsv/RCUVsIj8cyLFrvgZ3OFGsyf+m+8rpMhjuKn2rm/HChte8DAjI/tmT/033ldEdpbDt74FY1H71jSGxJGQ3Tr7Up96YhzzGOO5qXqvvUg9CNkVwQ4yKoyaXA8gYAjvV4n0xS55FIabRFDbJAPkFSsDxSluBSeuaAu3uIBj604HGKByacRxRqJsYPmuB7CluM4UD1pDw2QRk8YpxUscnrT6WDrcwvG2qnSvD89xH/rhhYhjq5IVR+ZFedaTaC20nyCf3jOBJIx4Zdxzk+hOWP1FdL8U7hWbRrMswInkuNoP3jHExXP/Aiv44rHa3b/AECBBuRy6s/bIOBn67a5K7baR1YdWTl/WpYs7eWdB5O+JIxtiweSBnLfiTQC0UjJLGN2VwWJByeQee3GK01jijsOX3MueRkc8Vm6pc3V28QZ1VomJVpCCxB4544rnvdm1izDAWf7Rp42X8D+a0KnBznlfTaRWFr0iWfimHVLcYjZo7xu2MHyphj12spI/wBnNa073Fo73yKFdIyJJVP3lx8oI781neKALy00psgyXcUquNuOZYm/9mC04SaabFKN0/LU9YVhJAjg547UZNZHgy6N74W02dhhpLeN2Gc4O3n9Qa1/pXoa9Th0voPB/KmnBNJnFNL44zzTQkhZMBRk9akKgoexqJsMgqRmwmDzx1ppXYPYajDGDz70YrLaa4juAiDKE9fStNSdmTxmpuk+W5bi0k31H9aYRQH7mo5mlLDygCMck0yUmSYyetLgDpUMcb53yN82MYB4FPPWkmOw8gH60KcEg9BTcn/9dA4JOODT3Aexz9KaM55oyAR39KaWOehxQJI81u/+SD+Pfp4i/wDSq7r0/t715fd/8kH8efTxF/6U3del3M6QhS+cMQtaT2RMVd2JM0E9c4o6gEUAVmMbgL0AH0FG+nHHGelIQCTkCgYuelHHejjFRHcyMxJwDgAf40bhYk6tx+NKQCOelQRLKrEHrjIB5psbXDXmWGIQAAM9+5NONm7eVweivcJbWMncWZfoabbwwRktHlm6bialkAll2O2EHJ9/anyRqAWGADgAUktGyr9GKetIw4zSnJx60HpQIYcHjtU+xdo4BHrUQXPBzSkFRgNxQJ6ihgchjXE+IPh1YXLy3ehOdKv3beXiGY3b/aTp+WK7QYC804EgcUnZ6MNtjxfU/wDhJPDWF1TRze2gJP2mwGQOOWIA4+hHNULTxHpN2oW7u4owASFkVoiv+96170COPX1qhqGhaVqOft2nWlxkYJkhViR9cVk8PB6rQ1jiZLR6+uv+T+9s8bF94RiuJLt7pZbhhn987OgPbAJqa48e6cIFh0ixuNTueEASMsAfYLwBmvTI/BHhqOQumiWAY4/5ZDHHtWzZ6baWSbbS2hgX0jQL/Kp+qx3lJsp4qVrLT+vU8o0LwDqviDxDba94ukSKKNlkjsV+Y8dNx7DPYV7CBgUnC0m8E10JJKyWhztuQh9aXHrSE0A0wAkU0SKTjODQhy5J7DNRw3EU5ZSV3dO3P0oQWJhQTgGsyRrqaSWO3kjVolB+fqSe1LpGoi9jZXXZPG2yRM52mle42i8dxfapA7896VXYZDjGKGUnB6EHINMZsLxRce45pGzT1m4561VkbHKn8Kr3ErKny8E8VPM7lqmmZ/wn/wCSWeDf+wLZf+iEoo+E/wDySzwb/wBgWy/9EJRXWcw3xt/yMHgX/sNSf+m+8ro9gY9uK5zxt/yMHgX/ALDUn/pvvK6Uisam5cRkXBZak75NRD79SdqzWhT3EoAoxzSgGgBD6ikCkZJNOA9etDcDimIAaJJBGm40KKbMgkjZD0IxTXmGl9StGJJF86R9qAZA9PrVq1l82IMDkGqixSeQ8ErAqeMjqauQRiONUXgAUc99v+GHJWR5p8T0Y65aTK75jtJvk7fei5/LNRarexosMMqFkfzAwU4LEMCFz9etaHxWiAfT5z/dnTjufLDgf+OGs9IRf6fHLEI9yXimPnorkA5+vzVx11ad2ddB/u3/AF0/4BNdyRm1il0+WLz4l8s7gTuPT2q7Z2y31mjvH++XarLJ/EcdPbv1rn7uC5Z5INNtNkMGzNxknJP3gB35rc0OV5o1G1SCXBm5yxHsec1zSVlobpC60gk0aSGcKtzDIoZQCMJg/Ln6ZP4VkazI32XSoHUoLe6hZS7DB3Y6DrxmoPHdteSaU0NquJJGCfeAJfIwfoM9fan+KsDUtMjhZbrcYcvHJvRgpUE8e4NP7P3iTSbv5/l/X3nZ/DNs+FLRByIw8efo7CunIrmPhmjL4UtCy7C298exdiP0NdQeBXpHmjCQP8KjxuOBxTtwV2ZugFMjlMu8gZBHy0JX1Ls0rkqqQKibPTnFRWUjoWEpx6A1c2BhkHrRHdg/deo2JFwOBUdxJIJ0RQPLwSx96V2Ef3jgetIjr54LkYI4Pakkr26sVuoZBHHU1Msg2AAc1G5Vpf3eDTvLA4B+anewOxGxk3oAq7cnNS4HWmhjjFByvWmFugpHNOXnrTC3FKp9TRsJjmT3NMxjipc8UwigEzzK6/5IN48+niL/ANKbuvS32rBI8i7lVckYzXml3/yQfx59PEX/AKVXdenIx7j2rWXQlEdtPHc26Sw52t6ipP4c0yRMoAo2gHoOM0qrgEYG3qMmsynZbAeT6UvPGaO3FJ1781ICkZ9KiZWKEI2CaS6L/Z22D5sVFbqqzx+TKz5B8zdTtca0VyZJ5UO2aIEf3lPFSxjOTjANKwpASBTu+ovQZJEGfcOtOEeSGc7sdBStyDSIGDcnil1Hd2Dvk048/Wg4zUDRN9oEgkO0DG31o1FuTjrTSMn1pAjpHK0Y3vjKqx4JpIfNeNDcIEk6sFOQDQkD01HY9KVR704DAprEihgncd/KmhgwBDdeKAxzimPEGUbSVwc0Al3JOQaVsjrTSOAcnNKSc84oEI2QAVGcc49aaxV3VlHLDOfSnl1xgkUAcnApp9ADGetDfKuacMYzUchyVXsTQC1ZFdDbbE72jHALDqBmhBbeUiwhcIRj1qe4UNAyMc7uKYkIVt7szNjHPSntohp9WZCaX9i1+S6WWd0vHzIrvlUIXAwOwqRtNEOrfbLaMI7485k43EdyO/H5VsOodQCOnI9qpyiVN7KxOegPY1Mo31HBtsnZyy5UZHrUX8qllASMf7K81DvyKmSsVHyGyAVnXsmAcc4qzPKcn0rEvpiM89OlZNm8FYufCf8A5JZ4N/7Atl/6ISij4T/8ks8G/wDYFsv/AEQlFegcA3xsca/4Fx/0GZP/AE33ldJyV9PrXM+OTjXfAx/6jMn/AKb7yulJXI6Y96ynuXHYjyA/Bz71KOlRGSNxkcHpT0bsayafUtjmpc5PFKe3FRPKsKlpAQo7gZprXRESkoq76CsTn5Rn1p4Oce9Aw3I70jcEUXGnceuMcU085NIM9hTv4aExDR83I4FPUEdaAMoMUOwXintqHkcb8U7WWTQorqGJZfsk6yupOMR/dc+/ys3FcrpImWx1G1fAdQuxgcktESAR9Vw1er3UKXNrJDKgdHUqynuCMEV5BCjWF/NYMZI7iH90H7sVB8tj/vR/Ln1U1zYmOnMjqw0teX+v63L15dyR3rogVYJGKiSNs4ZhkZx9a1tM+y2tw8N4xZiRscsAcD7xJ6ADvWTBp0Vlc2SQXM4jvAWkcx7sHjb+RBFW/Gejre6ZIqrKJmCqHiZRvUkblx6EdfauSybsbeS3KGqNHqPh5liUqm9nR2Ody8AD1x+FYjxMIYdRRI4I0t3DgYQErhg2Bx7CtfW7qbSbV7CyiaS6CIn7iM5xgZO48ZJzmopopdXv7LTriNhNJsjlRudqgh35HH3FA/4FVwT0XS4Ss05f1dnpnhC1ay8N6dbuCGjt41OfXaP65rWYZxTIVKRovTA5p45+ld62OBu7bI8c8daImCMwKge4pWGDxTKXmVuiJgHdmAPXFVQJUlJhYkpyVz1FaEZ44GeetDohYnb8/rT1ew1JLQZHOkwA701rZN2VJB9ulPEILbuAc5+WpQOmaSuwvb4SPZgAjg+tP8w4+783rUmM9abwKpKxN7kY+XkkA0MwY4U5H1pzqGQjGai8kKBt+U0DVnuPABo6HjimAkfSk3fNxSbHYnGce1KBTDnC9QM84p+aatYhnmF5/wAkI8e/TxF/6VXdennhgF615jef8kI8e/8Acxf+lV3XpjbgQ2DxWs+hMR5OCAcc9xTZAHQq2DmkmBYFQOByDmmxPvjVsVm7lJaXHYAAAHHpSgY5pwxikJoYEfVuSCPp0peFGABml70Hn8KQwXJpxFReYofBOCad5hzQDTHdqTJpc5GaQ/Si4CZ45oz07UgIVxxmlbcV5Kk5pjFLgcZ5p2cng1GoyQeR9KeCfbFFxND+gyeKijlilLbWB2nBGalGCCDVGOwS3mmltxiSTk5PBos21roJOKi29y0Qd20D3oDYO1hg0isyzD5cgjk56U44dgfSgYvFRyE4LDmnNikVc8kgD0pbgtCvaQxvAJJcu7nkntU1rlUZSSQrHB9RSCBVJCkqCc4B609nSEKCQo75p3tuD1Hc8+9BRWYHB4pwIOCDnPQ0HrTFcYcL7k9BT+dvKmmbtrqT0qUsME7gfShAxM4A96YwyBx3zTwMrSHihiRATmViTu44FQTs2ecVPNzyODUDqTyfzrOTubR7mbM53EGsbUm3ccjPpW/LCMkmqFzaiQYx0rKSOmJL8J/+SWeDf+wLZf8AohKKPhP/AMks8G/9gWy/9EJRXoHmjPG4zr/gYE4/4nMn/pvvK6GDBJDLnB61z/jb/kP+Bf8AsMyf+m+8roeMnGKxqWujSO1hk+wuoGD9BSoD1pSncdaVeDWRd9CQUYyMHpQp6dqXFUiCjax3KajcSyXQktnA2RY5Q1dOS3SkCAHIGCetO6Uk5SXv2v5FSlzO4uMCmtTXk2kZzTjzzVW0JsKOR1pCvOduTSc00s6/d9aQWJV69xXn/wATdJIgbW7JXeWFBFcInJaPcCCB/eRsMPxHeu8V2J+bFRxwIiyAgFXJJBHXNErONhrR3PO/C+s2WqWbQTPE9zjPkFhg/wC2n+yeuOxyK3nu7SzA8zcibcFNu7P4jpWD4l+HLGd7rw61uhdzI9ncA+WWPVkZfmjb6cHuK8+1K28S2usWul3trrublykSjUVkibAyQpK+gzz6VxyoNPTY6o1tPe/r8zvNb1+3t5G+zyvNdTjbHAGyXUcjcegUdSfStL4d6ZJcO+r3J8wuu2KQjG8E5Z/oTjHsBWL4Z+H5vY47q/aL7G5DPCjs5nxz88hwWAP8I44r1OCJYYkjjAVFAAAGBWlKl1ZnVqX0Q8qT1Y59qUNgU7cF6jHvTGwfung10W6mAh54xxQMgHHengYb2pCuAaQXGYwq+hoJ+QE+tG7Hy4JpCSW547gGjQod2pRkdRQOlKTQIXOaQjNA5JC0btrbW4NNCACkcZHWlJ5pT0poCJMEEH8KdGAM5HNLt54p4FSxtjSBjmnBQBQ2PSmsxoSSJ3PMbz/khHj3/uYv/Sq7r1BumK8uvP8Akg/jz6eIv/Sq7r08oRKGDHbjGK2l0EhpTI5JA9qUADgdBT2HBxTEUZGPxqCr6ATSAZokVi2VwF60AnncAB9etL1H0GJKrTGLP7wDcR7ZqRThuaYiIJnlCjzHABb1A6VJRa1hFcwMZXII2sQ3Xpj2qYxZOafSGTBxRoh3bF24FRMwBx3p2/d1NIGwNuO/ahghyYJHFDKoIYYpgyG4/Knk5GMCgBRgUn4UDr7UpGcUhCbu2Kdz26UmKM0wDGBTe/FO7U0n1obBCHp9aevHXmogec4BPvT9x4GetCG0Kclqgv7OO9SPzBkxsGAJ4P19RVghTn5cY70meKewrvpoAAVFUHpwKTdg4PSkLZ4zTcbiOT1zSBKyJTjFNygPApTSRHEjK3fmmPoShhilPNRRg4yfXFSjjgmmQ1YidOajZcKc1MzjcFz83XFNlUvgdKlopPuUXhLgnoAOc1H9nO3dmryoTG+ScduKYilRtY5yPSsnE3VRmJ8J/wDklng3/sC2X/ohKKPhP/ySzwb/ANgWy/8ARCUV2nIM8bgnX/AoHX+2ZP8A033ldGgOSDyRXOeNm26/4FIGf+JzJx/3D7yuiTcWLNxntWNTc0jsSPwOmaYB6fyoOT07UEldoI6/pUPUG+VDgD3oBxTsiozhmGeKQLUlByBSUwcHg8U6mFhWAI6c1UtL1J5ZIgfmjOCDVsc1n3dqyS+dAoEmfm96HJRi2yoRi9GaOOKQrTIXJUE9ae7YGT2oi1LVE2adhNoxxQOKasgZd3TNMjkYyMjrjHII6EU7dQsyUk9qo6zpVjrNn9l1S2SeAMHCtkYYdCCOQfpV3pinDGPWldgR20UcMEcUChIUUKijoAOgqUnmkXjpSmjoIRhkEEZpu3aPlAH0p2aO3PNAEe/160kkmI2PfFOK80119RxUlqwi7hGq7gNwznvQAfKUtncDjJoUsoww3DPFOYs7DPAp3voA7HHejvRg5o9aYhAwBYP0NNLhnGOFH60jmmgZGRnFF9BpdSYNSbsnrUeCO9OUUr3CxL2FLnimClA560yQPIFGKdijIFArnl15/wAkI8efTxF/6VXdeoEnA9eleYXn/JCPHv8A3MX/AKVXdemYYKu7G7AyfetJ7ISJcD8ailDEDYcEGnb/AG5pVyQc1GjKWmomePmNIRkcGnNSKPWgBoBp1KcCmk0BuKKayZ5pw4pcgUMCLbg9KeD270pYU1fu/KeaYwOCM80q9KQnn8OaM0gH5GaCTjim9aTOBQKwA84pCwDAHg9qHDMqlGxzzgdR6U0keYu8gE/w0DRL1FGBS8dKKBDCOPalVARz1p1JmgLiMpJ68UMDijkUueKAGYpccU80n1oVh3EUdKUqBSZ596U8imIVTSOT2oB5p2MUBsIoHDHGfWiRsEDnPbFA+lNZhG4duABzQLqKpZgVbr2NAjJ5brTlkVn2/wAWM9O1SU7X0E20ct8J/wDklng3/sC2X/ohKKPhP/ySzwb/ANgWy/8ARCUVsSN8bf8AIweBc/8AQZk/9N95XS8VzPjcga/4Fz/0GpB/5T7yunxWNTcpbCAc8025VjA4Q4bHFKTinBsis1vcrZ3KOmtKsZSY5IPU1eIGBxTPLG7dRJnYQuKUZym25KxU5czuIXQd6VNzDjp700kOoXbz169KkjJjG3HGapIT2EUnnPUcUMc8ZpDk5PelUKQMAg0bi0HKoHNNcj8KceMDNMYZai1gQ11DIV6e9KpOAD1HGaBjOc59qU4JqWrleQPkjimoWJ5p/wB7gUuOfend9BX6C45o7U1zzgUZ45poVgLc0p6UgCjJPApqSxykiN1YgdjRZvYLrYdk0xjzzSuyjvyKidgASuT9KRSRMvTGaeMVCu4AFhTskdKSE0SYpDwKBk0uAwqtySteZVcr1qNbpQiowwf0p+oo5tmMTBWHcjNULCRdQMqmNlMRAO4cGlKSikzWHvJ3Wi6morBl4p3eq9rE0WVfnB4+lW8cVKkpbEysnoIKAegJ5PSg/pTFLbcgA46Zq9kTa49W6gjGKRjmmRd89aeRQO1meY3Zz8B/Hn08Rf8ApVd16DouoyalbvLJbNAobC7j94etefXf/JB/Hn08Rf8ApVd16icKMLxWstkQiM9c/pT0Iz0pMZPNLjFZopjYlkXf5j7ssSuBjA9KVjTj2pOooFchflgAAfUUJgcDvnA9KemN7DjP86R1yyk/fHpQXfoLjJx09aGUAZBOPehsg9aaSSeaBABgY/WlCjqTzQc44ppJz3oGP4xTSQCKBnrTCrv8wHy+/elq3oCRMpBFBFRRjaMjoacHok7BbsOAJpxOF3Y5FQRTs7OGiZUXgMf4j7Cp2PYfrTafUl6OzIrZT5akkkn1pZZdrhFBdz2HYVHKJIiGjGV7j2p1v9+RiCGfnJ6AUays2U/5gjcsxV1KMOme4qXFRFd7RAkO6HJb0qU/pT9BMM+g5pedwBGKOhzTQRkAZxRshFK+muIH3xpvH9wclj7Vct5GkhHmKFkxyByAaVmBBz9KFVeqiphGEVZLUcm2krDiuKXNM5AbqfQGkDEqCV2nuDVCsOJp2ePWmgZPNHTseKAFFNmXfHgYHPB96XPNIecfXNAEhUqN5OWC44ohk3xBietIXJWmqoUAU766Ctpqc78J/wDklng3/sC2X/ohKKPhP/ySzwb/ANgWy/8ARCUVsQReOgW13wMFOD/bUnP/AHD7yuoQ/IuefrXNeNRnxB4FH/UZk/8ATdeV0wXbxmsKnNzrsWtrCFc0hyB7U7saQ/dqRjc8cdac20oQ/Q00DvTWdMsrkfjQga7CRRJH/qgMevWph0rLS5aGU7lbymOA1aanI9jRKLjLUqcZLWQmKjlgLuHWVl4xgdKnxkVEcliOQKXkJN9BwzgZOaUjigfWlNNaCG0jDFBODS5z24pDI+QwIPNSg7uvemsMChAx57UXsD1I5WZGQKhKk8n0p/vStnvQTkU9w6EdxzAy888VVsbQWksnzD96eO2KtlvxqG4cgKGXIc4HtSbla0XZFJeRNNhU2oR83BpvzwRZZSwU/nSrF9njwgLntntVWKW4k3CcdDgjFLS+oRTe2xNDPFKu9NwLHBFWVXjFVFt08zzBnPpnj8qk86UPKPIYoi5DA/ePoBVJSbfYmbUbLuTkHFImVwOtRafcNd2qyvEYWPVG6ipT9aPRjaabixZRuUqfusMU2MbQP506k6cAUmk9xdLC9TSMSMAYyaTdxjGKinZ/LYIvzLz83AI+tOyuGxK/7vAZsg8UGRURSw6VSto3lhd7wjzATgA8L7CraOHG1fmGOTRdX0Ww7CI4aViOFPape49KaqDtxzTJpkgAMxChm2r75oScmJ6tJHm15/yQfx79PEX/AKVXdeoFhXl93/yQfx59PEX/AKVXdemgZFaT2REQVyT8qkj1pQ4IyD0pQRgYbAHagBeSBwagoTP50ZGOTS/hQRxQAxgDj2pBwfendO4pp68UikBalUfnSYNOHyjNMB1JgYpolyOBzTdzE0X6Csxz8A4GaAzdSBnHTNMYnGRSblwByWpFW0JEQkYPFJs5welOU8e5pwpk3YADHTmjt6U2ZjHGXwW2jO0d6bbTCeJWZDG5XJRuoqVOPM4dRW0uPJyKYwGMdAakK0gFUNMTcI4HYAEKCeOM0yGYS28c2NodQ30zT3A2kEZU8EeoqICLYgJxG3yqo7Ypq72DzJs5HHSnIDtGKiljaMhouQOo9aehJXdyB6UC6aEciZY+lCAipdp7nGaBxwaFoO+lhCcKT7UzaoALksxx36VJjj2pgVgQODjoTQIUAqGA5I4GaMMQM4H0pRwOTk1G75kRc4B70vIaHqM496UYpAAMr6e9J/FTAkBFKSKb0XNIPWgVjnfhP/ySzwb/ANgWy/8ARCUUfCf/AJJZ4N/7Atl/6ISitzMb4148QeBf+w1J/wCm+8rpWJ5rmPHLBNd8DFiABrMnJ/7B95XSoSQCQQTzisp7lxWlyRcFaTimNgHg0qms7DsBpjZUHK7h1p7dM0vX5u57UbBcgWPco3KAvYHtVhRxg0nQADtSk1EaaTuNtsX6Ug9KUkLjNNBBPXtWhINxSA5HNLjPel245pDGH6ULnPSnMtAGMUmFxHZV696Eb5cDFJLH5gxzj2qKJQpCDOKblFeo0k0TMD161C7c1NKdpHvUJXJpN6DiJ1FLMBJBsK55pwXFNJwCO1TcrqQGCZSpVzkHPNWNwY5KgMetAfqBn8aazYIXimG5J27U9T2qFcnpT+QKaJaH8LnaMZ5NMxzSjJHSndOaEklZC2Gd6OgB55NPHPpSgUA2NXEinB5/kagvbdriB0LbXx8rADg/TvUttCYmfn5SxanSv8uRVRfvXXQmUVL3d0Yml6e9nGI52JQAAKshIGBjPPr6VrRZCIM4IqJJl3bWO09AG4zUgJBznNQ04vV3NnLmJI9zKSD07U4AOBkA1GF3DOT68VIo2inchnmV2MfAfx4M548Rf+lV3XpwOK8xu/8Akg/jz6eIv/Sq7r07J6PjNaz0SM4iYHGQDTh9OKaygjIp6EDjNQimNbFO4K9CaTqc04dDTBkWF/ukUqjilYAjGODUaMkbBFVhnoeTSW9h7okAzk/pRjikLLuxnBp4GRwRQIbt5oI5woyajjMochwCvYipSSORgUaDejGnrzSEAdKUcnkilI5oAaP504nAzQBilI4oYDFkBOMZFZ9to0UN+93HNKpckum75ck9R6VeKqG5HFS8Y4qoTcb2YS2cVsw4ySOM0U3npS9Km9xWA4NQvCChG0HB3L7GpgKU96LDvbYQSA4JODjpQDlTim4BOcc07FF+4WQu7P1oX5s5wG9KAcGodgTzGTO5jk5P8qa1e4rE3el7UxGXJwcjjvUhxRYGNokVXXBUEfSjpRmi9gGEYIC9aM7fT8KceueuRg0gHYUDFJzxSnpTcYPFP/CgRzfwn/5JZ4N/7Atl/wCiEoo+E/8AySzwb/2BbL/0QlFbmZB4/QSaz4HUnAOsyc/9w+8rpY2wgGSSB1rk/iZqNjpV/wCCr3Vby2srKLWX8ye5lWONM2F4BlmIAySB9SKVviH4KDDb4w8OHA/6CcHH/j1YVFJzVnoaRfu2OryT1oH41yw+IfgnP/I4+G//AAZwf/FUp+IngnZgeMPDef8AsJwf/FVOpV0dXuAOCaAwJyK5UfEPwOG/5G/w22Byf7Ug5/8AHqU/ETwSJFA8YeG9hH/QTg4/8eosxXR0xctJ5ceM9TThkNtY5Ncl/wALB8ErceYni/w2OMf8hSD/AOKpyfEXwWSWfxj4cJ6f8hOD/wCKofYbt0Otl5TioAcMzH0wPeuePxF8EEf8jj4c/wDBpB/8VVaT4heCWQ58XeHM9v8AiZw//FU7MUX0OzHNOrkoviP4K3EN4w8OD0P9qQf/ABVOb4jeCc8eMfDf/g0g/wDiqUVoT1OqpD2zXLf8LF8E5/5HLw3n/sKQf/FUh+I3gj/ocfDh/wC4pB/8VRZgdUx5601lG4Eda5X/AIWR4L6f8Jh4b+v9pwf/ABVA+I/gnOW8YeHM/wDYTg/+KocbjR1JXJyTk0hxXLn4jeCT/wAzh4b/APBnB/8AFU0/EPwT/wBDj4b/APBpB/8AFUWfUaZ1JNJ1rl/+FieCeP8AisPDn/g0g/8AiqafiJ4Kwf8AisPDn/gzg/8AiqVhpo6pQAc4pCoLZwMjvXLH4h+CgM/8Jh4c/wDBnB/8VSj4ieCc/wDI4eHP/BnB/wDFUWHc6jIUcnmmNLnJAyB1NcxJ8Q/BRbjxh4c4/wConB/8VUy/EDwNsAPjHw2CO41SD/4qhRb0Qrpas31ulHH9KcGlc5VPkPfNcy3xA8EAFpfGfh2TB4A1KD/4qp4/iL4HCD/isPDYB7f2nB/8VVKLvZg5Jao6Q7XgI3cnjKmq4aa1IMr+ZCf4iOV+tc1J8Q/BBnATxd4dCjnP9pw9f++qmf4h+CWQqfGPhvkY/wCQnB/8VRrZoNEdSrOy5Urg9PpVWaYiF8jDgdK5xfiX4KRNn/CW+HsDgY1OH/4qmy+P/A5QkeL/AA4SRjH9pwE/+hU1fS4LfU19PsReW4mlY5Ofw5qzbl43aFyW29G9RXJR+PvCNtuEPjDw2yMcgf2nDx/49U9v4/8ABm8vL4w8Obj/ANROD/4qspXd273/AENNVe7VjsVPPFPB7cVyg+Ivghsj/hMPDo/7iUP/AMVR/wALE8Ej/mcPDn/g0h/+KoszO6Zz13/yQfx59PEX/pVd16YQS2e3vXlouILz9nzxtc2k0c9tNH4hkiliYMkiG5uyGUjggg5BFda3xE8EH/mcvDf/AINIP/iq3mrpERdjpwOOKcFxzXLj4i+CAP8AkcfDf/g0g/8AiqD8RvBH/Q4+G/8AwaQf/FVNgudPjBoJOK5c/EXwRj/kcfDf/g0g/wDiqaPiP4IPH/CYeHR/3E4P/iqVhnU49aXj15rlj8RPBH/Q4+G//BpB/wDFUx/iJ4JIP/FY+HP/AAaQf/FUw3OqJDcGkCbDkE81yzfELwPldnjDw4D3P9qQf/FU/wD4WL4Ixj/hMfDZH/YUg/8AiqLMLnUEjPSjgsBXKn4ieCB/zOHhv8NTg/8AiqP+Fi+CSP8AkcfDn/gzg/8AiqAOrPOeBxTVJxzXKn4ieCjwfGPhzH/YTg/+Kpk/xF8GBP3fjHw3nHH/ABM4T/7NSd+g0uh15YAc0Kc9ORXF23xB8FeY3neMPDrHtnU4Mf8AodSRfELwVHO4HjHw4Y+o/wCJnBx/49TswaS0OslUmli4GM1zR+Ivggj/AJHHw3/4NIP/AIqmH4i+Cf8AocfDf/g0g/8AiqXLYOa6sdX2pM81y3/CxfBJH/I4+G//AAaQf/FUg+IngnP/ACOHhwf9xSD/AOKp2EdVmmOeVUfePQVzP/CxPBP/AEOPhv8A8GkH/wAVTf8AhYnggPu/4TDw3kDAP9pwcf8Aj1Kw0zqDG6qW4BHPFRxSM53Bv+A46VzjfEnwXsx/wmHh3d7anB/8VTY/iJ4JUY/4TDw4P+4nB/8AFUWHfTU6hs801sqjEdcVzTfETwTz/wAVh4c/8GcH/wAVSH4ieCT18YeHMf8AYTg/+Los9gTOmt4EWEODvLfeJP8AKpkOF9q5GPx/4HU8eMfDgHp/akH/AMVUp+Ingn/ocfDf/g0g/wDiqaVtEhSd3udZwaTFcoPiL4J/6HHw5/4NIP8A4ql/4WN4J/6HHw3/AODOD/4qgk6hsDAJ69KUfL1rlz8RfBBHPjDw2f8AuKQf/FVSv/iH4OlaKKLxl4dVXPzONTg+Uf8AfVFrDWp2gIJODmlPGfeuLfxz4It0D2/jTw+XU9DqsJ3fhuqyPiN4KJBPjDw50/6CkH/xVFtbBpuWPhP/AMks8G/9gWy/9EJRR8J/+SWeDf8AsC2X/ohKK3MzqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Eggs of",
"    <em>",
"     O. viverrini",
"    </em>",
"    in an unstained wet mount of concentrated stool. Images taken at 400x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Clonorchiasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/opisthorchiasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/opisthorchiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5330=[""].join("\n");
var outline_f5_13_5330=null;
var title_f5_13_5331="US U funnel cervix";
var content_f5_13_5331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    US U funnel cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nearly completely effaced cervix, with \"U-shaped\" funnel. Membranes are seen prolapsing just beyond the internal os. Note the cerclage visible in the anterior and posterior lips of the cervix. The LUS is thin and bulging somewhat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey R. Johnson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5331=[""].join("\n");
var outline_f5_13_5331=null;
var title_f5_13_5332="Ganirelix: Patient drug information";
var content_f5_13_5332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ganirelix: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30099?source=see_link\">",
"     see \"Ganirelix: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Orgalutran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700271",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug if you are pregnant. A pregnancy test will be done to show that you are NOT pregnant before starting this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ganirelix or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit working out while undergoing ovarian stimulation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699109",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11955 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-1FFB8D27E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5332=[""].join("\n");
var outline_f5_13_5332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177286\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026317\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026319\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026318\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026323\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026324\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026326\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026321\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026322\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026327\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026328\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30099?source=related_link\">",
"      Ganirelix: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_13_5333="Progressive calciphylaxis";
var content_f5_13_5333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Progressive calciphylaxis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ischemic changes observed clinically as livedo reticularis prior to development of necrotic ulcer with eschar that is clinically evident in the calciphylaxis lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter W Santos, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5333=[""].join("\n");
var outline_f5_13_5333=null;
var title_f5_13_5334="Female condoms";
var content_f5_13_5334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Female condoms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Theresa Hatzell Hoke, PhD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Katherine M Stone, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Markus J Steiner, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Lee Warner, PhD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Willard Cates, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5334/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/13/5334/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The female condom covers the cervix, lines the vagina and shields the introitus, thus providing a physical barrier between male and female genitalia and secretions during sexual intercourse. It is designed to protect against both pregnancy and sexually transmitted infections (STIs), and is available without prescription. No contraindications exist to its use, but it may not be appropriate for women who are not comfortable touching their genitals or who may have other problems with insertion. Female condoms account for less than 1 percent of condoms produced globally [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FEMALE CONDOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All female condoms currently available or in development have an anchor (eg, ring, frame) outside the vagina to prevent the condom from being pushed inside the vagina during use; the anchor is also used for removing the condom. Female condoms have been made out of natural rubber latex, synthetic latex (nitrile), and polyurethane. They prevent preejaculatory fluid and semen from entering the vagina. No spermicide is required, but a lubricant is often needed.",
"   </p>",
"   <p>",
"    The FC1 (Reality&reg;, Femy&reg;, Care Contraceptive Sheath&reg;, Femidom&reg;) was the first condom marketed to women, but is no longer in production. It was a soft, loose-fitting polyurethane sheath or pouch with two flexible polyurethane rings. One ring was contained within the closed end of the sheath and served as an insertion mechanism and internal anchor. The other ring formed the external, open edge of the device; it remained outside the vagina after insertion. Silicone-based lubricant lined the inside of the condom, but additional lubrication for the inside",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    outside could be used. The condom was about 17 cm (6.5 inches) in length (similar to a male condom). The expiration date was five years from the date of manufacture.",
"   </p>",
"   <p>",
"    Variations to the FC1 have been developed. Most widely available today, the FC2 replaced the FC1 and is similar in design, but made of nitrile and without a seam. In comparative trials, it performed as well as the FC1 in terms of patient satisfaction, breakage, slippage, and invagination (ie, when the outer frame of the condom pushes into the vagina during intercourse) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. No data on pregnancy prevention or STI prevention are available, but effectiveness is assumed to be similar to the FC1 given the similar design, specifications, and functionality. The FC2 is indicated for preventing pregnancy,",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    and other sexually transmitted infections [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/4\">",
"     4",
"    </a>",
"    ]. It may make less noise during intercourse than the FC1 and is projected to be cheaper when mass produced. It is available in about 100 countries. It has been approved by United States Food and Drug Administration (FDA); has CE Marking, which certifies that the device meets consumer safety standards and can be marketed in countries in the European Union; and has been cleared by the World Health Organization (WHO) for purchase by United Nations agencies.",
"   </p>",
"   <p>",
"    The Program for Appropriate Technology in Health (PATH) Woman's Condom (WC) is another recently developed female condom [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/5\">",
"     5",
"    </a>",
"    ]. It is made of polyurethane and inserted using an insertion capsule, which dissolves after insertion and releases the condom. Hydrophilic areas on the condom allow it to cling lightly to the vaginal wall and keep it in place. It is not prelubricated, but is sold with a water-based lubricant [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/6\">",
"     6",
"    </a>",
"    ]. The WC was granted CE Marking in 2010. To support market registration in China, a single-arm couples&rsquo; use study was conducted to assess WC performance and safety. The study showed levels of functionality consistent with condom performance data from other female condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The VA w.o.w&reg; (worn of women) (also known by the brand names Condom Feminine&reg;, L'amour female condom, Reddy FC) is made of natural rubber latex and is available in some parts of Europe, Asia, and Latin America. It has been granted CE Marking and India Drug Control Authority approval. The condom has a medical grade sponge at one end that is used for insertion; the other end has a triangular frame to anchor it outside the vagina. It is prelubricated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other female condoms with more limited availability include the polyurethane Phoenurse, manufactured and distributed in China [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/8\">",
"     8",
"    </a>",
"    ]; the natural rubber latex Cupid FC, manufactured and distributed in India [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/6\">",
"     6",
"    </a>",
"    ]; and the Natural Sensation Panty Condom, available in parts of Europe and South America [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No published randomized trials have compared the clinical effectiveness of male and female condoms for prevention of either pregnancy or STIs (including HIV). However, two randomized crossover trials in the United States and Brazil used the proxy measures of breakage, slippage, and prostate-specific antigen (PSA) as indicators of semen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Participants used both condom types, completed condom-specific questionnaires to report problems, and collected precoital and postcoital samples of vaginal fluid for PSA. Although PSA detection rates were similar for both female and male condoms, users in both trials reported female condoms were associated with significantly more mechanical problems (eg, slippage, breakage, incorrect penetration) than male condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pregnancy prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most rigorous data regarding contraceptive effectiveness of female condoms were derived from a cohort study of 221 couples using the FC1 (Reality) female condom [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/12\">",
"     12",
"    </a>",
"    ]. The estimated rates of pregnancy during the first 12 months of perfect use and typical use were 5 and 21 percent, respectively; these pregnancy rates are higher than those associated with use of the male condom (perfect and typical use pregnancy rates of 2 and 18 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/13\">",
"     13",
"    </a>",
"    ]). The effectiveness of the FC2 is assumed to be similar to that of the FC1, given its similar design, specifications, and functionality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies conducted with FC1 have suggested somewhat lower pregnancy rates with use of female condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sexually transmitted infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of laboratory and clinical studies suggest that female condoms help to protect against transmission of STIs, but data are much more limited than for male condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/16-24\">",
"     16-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30696?source=see_link\">",
"     \"Male condoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro data suggest the female condom may provide an impermeable barrier to HIV and cytomegalovirus, as well as other STIs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], but no clinical studies have specifically evaluated the female condom's ability to prevent HIV transmission. Two of three randomized trials of behavioral interventions to promote use of the female condom observed that groups assigned to use FC1 had lower STI rates than groups assigned to use male condoms, but the differences were not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In the third trial, the STI rate in the group who only had access to male condoms was the same as that for the group with access to both male and female condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An observational study provided evidence that adding female condoms (FC1) to a male condom distribution program targeting sex workers significantly increased the proportion of protected sex acts and significantly reduced STI prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADVANTAGES AND DISADVANTAGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     General advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The female condom offers several contraceptive and noncontraceptive benefits to users:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is a safe, effective, reversible method of contraception with no delay in return of fertility following discontinuation of the method.",
"     </li>",
"     <li>",
"      It can be obtained without a medical examination, prescription, or special fitting.",
"     </li>",
"     <li>",
"      Its use is associated with minimal side effects since it is relatively inert and the body is exposed to it only in anticipation of coitus, not at other times.",
"     </li>",
"     <li>",
"      It provides protection against STIs and offers an option to at-risk women whose partners cannot or will not use the male condom. It offers broader coverage of external genitalia than the male condom, and thus may give better coverage against STIs transmitted via skin lesions or shedding. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Sexually transmitted infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The external ring may stimulate the clitoris, thus enhancing sexual arousal [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to male condoms, female condoms can be placed before intercourse, does not require an erect penis, and can be removed any time after ejaculation so it is potentially less disruptive of intimacy.",
"     </li>",
"     <li>",
"      In contrast to male condoms, which are usually made of latex, female condoms are usually made of synthetic materials (nitrile, polyurethane), which have several advantages: no special storage requirements are needed because synthetics are not affected by changes in temperature and dampness, oil based lubricants do not weaken synthetics, allergic reactions to synthetics are unlikely, and synthetics are stronger than latex.",
"     </li>",
"     <li>",
"      In contrast to the diaphragm, the female condom does not need to be fitted, does not require a prescription or medical examination, and is not affected by large weight changes or recent birth. It provides better protection against STIs than the diaphragm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The female condom also has disadvantages that may lead to inconsistent, incorrect, or nonuse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some women find it difficult to insert and remove.",
"     </li>",
"     <li>",
"      The outer ring is visible outside the vagina, which can be unacceptable to either partner.",
"     </li>",
"     <li>",
"      It has a higher failure rate in preventing pregnancy than nonbarrier methods and the male condom.",
"     </li>",
"     <li>",
"      It can make noise during intercourse.",
"     </li>",
"     <li>",
"      Some women feel embarrassed or uncomfortable when obtaining condoms or suggesting use of condoms.",
"     </li>",
"     <li>",
"      Female condoms are not widely available worldwide.",
"     </li>",
"     <li>",
"      Female condoms are more expensive than male condoms (about $2.50 versus less than $1.00), but are available for free or at a reduced cost through Medicaid and other family planning programs in many states [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/26-29\">",
"       26-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The female condom is a vaginal device. Unlike the male condom, it is not recommended for anal sex due to reported problems with use and sparse evidence about clinical effectiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unlike the diaphragm, the female condom should not be reused (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Reuse'",
"      </a>",
"      below). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INSTRUCTIONS FOR USE OF FC2",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The female condom should not be used concurrently with a male condom, as friction between the two condoms may cause breakage.",
"     </li>",
"     <li>",
"      The woman can assume any position she finds comfortable for inserting the condom. It can be inserted up to eight hours before intercourse. Before insertion, she should make sure the condom is adequately lubricated for passage through the vagina and to minimize noise during sex. Either water based or oil based lubricants can be used.",
"     </li>",
"     <li>",
"      The inner ring at the closed end of the FC2 is squeezed with the thumb and middle finger, and then inserted into the vaginal opening like a diaphragm. The index finger is then placed inside the condom and used to push the inner ring as far up as it will go, without allowing the condom to twist. The outer ring remains outside the vagina and extends about an inch beyond the labia.",
"     </li>",
"     <li>",
"      At intromission, it is important to ensure that the penis does not slip between the vagina and the outer surface of the condom. During intercourse, it is important to ensure that the outer ring does not get pushed into the vagina.",
"     </li>",
"     <li>",
"      The female condom can be removed any time after intercourse. It should be taken out before the woman stands up to avoid having the semen spill out. The outer ring of the condom is twisted (clockwise or counterclockwise) to seal the condom, and then pulled out and wrapped in the package it came in",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in tissue. It should be disposed of in waste containers, not in the toilet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A free interactive online FC2 training program is available for healthcare providers at www.fc2training.com.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18927040\">",
"    <span class=\"h2\">",
"     Obtaining female condoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;FC2 can be purchased online or from some pharmacies (eg, CVS, Walgreens). It is also available from some state and municipal health agencies and nonprofit organizations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guided by a 2002 expert consultation, WHO recommended use of a new male or female condom for every act of intercourse where a risk of unplanned pregnancy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    STI, including HIV, exists. Panelists acknowledged, however, that this may be difficult for some women because of cost or access. One approach to this problem is reusing the device. Different protocols for disinfecting FC1 have been evaluated for their safety and effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5334/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. These studies provided evidence supporting the safety of FC1 re-use. Since no data yet exist supporting re-use of other&nbsp;female condoms, including FC2, additional studies would be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"       \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FC2 female condom is a loose-fitting nitrile sheath with two flexible rings. After insertion, one ring serves as an internal anchor deep in the vagina and the other forms the external, open edge of the device. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Female condoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best estimates for the rates of pregnancy during the first 12 months of perfect use and typical use of the FC2 female condom are 5 and 21 percent, respectively; these rates are higher than those associated with use of the male condom (perfect and typical use pregnancy rates of 2 and 18 percent, respectively). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pregnancy prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of female condoms can provide protection from acquisition and transmission of sexually transmitted infections, although data are limited. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Sexually transmitted infections'",
"      </a>",
"      above.) In couples at risk of infection who cannot use a male condom, we recommend use of the female condom (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The female condom is a useful alternative to the male condom for couples who want to use &ldquo;dual methods&rdquo; (ie, condoms along with another contraceptive) in order to achieve simultaneous protection from sexually transmitted infections (STIs) and pregnancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pregnancy prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Sexually transmitted infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The female condom offers several advantages over the male condom (eg, it can be placed before intercourse, does not need to be removed immediately after ejaculation, and is not made of latex), as well as some disadvantages (eg, it is more expensive and should not be used for anal intercourse). Compared to the diaphragm, the female condom should provide better protection against acquisition of STIs, but, unlike the diaphragm, is not intended to be reused. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General advantages'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'General disadvantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The female condom should not be used with the male condom. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Instructions for use of FC2'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13705431\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for this topic review was provided with funds from the United States Agency for International Development (USAID) cooperative agreement GHO-A-00-09-00016-00 Preventive Technologies Agreement. The views expressed in this review, however, do not necessarily reflect those of USAID.",
"   </p>",
"   <p>",
"    The findings and conclusions in this topic review are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Center for Health and Gender Equity. Saving lives now: Female condoms and the role of US foreign aid. Takoma Park, MD, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/2\">",
"      Smit J, Beksinska M, Vijayakumar G, Mabude Z. Short-term acceptability of the Reality polyurethane female condom and a synthetic latex prototype: a randomized crossover trial among South African women. Contraception 2006; 73:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/3\">",
"      Beksinska M, Smit J, Mabude Z, et al. Performance of the Reality polyurethane female condom and a synthetic latex prototype: a randomized crossover trial among South African women. Contraception 2006; 73:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/4\">",
"      Second generation of female condom receives FDA committee approval. Contraceptive Technology Update 2009; 30:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/5\">",
"      Schwartz JL, Barnhart K, Creinin MD, et al. Comparative crossover study of the PATH Woman's Condom and the FC Female Condom. Contraception 2008; 78:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/6\">",
"      Beksinska M, Smit J, Joanis C, et al. Female condom technology: new products and regulatory issues. Contraception 2011; 83:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/7\">",
"      Zirong H, Junqing W, Coffey PS, et al. Performance of the woman's condom among couples in Shanghai, China. Eur J Contracept Reprod Health Care 2012; 17:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/8\">",
"      Hou LY, Qiu HY, Zhao YZ, et al. A crossover comparison of two types of female condom. Int J Gynaecol Obstet 2010; 108:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/9\">",
"      Galv&atilde;o LW, Oliveira LC, D&iacute;az J, et al. Effectiveness of female and male condoms in preventing exposure to semen during vaginal intercourse: a randomized trial. Contraception 2005; 71:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/10\">",
"      Macaluso M, Blackwell R, Jamieson DJ, et al. Efficacy of the male latex condom and of the female polyurethane condom as barriers to semen during intercourse: a randomized clinical trial. Am J Epidemiol 2007; 166:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/11\">",
"      Chen MP, Macaluso M, Blackwell R, et al. Self-reported mechanical problems during condom use and semen exposure. Comparison of two randomized trials in the United States of America and Brazil. Sex Transm Dis 2007; 34:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/12\">",
"      Farr G, Gabelnick H, Sturgen K, Dorflinger L. Contraceptive efficacy and acceptability of the female condom. Am J Public Health 1994; 84:1960.",
"     </a>",
"    </li>",
"    <li>",
"     Trussell J. Contraceptive Efficacy. In: Contraceptive Technology, 20th ed, Hatcher RA, Trussell J, Nelson AL, et al.  (Eds), Ardent Media, New York 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/14\">",
"      Bounds, W, Guillebaud, J, Newman, GG. Female condom (Femidom). A clinical study of its use-effectiveness and patient acceptability. The British Journal of Family Planning 1992; 18:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/15\">",
"      Trussell, J. Contraceptive efficacy of the Reality female condom. Contraception 1998; 58:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/16\">",
"      Vijayakumar G, Mabude Z, Smit J, et al. A review of female-condom effectiveness: patterns of use and impact on protected sex acts and STI incidence. Int J STD AIDS 2006; 17:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/17\">",
"      Drew WL, Blair M, Miner RC, Conant M. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990; 17:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/18\">",
"      Voeller B, Coulter SL, Mayhan KG. Gas, dye, and viral transport through polyurethane condoms. JAMA 1991; 266:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/19\">",
"      Soper DE, Shoupe D, Shangold GA, et al. Prevention of vaginal trichomoniasis by compliant use of the female condom. Sex Transm Dis 1993; 20:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/20\">",
"      French PP, Latka M, Gollub EL, et al. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis 2003; 30:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/21\">",
"      Fontanet AL, Saba J, Chandelying V, et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS 1998; 12:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/22\">",
"      Hoke TH, Feldblum PJ, Van Damme K, et al. Temporal trends in sexually transmitted infection prevalence and condom use following introduction of the female condom to Madagascar sex workers. Int J STD AIDS 2007; 18:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/23\">",
"      Feldblum PJ, Kuyoh MA, Bwayo JJ, et al. Female condom introduction and sexually transmitted infection prevalence: results of a community intervention trial in Kenya. AIDS 2001; 15:1037.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health and Human Services, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010. www.cdc.gov/std/treatment/2010. (Accessed May 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/25\">",
"      Philpott A, Knerr W, Boydell V. Pleasure and prevention: when good sex is safer sex. Reprod Health Matters 2006; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/26\">",
"      Witte SS, Stefano K, Hawkins C. Can medicaid reimbursement help give female condoms a second chance in the United States? Am J Public Health 2010; 100:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/27\">",
"      Hoffman S, Mantell J, Exner T, Stein Z. The future of the female condom. Perspect Sex Reprod Health 2004; 36:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/28\">",
"      Hatzell T, Feldblum PJ, Homan RK, Gmach RD. The female condom: is \"just as good\" good enough? Sex Transm Dis 2003; 30:440.",
"     </a>",
"    </li>",
"    <li>",
"     Peterson, K, Herman, L, Fiske, L, Marseille, E, Kahn, JG. Smarter Programming of the Female Condom: Increasing Its Impact on HIV Prevention in the Developing World. FSG Social Impact Advisors, Boston 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/30\">",
"      Renzi C, Tabet SR, Stucky JA, et al. Safety and acceptability of the Reality condom for anal sex among men who have sex with men. AIDS 2003; 17:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/31\">",
"      Joanis C, Latka M, Glover LH, Hamel S. Structural integrity of the female condom after a single use, washing, and disinfection. Contraception 2000; 62:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/32\">",
"      Potter B, Gerofi J, Pope M, Farley T. Structural integrity of the polyurethane female condom after multiple cycles of disinfection, washing, drying and relubrication. Contraception 2003; 67:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5334/abstract/33\">",
"      Pettifor AE, Rees HV, Beksinska ME, et al. In vitro assessment of the structural integrity of the female condom after multiple wash, dry, and re-lubrication cycles. Contraception 2000; 61:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5471 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-C85CA16B23-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5334=[""].join("\n");
var outline_f5_13_5334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FEMALE CONDOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pregnancy prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADVANTAGES AND DISADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      General advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INSTRUCTIONS FOR USE OF FC2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18927040\">",
"      Obtaining female condoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13705431\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30696?source=related_link\">",
"      Male condoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=related_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_13_5335="Transtentorial herniation";
var content_f5_13_5335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Transtentorial herniation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 597px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pulm, F, Posner, JB. The Diagnosis of Stupor and Coma III. FA Davis, Philadelphia 1982. p. 103.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5335=[""].join("\n");
var outline_f5_13_5335=null;
var title_f5_13_5336="Dermatitis of the vulva";
var content_f5_13_5336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dermatitis of the vulva",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5336/contributors\">",
"     Elizabeth Gunther Stewart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5336/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5336/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5336/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5336/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/13/5336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar dermatitis (also called vulvar eczema) is the most common vulvar dermatosis in women. One-third to one-half of women's vulvar complaints stem from this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It can develop in isolation or may occur as part of dermatitis in other areas of the body.",
"   </p>",
"   <p>",
"    Women with vulvar dermatitis experience chronic irritation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pruritus, which causes them to persistently rub and scratch the vulva. These activities lead to histological changes in the dermis, termed squamous hyperplasia or lichen simplex chronicus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENDOGENOUS VERSUS EXOGENOUS DERMATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two types of vulvar dermatitis are endogenous and exogenous.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endogenous vulvar dermatitis is the term used to describe atopic dermatitis of the vulva. Atopic dermatitis has a familial predisposition, often begins in childhood, and is characterized by pruritus. Although some experts feel that vulvar involvement is unusual, even when there is severe and widespread atopic dermatitis elsewhere (",
"      <a class=\"graphic graphic_picture graphicRef52163 \" href=\"UTD.htm?27/57/28575\">",
"       picture 1",
"      </a>",
"      ), others believe it is more prevalent than previously acknowledged [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. In women with atopic dermatitis at nongenital periorificial sites, the occurrence of erythema in the labial folds, the perianal region, and in the skin between the buttocks probably represents endogenous vulvar dermatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exogenous vulvar dermatitis results from external factors, and is also called contact dermatitis (",
"      <a class=\"graphic graphic_picture graphicRef85722 graphicRef66955 \" href=\"UTD.htm?5/24/5513\">",
"       picture 2A-B",
"      </a>",
"      ). In allergic contact dermatitis (20 percent of cases), the trigger (allergen) induces an immune response, while in irritant contact dermatitis (80 percent of cases), the trigger (irritant) itself directly damages the skin. Although exposure to irritants may have been the initial cause of the dermatitis, secondary sensitization to allergens can also occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common agents that cause irritant or allergic contact dermatitis of the vulva are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef71478 \" href=\"UTD.htm?31/27/32188\">",
"     table 1",
"    </a>",
"    ). Active and inert constituents of topical medications are a very common etiology of allergic dermatitis of the vulva in women with persistent vulvar symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/6\">",
"     6",
"    </a>",
"    ]. Sensitivity to latex or proteins in seminal plasma are infrequent etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of dermatitis\", section on 'Contact dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar tissue is more permeable than exposed skin due to differences in structure, occlusion, hydration, and susceptibility to friction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/8\">",
"     8",
"    </a>",
"    ]. The vulvar skin is particularly vulnerable to irritants. Compared with other body regions, the stratum corneum overlying the vulva appears to function less efficiently as a barrier, thereby permitting increased susceptibility to irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/9\">",
"     9",
"    </a>",
"    ]. As an example, benzalkonium chloride and maleic acid induce a greater response after application to normal vulvar skin than when applied to the skin of the forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vulvar skin is also sensitive to allergens. New exposure to an allergen is most likely to induce a reaction, although patients may also react to products that they have used for months or years. In contrast to the immediate response to irritants, an allergic reaction takes from 12 to 72 hours to develop, is usually pruritic, and often lasts for several weeks. In acute cases, an exposure occurring up to two weeks prior to the dermatitis can often be identified. In chronic cases, the dermatitis may have been present for months or years; identifying the offending trigger in these patients can be difficult.",
"   </p>",
"   <p>",
"    Self-medication and persistent rubbing and scratching because of pruritus and excessive washing of the vulva by women fearful of a lack of cleanliness often aggravate the dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptom of vulvar dermatitis is pruritus, which can be intense and nocturnal. Other symptoms include burning, rawness, or stinging. Symptoms may be exacerbated by heat, sweat, stress, or menstruation. The diagnosis is clinical, based upon a history of chronic vulvar irritation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pruritus causing persistent rubbing and scratching.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with vulvar complaints should be questioned regarding a personal or family history of atopy, asthma, rhinitis, conjunctivitis, or hives. The presence of symptoms indicating skin involvement elsewhere on the body or chronic pruritus should be ascertained. Specific areas to address in the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What are her major complaints? Pruritus can vary from mild to intolerable, sometimes interfering with sleep or other activities. When the dermatitis involves mucosal areas, burning, rawness, and stinging are more common than pruritus and the symptoms are often exacerbated during menstruation and with coitus.",
"     </li>",
"     <li>",
"      What are her hygienic practices (eg, daily use of panty liners, feminine products, baby wipes)? Women often erroneously regard their personal practices as safe since they have engaged in them for a long time.",
"     </li>",
"     <li>",
"      Does she wear occlusive clothing, such as tight lycra garments, or confining undergarments, such as non-cotton underwear or thongs? These types of garments trap sweat, promote candidiasis, and chafe the skin.",
"     </li>",
"     <li>",
"      Does she apply any medications (antifungal drugs) or other agents (eg, contraceptives, perfumed or deodorant soaps) to the vulva? Women seldom reveal this information unless asked directly. Patients with vulvar dermatitis have often been treated with multiple antifungal agents without success. A report that these creams never helped their symptoms is significant information, indicating that candida is probably not the source of the complaints.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The answers to these questions help to differentiate an endogenous process (eg, atopy) from that induced by an exogenous agent. Conscientious analysis of the woman's personal practices is the best way to detect potential irritants and allergens in her environment, as well as habits unhealthy for the vulvar skin. In a study of 530 women attending a specialty clinic for vulvar diseases, over 60 percent of patients described adverse personal hygiene",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    self-treatment practices when specifically questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute vulvar dermatitis &minus; In acute cases, the skin displays mild to severe erythema of varying extent with some scaling in dry areas. Fissures may be present along the labial folds. Excoriations from scratching are common and can be complicated by secondary infection with yeast or bacteria (eg, Staphylococcus aureus, Streptococcus pyogenes, or Escherichia coli). Although crusts and scales are commonly observed with dermatitis elsewhere on the body, these signs are often not present in the moist areas of the vulva.",
"     </li>",
"     <li>",
"      Chronic vulvar dermatitis &minus; In chronic cases, the vulvar mucosa is erythematous and may display papillae, a sign of chronic inflammation. Papillomatosis is not a cause of vulvar pain. The origin of vulvar papillomatosis is uncertain; the papillae can be normal anatomical variants of the vestibular mucosa or a postinflammatory change (",
"      <a class=\"graphic graphic_picture graphicRef75027 \" href=\"UTD.htm?25/2/25633\">",
"       picture 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In response to the epithelial disruption and persistent irritation, the patient chronically rubs her skin, which thickens in a way that enhances the appearance of the normal crosshatch markings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Ultimately, the vulva become hypopigmented or hyperpigmented, and may show hyperkeratosis (hypertrophy of the epidermis). Labial skin folds appear greatly exaggerated, often edematous, and pubic hair can be broken or sparse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/6,14\">",
"     6,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The resulting appearance is typical of lichenification and is called lichen simplex chronicus (squamous cell hyperplasia) (",
"    <a class=\"graphic graphic_picture graphicRef69453 \" href=\"UTD.htm?19/11/19634\">",
"     picture 4",
"    </a>",
"    ), the end-stage reactive process occurring in response to chronic irritation and scratching from any cause (",
"    <a class=\"graphic graphic_picture graphicRef69453 \" href=\"UTD.htm?19/11/19634\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/16\">",
"     16",
"    </a>",
"    ]. Lichen simplex chronicus is diagnosed when anatomic and clinical findings have excluded specific causes of hyperplastic epithelial changes, such as lichen sclerosus and lichen planus (",
"    <a class=\"graphic graphic_picture graphicRef85726 graphicRef78574 \" href=\"UTD.htm?28/54/29545\">",
"     picture 5A-B",
"    </a>",
"    ), psoriasis, seborrheic dermatosis, human papillomavirus infection, and Candida infection. The histology of lichen simplex chronicus (squamous cell hyperplasia) consists of elongation, widening of the rete ridges and irregular thickening of the Malpighian layer of rete ridges (acanthosis), hyperkeratosis, and parakeratosis with a mid-dermal inflammatory infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal discharge is usually unremarkable in women with vulvar dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patch test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patch testing may be required to distinguish between atopic and contact dermatitis; biopsy is not helpful. Patch testing is also useful to determine the cause of contact dermatitis. The recommended patch test series are a standard series, a panel of common medications, the patient's own topical medications, popular remedies, and other suspected products [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/18\">",
"     18",
"    </a>",
"    ]. In the United States, the standard series that includes the most common and important allergens is the North American series, administered by some dermatologists and allergists. Positive patch tests for relevant substances occur in 25 to 60 percent of women with vulvar pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/6,19-22\">",
"     6,19-22",
"    </a>",
"    ]. Skin prick tests are an alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A biopsy should be performed when the diagnosis cannot be determined after visual inspection and culture. Lichen sclerosus, lichen planus, psoriasis, and most primary diseases of the vulva (eg, vulvar intraepithelial neoplasia) display distinct histologic features that establish these diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatoses, infection, and primary diseases of the vulva are all sources of vulvar complaints (",
"    <a class=\"graphic graphic_table graphicRef63761 \" href=\"UTD.htm?6/61/7131\">",
"     table 2",
"    </a>",
"    ). Vulvar lesions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=see_link\">",
"     \"Diagnostic evaluation of vulvar lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=see_link\">",
"     \"Differential diagnosis of vulvar lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dermatoses",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seborrheic dermatitis results from chronic inflammation in areas of the body that are rich in sebaceous glands, such as the scalp, face (",
"      <a class=\"graphic graphic_picture graphicRef59104 \" href=\"UTD.htm?27/42/28320\">",
"       picture 6",
"      </a>",
"      ), axilla, groin, and upper trunk; involvement of the vulva is uncommon. The etiology is not known. The lesions are pink-orange, have scales, are poorly defined, and can be secondarily infected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of dermatitis\", section on 'Seborrheic dermatitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=see_link&amp;anchor=H34051773#H34051773\">",
"       \"Seborrheic dermatitis in adolescents and adults\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psoriasis appears as bright red, sharply demarcated lesions that are raised above the surrounding normal skin (",
"      <a class=\"graphic graphic_picture graphicRef56110 \" href=\"UTD.htm?32/48/33540\">",
"       picture 7",
"      </a>",
"      ). Silver scales, commonly observed in psoriasis, may be seen on the mons, but are not found elsewhere on the vulva. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lichen planus &minus; The classical papulosquamous form of lichen planus appears as shiny, purple papules, often in multiple sites on the body, especially flexor surfaces (",
"      <a class=\"graphic graphic_picture graphicRef70518 \" href=\"UTD.htm?23/38/24160\">",
"       picture 8",
"      </a>",
"      ). White striae sometimes occur on the inner aspects of the vulva and typical papules are seen on keratinized anogenital skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"       \"Vulvar lichen planus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Mucosal lichen planus may appear white, inflamed, or erosive. Erosive lesions are the most common type occurring in the inner aspects of the vulva and vagina (",
"      <a class=\"graphic graphic_picture graphicRef60224 \" href=\"UTD.htm?39/37/40530\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H20#H20\">",
"       \"Drug eruptions\", section on 'Drug-induced lichen planus'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Vulvovaginal-gingival syndrome is a variant of this disease that can affect the vagina, vulva, and oral cavity either concurrently or individually [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/23\">",
"       23",
"      </a>",
"      ]. Vulvar lesions are painful, glassy erosions, while those in the vagina are erythematous and friable. Synechiae can develop in the vagina, which may become obliterated with severe disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link&amp;anchor=H2#H2\">",
"       \"Vulvar lichen planus\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lichen sclerosus &minus; Lichen sclerosus is a chronic inflammatory mucocutaneous disease of the vulva that occurs in women of all ages. Intense pruritus is the predominant symptom, although women can be totally asymptomatic even in the presence of active disease. Lichen sclerosus is characterized by \"parchment-like\" or \"cigarette paper\" skin, although thickened, hyperplastic, or lichenified areas are not uncommon. Untreated disease leads to loss of the normal architecture of the external genitalia and constriction of the vaginal orifice (",
"      <a class=\"graphic graphic_picture graphicRef57562 \" href=\"UTD.htm?38/13/39125\">",
"       picture 10",
"      </a>",
"      ). Fissures and telangiectasia are common. The clinical diagnosis can be confirmed by histological examination of biopsy specimens. Patients also may develop lichen simplex chronicus from chronic scratching, and more than one biopsy may be necessary to confirm a diagnosis of lichen sclerosus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"       \"Vulvar lichen sclerosus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida vulvovaginitis causes irritation and pruritus of the vulva, and should be excluded by culture. Cutaneous findings of lichen simplex chronicus often accompany Candida infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link\">",
"     \"Candida vulvovaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for herpes simplex virus is recommended when recurrent ulcerations are noted, as these may be a sign of genital herpes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is a malodorous vulvar exudate, bacterial cultures of the vulva should be performed to aid in diagnosis of secondary bacterial infection. However, bacterial cultures of the vagina are not recommended, as the results are usually nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Vulvodynia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvodynia refers to vulvar discomfort usually described as burning pain; pruritus is uncommon. Nevertheless, persistent pruritus and erythema with a negative yeast culture, nonspecific vulvar biopsy, and failure to respond to standard treatment raises the possibility of vulvodynia. Vulvodynia is a diagnosis of exclusion, after specific, relevant infectious, inflammatory, neoplastic, and neurologic disorders have been ruled out. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8295?source=see_link\">",
"     \"Clinical manifestations and diagnosis of generalized vulvodynia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of vulvar dermatitis requires a two-pronged approach: behavioral modification and medication. An explanation of the condition, emphasizing the need for long-term treatment with maintenance regimens, and vigilance to prevent and diagnose recurrent yeast infections are important factors for success. Therapy that fails to interrupt the itch-scratch cycle will not lead to consistent, prolonged clinical improvement.",
"   </p>",
"   <p>",
"    In the absence of data from large, randomized trials, we suggest the following regimen based on our clinical experience and results from small and observational studies:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment of coexistent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of coexistent infections is essential. Candidiasis should be excluded in all patients by yeast culture if the organism is not present on wet mount with 10 percent potassium hydroxide (which is only 50 percent sensitive) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link&amp;anchor=H6#H6\">",
"     \"Candida vulvovaginitis\", section on 'Diagnosis'",
"    </a>",
"    ). Candidiasis may be present without the usual vaginal symptoms when the yeast infects the skin, and may be the cause of recurrent vulvar fissures.",
"   </p>",
"   <p>",
"    Candidiasis should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ; oral therapy is recommended because women with infection superimposed on vulvar dermatitis are at increased risk for worsening dermatitis from the irritant effects of topical drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/24\">",
"     24",
"    </a>",
"    ]. If the candida is not felt to be part of an ongoing chronic infection, fluconazole 150 mg can be given as a one-time dose and then repeated in three to seven days. However, recurrent or more complicated involvement with candida may require long-term suppression. Nonalbicans yeast will not usually respond to fluconazole, and will require alternative treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link&amp;anchor=H14#H14\">",
"     \"Candida vulvovaginitis\", section on 'Complicated infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a vulvar exudate is present, a vulvar bacterial culture is obtained. Heavy growth of Staphylococcus or Streptococcus should be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/25\">",
"     25",
"    </a>",
"    ]. We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    (500 mg orally three times per day) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    (500 mg orally twice daily) for five to seven days, if appropriate by sensitivity testing. For women allergic to penicillin, we prescribe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (250 mg as a single oral dose daily for six days). Vaginal bacterial cultures are not generally useful because many types of bacteria normally colonize the vagina.",
"   </p>",
"   <p>",
"    If herpes simplex virus is detected, appropriate suppressive therapy can be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Attention to personal habits and hygiene",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient has clothing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hygiene habits that facilitate dermatitis, these habits must be modified. Elements of healthy vulvar hygiene are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef64538 \" href=\"UTD.htm?35/49/36635\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Known or suspected allergens and irritants in the environment should be eliminated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soaking in warm water, without additives, for five minutes in the morning and night hydrates the skin and relieves vulvar discomfort and pruritus. If the patient does not have access to a bathtub or a sitz bath placed under a toilet seat, a hand-held shower device can be used for hydration. Moisture is then sealed into the skin with the application of petroleum jelly or a topical corticosteroid ointment.",
"   </p>",
"   <p>",
"    A sedating antipruritic agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    given in low dosages (10 to 50 mg at 7:00 pm) helps to control nighttime itching and scratching. Nonsedating antihistamines are of little benefit for vulvar pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mild symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild symptoms usually respond to low to medium potency topical corticosteroid ointments (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1% or 2.5%,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13828?source=see_link\">",
"     desonide",
"    </a>",
"    0.05%, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    0.1% daily for two to four weeks, then twice per week). Topical corticosteroid can be used one or more times daily, although a clear benefit has not been demonstrated with more than once daily application [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Therapy is continued indefinitely, at the minimum frequency necessary to control pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Moderate to severe symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;For moderate to severe symptoms, a higher potency corticosteroid ointment is often required (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 4",
"    </a>",
"    ). We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate 0.05% ointment at night daily for 30 days, and then reevaluate. Another acceptable regimen is to give one of these steroids twice daily for two weeks, then daily for two weeks, then Monday and Wednesday and Friday for two weeks, and then reevaluate. If there is a partial response, we either continue corticosteroids for another two weeks or else switch to intralesional injections or calcineurin inhibitors. Potent topical steroids have been used for up to twelve weeks on the vulva without adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Recalcitrant cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intralesional injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide 3.3 to 10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    may be tried in resistant cases; a total of 1 to 2 mL is given by injecting small amounts to include the entire lesion or plaque; this can be repeated monthly up to three times. Prior application of a small amount of a topical anesthetic, such as EMLA, facilitates injection.",
"   </p>",
"   <p>",
"    Recalcitrant cases have also been treated with the calcineurin inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.03% ointment or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    1% cream, which suppress cellular immunity (inhibit T-lymphocyte activation) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The ointment or cream is applied sparingly twice daily for 14 to 30 days, followed by maintenance therapy twice per week. Intermittent prolonged treatment may be necessary because the dermatitis recurs upon discontinuation in 35 to 54 percent of patients. Some patients cannot tolerate tacrolimus because of burning or stinging. These side effects may be minimized by applying a film of petroleum jelly before applying the ointment.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) has issued a public health advisory regarding a potential cancer risk (lymphoma, skin cancer) from use of topical calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/33\">",
"     33",
"    </a>",
"    ]. This concern was based on information from animal studies, case reports in a small number of patients, and knowledge of how drugs in this class work. Given the uncertainty, the FDA advises that these drugs be used only as labeled, and for patients in whom other prescription treatments have failed to work or cannot be tolerated.",
"   </p>",
"   <p>",
"    Another option for severe cases is the use of intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    , which can be used when topical corticosteroids have failed or when direct application of topical medications causes burning or irritation. Patients are treated with 60 mg of triamcinolone administered intramuscularly every six weeks for a total of three doses. Petroleum jelly can be applied twice daily after soaks for two weeks after the first injection, and then a superpotent topical corticosteroid can be substituted for the petroleum jelly. Intramuscular triamcinolone disappears from the circulation in approximately 21 days, potentially minimizing the side effects that can be seen with long-term oral glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5336/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    include hyperglycemia (diabetics may require more frequent blood glucose monitoring), menstrual irregularity, and adrenal suppression. Intramuscular triamcinolone is not recommended for women with a history of severe depression or bipolar disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/54/33634?source=see_link\">",
"       \"Patient information: Vulvar itching (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endogenous vulvar dermatitis is an atopic disorder. Exogenous vulvar dermatitis is a type of contact dermatitis caused by an irritant or allergen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Endogenous versus exogenous dermatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptom of vulvar dermatitis is pruritus, which can be intense and nocturnal. Other symptoms include burning, rawness, or stinging. Physical signs depend upon the chronicity of disease and include erythema, papillae, and lichenification. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Self-medication and persistent rubbing and scratching because of",
"      <span class=\"nowrap\">",
"       irritation/pruritus,",
"      </span>",
"      and excessive washing of the vulva by women fearful of a lack of cleanliness often aggravate the dermatitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of endogenous or exogenous vulvar dermatitis can usually be made clinically, based upon characteristic symptoms, a personal or family history of atopy, or personal history of vulvar exposure to medications, perfumes, or other chemicals. Infection should be excluded by vulvar cultures for candidiasis, herpes simplex virus (if fissures or ulcers are noted), and potential bacterial pathogens. In uncertain cases and those not responding to treatment (see below), patch testing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biopsy may be necessary to identify the",
"      <span class=\"nowrap\">",
"       allergen/irritant",
"      </span>",
"      or an underlying dermatosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of vulvar dermatitis involves attention to personal",
"      <span class=\"nowrap\">",
"       habits/hygiene",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef64538 \" href=\"UTD.htm?35/49/36635\">",
"       table 3",
"      </a>",
"      ) and medication. An explanation of the condition, emphasizing the need for long-term treatment with maintenance regimens, and vigilance to prevent and diagnose recurrent yeast infections are important factors for success. Therapy that fails to interrupt the itch-scratch cycle will not lead to consistent, prolonged clinical improvement. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis and treatment of coexistent infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Attention to personal habits and hygiene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Soaking in warm water temporarily relieves vulvar discomfort. Sealing in the moisture with medication prescribed or plain petroleum jelly is also a mainstay of therapy. A sedating antihistamine such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      (10 mg at 7:00 pm) helps to control nighttime itching and scratching. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with mild symptoms, we suggest low to medium potency topical corticosteroid ointments rather than high potency corticosteroids or intralesional therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      1% or 2.5% percent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13828?source=see_link\">",
"       desonide",
"      </a>",
"      0.05%, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      0.1% ointment is applied daily for two to four weeks, then twice per week indefinitely at the minimum frequency necessary to control pruritus. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mild symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with moderate to severe symptoms, we suggest a higher potency corticosteroid ointment (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      dipropionate 0.05%) rather than intralesional corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The topical steroid is applied at bedtime daily for 30 days. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Moderate to severe symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women in whom high potency corticosteroids have failed, we suggest an intralesional injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide rather than calcineurin inhibitors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Recalcitrant cases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/1\">",
"      Ball SB, Wojnarowska F. Vulvar dermatoses: lichen sclerosus, lichen planus, and vulval dermatitis/lichen simplex chronicus. Semin Cutan Med Surg 1998; 17:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/2\">",
"      Fischer G, Spurrett B, Fischer A. The chronically symptomatic vulva: aetiology and management. Br J Obstet Gynaecol 1995; 102:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/3\">",
"      Fischer GO. The commonest causes of symptomatic vulvar disease: a dermatologist's perspective. Australas J Dermatol 1996; 37:12.",
"     </a>",
"    </li>",
"    <li>",
"     Ridley CM, Neill SM. Non-infective cutaneous conditions of the vulva. In: The Vulva, Ridley CM, Neill SM (Eds), Blackwell Science, Oxford Ltd 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/5\">",
"      Pincus SH. Vulvar dermatoses and pruritus vulvae. Dermatol Clin 1992; 10:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/6\">",
"      Marren P, Wojnarowska F, Powell S. Allergic contact dermatitis and vulvar dermatoses. Br J Dermatol 1992; 126:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/7\">",
"      Nardelli A, Degreef H, Goossens A. Contact allergic reactions of the vulva: a 14-year review. Dermatitis 2004; 15:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/8\">",
"      Farage M, Maibach HI. The vulvar epithelium differs from the skin: implications for cutaneous testing to address topical vulvar exposures. Contact Dermatitis 2004; 51:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/9\">",
"      Elsner P, Wilhelm D, Maibach HI. Multiple parameter assessment of vulvar irritant contact dermatitis. Contact Dermatitis 1990; 23:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/10\">",
"      Britz MB, Maibach HI. Human cutaneous vulvar reactivity to irritants. Contact Dermatitis 1979; 5:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/11\">",
"      Marin MG, King R, Sfameni S, Dennerstein GJ. Adverse behavioral and sexual factors in chronic vulvar disease. Am J Obstet Gynecol 2000; 183:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/12\">",
"      Bergeron C, Ferenczy A, Richart RM, Guralnick M. Micropapillomatosis labialis appears unrelated to human papillomavirus. Obstet Gynecol 1990; 76:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/13\">",
"      Prieto MA, Guti&eacute;rrez JV, Sambucety PS. Vestibular papillae of the vulva. Int J Dermatol 2004; 43:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/14\">",
"      Marren P, Wojnarowska F. Dermatitis of the vulva. Semin Dermatol 1996; 15:36.",
"     </a>",
"    </li>",
"    <li>",
"     Lynch PJ. Dermatology, Williams &amp; Wilkins, Baltimore 1994. p.4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/16\">",
"      Lynch PJ. Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. Dermatol Ther 2004; 17:8.",
"     </a>",
"    </li>",
"    <li>",
"     www.asccp.org/edu/practice/vulva/squamous.shtml (Accessed on January 10, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/18\">",
"      Bauer A, Rodiger C, Greif C, et al. Vulvar dermatoses--irritant and allergic contact dermatitis of the vulva. Dermatology 2005; 210:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/19\">",
"      Goldsmith PC, Rycroft RJ, White IR, et al. Contact sensitivity in women with anogenital dermatoses. Contact Dermatitis 1997; 36:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/20\">",
"      Lewis FM, Harrington CI, Gawkrodger DJ. Contact sensitivity in pruritus vulvae: a common and manageable problem. Contact Dermatitis 1994; 31:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/21\">",
"      Virgili A, Bacilieri S, Corazza M. Evaluation of contact sensitization in vulvar lichen simplex chronicus. A proposal for a battery of selected allergens. J Reprod Med 2003; 48:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/22\">",
"      Margesson LJ. Contact dermatitis of the vulva. Dermatol Ther 2004; 17:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/23\">",
"      Pelisse M. The vulvo-vaginal-gingival syndrome. A new form of erosive lichen planus. Int J Dermatol 1989; 28:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/24\">",
"      Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/25\">",
"      Herbst R. Perineal streptococcal dermatitis/disease: recognition and management. Am J Clin Dermatol 2003; 4:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/26\">",
"      Jones SM, Sampson HA. The role of allergens in atopic dermatitis. Clin Rev Allergy 1993; 11:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/27\">",
"      Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/28\">",
"      Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005; 152:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/29\">",
"      Dalziel KL, Wojnarowska F. Long-term control of vulval lichen sclerosus after treatment with a potent topical steroid cream. J Reprod Med 1993; 38:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/30\">",
"      Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991; 124:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/31\">",
"      Goldstein AT, Parneix-Spake A, McCormick CL, Burrows LJ. Pimecrolimus cream 1% for treatment of vulvar lichen simplex chronicus: an open-label, preliminary trial. Gynecol Obstet Invest 2007; 64:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/32\">",
"      Black RJ. Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. Clin Exp Dermatol 2005; 30:91.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/cder/drug/infopage/protopic/default.htm (Accessed on January 10, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5336/abstract/34\">",
"      Robins DN. Intramuscular triamcinolone: a safe, effective and underutilized dermatologic therapy. J Drugs Dermatol 2009; 8:580.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5563 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5336=[""].join("\n");
var outline_f5_13_5336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENDOGENOUS VERSUS EXOGENOUS DERMATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patch test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dermatoses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Vulvodynia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis and treatment of coexistent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Attention to personal habits and hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - General measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mild symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Moderate to severe symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Recalcitrant cases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5563|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/57/28575\" title=\"picture 1\">",
"      Flexural atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/26/15781\" title=\"picture 2A\">",
"      Contact dermatitis vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/14/10467\" title=\"picture 2B\">",
"      Contact derm vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/2/25633\" title=\"picture 3\">",
"      Vulvar papillomatosis papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/11/19634\" title=\"picture 4\">",
"      Lichen simplex chronicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/59/20404\" title=\"picture 5A\">",
"      Lichen sclerosus vulvar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/38/42597\" title=\"picture 5B\">",
"      Lichen sclerosus vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/42/28320\" title=\"picture 6\">",
"      Seborrheic dermatitis face 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/48/33540\" title=\"picture 7\">",
"      Vulvar psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/38/24160\" title=\"picture 8\">",
"      Lichen planus arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40530\" title=\"picture 9\">",
"      Erosive lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/13/39125\" title=\"picture 10\">",
"      Lichen sclers lost archectectur",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5563|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/27/32188\" title=\"table 1\">",
"      Cause vulval contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/61/7131\" title=\"table 2\">",
"      Causes of vulvovaginal pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/49/36635\" title=\"table 3\">",
"      Healthy vulval hygiene practice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 4\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8295?source=related_link\">",
"      Clinical manifestations and diagnosis of generalized vulvodynia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=related_link\">",
"      Diagnostic evaluation of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=related_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/54/33634?source=related_link\">",
"      Patient information: Vulvar itching (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21961?source=related_link\">",
"      Seborrheic dermatitis in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_13_5337="Hypernatremia in children";
var content_f5_13_5337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypernatremia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5337/contributors\">",
"     Michael J Somers, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5337/contributors\">",
"     Avram Z Traum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5337/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5337/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/13/5337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1304699201\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is typically defined as a serum or plasma sodium greater than 150",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    Although pediatric hypernatremia is an uncommon electrolyte abnormality, there can be significant neurologic injury in patients with severe hypernatremia, especially those with acute and rapid changes in serum sodium.",
"   </p>",
"   <p>",
"    The etiology, clinical findings, diagnosis, and evaluation of pediatric hypernatremia are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536507079\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true incidence of pediatric hypernatremia is unknown, as published data are based on hospitalized children.",
"   </p>",
"   <p>",
"    As an example, a Scottish study reported an overall incidence of hypernatremia (defined as a plasma sodium &gt;150",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    of 0.04 percent for all pediatric hospitalizations in pediatric patients over two weeks of age over a study period from 1996 to 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the risk of hypernatremia was 10 times greater in neonates less than two weeks of age, with an incidence of 0.4 percent. Neonatal hypernatremia was almost exclusively seen in breastfed infants with excessive weight (water loss). Of note, the incidence of neonatal hypernatremia in breastfed infants was higher than reported in previous studies (0.03 to 0.07 percent) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link&amp;anchor=H20#H20\">",
"     \"Initiation of breastfeeding\", section on 'Excessive weight loss'",
"    </a>",
"    ). In older patients between two weeks and 17 years of age, the most common cause of hypernatremia on admission was excess water loss due to gastroenteritis or systemic infection. However, in this cohort, it was more common for hypernatremia to develop during hospitalization, particularly in patients with systemic infection or those who underwent cardiac surgery. In addition, approximately one-third of the patients had an underlying neurologic condition.",
"   </p>",
"   <p>",
"    In an earlier study from a tertiary children&rsquo;s hospital in Texas from 1992 to 1994, hypernatremia (defined as a serum sodium greater than 150",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    was detected in 1.4 percent of sodium values in a laboratory database, but only 0.2 percent of patients were discharged with a diagnosis of hyperosmolality due to hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/2\">",
"     2",
"    </a>",
"    ]. Of the 68 children with a final discharge diagnosis of",
"    <span class=\"nowrap\">",
"     hyperosmolality/hypernatremia,",
"    </span>",
"    two-thirds of the children developed hypernatremia during hospitalization, and the most common cause of hypernatremia was inadequate fluid intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536507266\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is caused by an imbalance in the body&rsquo;s handling of water, resulting in a relative excess of effective plasma osmolality (tonicity) to total body water. The tonicity is determined by the concentration of solutes that do not easily cross the cell membrane, which is primarily due to sodium salts in the extracellular space. As a result, serum or plasma sodium is used as a surrogate for assessing tonicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H37261099#H37261099\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'Plasma tonicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The formulas used to estimate plasma tonicity are similar to those for the plasma osmolality, with the one exception that the contribution of urea (an ineffective osmole) is not included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma tonicity = 2 x [Na] +",
"      <span class=\"nowrap\">",
"       [glucose]/18",
"      </span>",
"      (if glucose is measured in",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Plasma tonicity = 2 x [Na] + [glucose] (if glucose is measured in",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plasma tonicity is tightly regulated by the release of antidiuretic hormone (ADH) from the posterior pituitary promoting water retention, and by thirst-prompting water ingestion (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 1",
"    </a>",
"    ). These homeostatic mechanisms that mediate plasma tonicity and water balance are similar in adults and children, resulting in a normal range of plasma sodium between 135 and 145",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    that does not vary by age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H96014898#H96014898\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'Regulation of plasma tonicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypernatremia is most often caused by the failure to replace water losses, which, in children, are most commonly due to gastrointestinal fluid loss. In these patients, the sodium plus potassium concentration in the fluid that is lost is",
"    <strong>",
"     less",
"    </strong>",
"    than the plasma sodium concentration. As a result, water is lost in excess of sodium plus potassium, which will tend to",
"    <strong>",
"     increase",
"    </strong>",
"    the plasma sodium concentration. In individuals with intact thirst mechanisms, the intake of free water promptly corrects any increase in plasma sodium. However, when water losses cannot be replaced because of a lack of free access to water, excessive loss in acute illnesses, or impaired thirst mechanism, sodium concentration increases and may result in hypernatremia. Infants and children who are significantly neurodevelopmentally impaired are at particular risk for hypernatremia, as they may be unable to communicate their thirst and are dependent on others for fluid repletion. Pediatric hypernatremia also may result from urinary or skin loss of free water without adequate water replacement.",
"   </p>",
"   <p>",
"    Less commonly, pediatric hypernatremia may be caused by intake of sodium in excess of water (eg, administration of a hypertonic salt solution). In this setting, patients also are unable to access free water to correct the plasma tonicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699208\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of pediatric hypernatremia can be separated into the two previously discussed mechanisms that result in pediatric hypernatremia (see",
"    <a class=\"local\" href=\"#H536507266\">",
"     'Pathophysiology'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Water loss that is not replaced",
"     </li>",
"     <li>",
"      Excessive salt intake relative to water ingestion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699334\">",
"    <span class=\"h2\">",
"     Excess water losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of body fluids with a sodium plus potassium concentration that is less than serum or plasma sodium (hypotonic fluids) will result in an increase in sodium concentration if the water losses are",
"    <strong>",
"     not",
"    </strong>",
"    replaced. Sources of hypotonic body fluid losses include gastrointestinal fluids, dilute urine, and skin loss due to sweat or burns. In addition, inadequate water intake that fails to replace ongoing normal fluid losses will result in excess water loss and increases in serum or plasma sodium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699215\">",
"    <span class=\"h3\">",
"     Gastrointestinal loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the most common cause of hypernatremia is hypotonic gastrointestinal losses without replacement, which result in effective water loss. In particular, gastroenteritis due to rotavirus can present with profuse watery diarrhea and hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, losses due to vomiting or nasogastric drainage can lead to excess free water loss and hypernatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192147411\">",
"    <span class=\"h3\">",
"     Urinary water loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive urinary free water loss may be caused by disorders with impaired urinary concentration defects (eg, diabetes insipidus [DI]) or osmotic diuresis. Without adequate water replacement, sodium concentration will rise and may result in hypernatremia (",
"    <a class=\"graphic graphic_table graphicRef88819 \" href=\"UTD.htm?33/25/34204\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536507457\">",
"    <span class=\"h4\">",
"     Urinary concentration defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired urinary concentration is typically due to antidiuretic hormone (ADH) deficiency or resistance, which leads to excretion of a dilute urine (urine osmolality less than plasma osmolality) and excessive urinary free water loss.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central DI &ndash;",
"      <em>",
"      </em>",
"      Central DI is caused by inadequate production or release of ADH. Central DI has multiple etiologies, including congenital central nervous system (CNS) malformations and genetic syndromes with associated CNS anomalies, and acquired causes due to CNS tumors, infiltrative processes of the hypothalamic-pituitary stalk, and sequelae from neurosurgery and trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and causes of central diabetes insipidus\", section on 'Causes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrogenic DI &ndash;",
"      <em>",
"      </em>",
"      Nephrogenic DI is caused by an inadequate renal tubular response to circulating ADH. The multiple causes of pediatric nephrogenic DI can be further divided into the following categories (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Causes'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Congenital nephrogenic DI &ndash; Congenital nephrogenic DI is most often the result of mutations in the vasopressin type 2 receptor (",
"      <em>",
"       AVPR2",
"      </em>",
"      ), found at the locus Xp28. In this X-linked disorder, male infants typically present in the first weeks of life with fussiness, low-grade fever, and polyuria with hypernatremia. In addition, hereditary nephrogenic DI may be caused by a mutation in the aquaporin-2 gene (",
"      <em>",
"       AQP2",
"      </em>",
"      ) at 12q13, which encodes the ADH-sensitive water channels. Congenital nephrogenic DI is also observed in other inherited disorders, including Bardet-Biedl and Bartter syndromes, nephronophthisis, cystinosis, and familial hypomagnesemia with hypercalciuria and nephrocalcinosis.",
"     </li>",
"     <li>",
"      Acquired nephrogenic DI &ndash; Drug toxicity is the most common cause of acquired DI.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"       Lithium",
"      </a>",
"      toxicity is the most frequent cause of drug-induced nephrogenic DI, and its use has increased in children and adolescents with mood disorders. Lithium also can cause interstitial nephritis and fibrosis, further exacerbating urinary concentrating capacity. The effects of lithium on urinary concentrating ability can be permanent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link&amp;anchor=H2#H2\">",
"       \"Renal toxicity of lithium\", section on 'Nephrogenic diabetes insipidus'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other medications associated with drug-induced nephrogenic DI include amphotericin,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/5/6229?source=see_link\">",
"       demeclocycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/4/24646?source=see_link\">",
"       foscarnet",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/34/14886?source=see_link\">",
"       cidofovir",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      Hypercalcemia and hypokalemia also can produce functional defects in water reabsorption that are usually reversible once the electrolyte perturbation resolves. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations and causes of nephrogenic diabetes insipidus\", section on 'Hypercalcemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=see_link&amp;anchor=H3#H3\">",
"       \"Hypokalemia-induced renal dysfunction\", section on 'Impaired urinary concentrating ability'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal disease &ndash;",
"      <em>",
"      </em>",
"      In children, impaired urinary concentration is seen in a variety of renal diseases, including obstructive uropathy, sickle cell disease, nephronophthisis, cystinosis, and acute or chronic kidney disease. In these disorders, the decline in urinary concentrating ability may be due to a number of different factors, including resistance to ADH; impairment of the renal medulla countercurrent mechanism;",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decrease in the number of functioning nephrons, which can lead to osmotic diuresis as the ability to reabsorb the increasing solute load is exceeded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536509723\">",
"    <span class=\"h4\">",
"     Osmotic diuresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia can also occur from urinary water losses due to renal excretion of nonelectrolyte, nonreabsorbed solutes, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    or glucose (eg, patients with diabetic ketoacidosis and hyperglycemia). While the urine osmolality is augmented with the presence of these substances, the urinary concentration of sodium plus potassium is below plasma levels. If there is inadequate water repletion, the enhanced urinary free water loss leads to an increase in sodium concentration, and potentially hypernatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of mannitol therapy\", section on 'Volume depletion and hypernatremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Serum sodium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699229\">",
"    <span class=\"h3\">",
"     Skin loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sodium plus potassium content of sweat is less than half that of plasma, but normal sweating causes only modest overall free water losses and does not typically lead to hypernatremia. However, with vigorous or sustained exercise, or significant febrile illness, water losses from sweat can become more substantial and can result in hypernatremia if not corrected with water intake. Increased insensible water losses due to burns can also lead to hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link&amp;anchor=H22#H22\">",
"     \"Emergency care of moderate and severe thermal burns in children\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699243\">",
"    <span class=\"h3\">",
"     Inadequate water intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia can develop if normal free water losses are not replaced, either because of lack of access to water or lack of thirst. Infants and children who are dependent on others for fluid intake or who have an impaired thirst mechanism are more vulnerable to hypernatremic hypovolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536507544\">",
"    <span class=\"h4\">",
"     Infants and young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with older children and adults, infants and young children are at increased risk for hypernatremic hypovolemia because they have a higher ratio of surface area to volume, resulting in greater insensible water losses from the skin; and, while their thirst mechanism is intact, they are unable to communicate their need for fluids and cannot independently access fluids to replenish fluid losses.",
"   </p>",
"   <p>",
"    In neonates, the most common cause of hypernatremia is inadequate intake in infants who are breastfed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/1,5-8\">",
"     1,5-8",
"    </a>",
"    ]. Careful attention to weight loss and breastfeeding adequacy has been shown to prevent this potentially devastating complication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link&amp;anchor=H20#H20\">",
"     \"Initiation of breastfeeding\", section on 'Excessive weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H976490264\">",
"    <span class=\"h4\">",
"     Impaired thirst mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with structural midline brain abnormalities may have an impaired or no thirst mechanism (adipsia or hypodipsia), which may result in chronic hypernatremia. These lesions include congenital abnormalities, such as holoprosencephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], acquired lesions (eg, craniopharyngioma), and infiltrative processes of the hypothalamic-pituitary stalk. These patients may have concomitant central DI, and careful attention to both water intake and the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     desmopressin",
"    </a>",
"    therapy makes their management especially challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Hypothalamic lesions affecting thirst or osmoreceptor function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699250\">",
"    <span class=\"h2\">",
"     Excess salt intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia can be a consequence of salt intake out of proportion to water. In children, excessive salt intake is generally due to iatrogenic administration of excess sodium (eg, hypertonic saline solution), or due to salt poisoning. In either setting, patients are unable to access free water in order to restore plasma tonicity and correct hypernatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699257\">",
"    <span class=\"h3\">",
"     Iatrogenic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iatrogenic causes of hypernatremia include the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    infusions for metabolic acidosis or hypertonic saline, which may be used in the acute management of increased intracranial pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H32#H32\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Hypertonic saline bolus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the administration of isotonic saline to replete hypotonic losses can also lead to increased sodium, and potentially hypernatremia, by net sodium gain in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncontrolled diabetes, in which the free water lost in an osmotic diuresis from nonreabsorbed glucose is replaced with isotonic saline.",
"     </li>",
"     <li>",
"      Recovery from acute kidney injury, in which the free water lost in an urea-induced osmotic diuresis is replaced with isotonic saline.",
"     </li>",
"     <li>",
"      Nasogastric suction, in which patients receive isotonic saline to replace hypotonic intestinal fluid losses with a sodium plus potassium concentration well below that of plasma.",
"     </li>",
"     <li>",
"      Edematous, critically ill patients who have received large volumes of saline and then receive loop diuretic therapy, which impairs renal concentrating ability, resulting in inappropriately high water losses [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699264\">",
"    <span class=\"h3\">",
"     Salt poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salt poisoning has been described both from incorrect formula preparation and as an intentional form of child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Infants and young children are especially susceptible due to their inability to communicate their thirst, and their reliance on others for access to water. A teaspoon of salt contains 100 mEq of sodium (Na), which can increase the serum sodium concentration in a 10 kg child by 17",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    The unpleasant salty taste of such preparations should limit their voluntary ingestion, but in situations of intentional poisoning these children are often subjected to limited access to other fluids, thereby ensuring the ingestion of the hypertonic preparations.",
"   </p>",
"   <p>",
"    Salt poisoning causes a rapid onset of hypernatremia, often resulting in cerebral hemorrhage and irreversible neurologic injury. Osmotic demyelination can occur, similar to the injury caused by a rapid elevation in serum sodium in patients with chronic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Salt poisoning has a number of distinguishing features from excessive water loss, which, as noted above, is the most common cause of hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1304699334\">",
"     'Excess water losses'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salt poisoning is initially associated with weight gain due to the stimulation of both thirst, which increases fluid intake, and ADH release, which diminishes water loss. In contrast, unreplaced water losses severe enough to produce hypernatremia are usually associated with weight loss.",
"     </li>",
"     <li>",
"      Urinary sodium excretion is appropriately increased with salt poisoning, and is appropriately reduced with hypovolemia due to unreplaced water losses. The fractional excretion of sodium (FENa) may be useful, as a FENa greater than 2 percent is strongly suggestive of salt poisoning, whereas a FENa less than 1 percent is suggestive of hypernatremia caused by water loss [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/1,17\">",
"       1,17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H653430899\">",
"       'Laboratory evaluation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536507069\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653430718\">",
"    <span class=\"h2\">",
"     Acute hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings in acute pediatric hypernatremia are generally manifested by neurological symptoms as water moves out of brain cells leading to cerebral contraction. The presence and severity of symptoms correlate with the degree of plasma sodium elevation and its rate of rise.",
"   </p>",
"   <p>",
"    Nonspecific initial manifestations of hypernatremia include irritability, restlessness, weakness, vomiting, muscular twitching, fever, and, in infants, high-pitched cry and tachypnea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/18\">",
"     18",
"    </a>",
"    ]. Severe symptoms are observed with an acute rise of sodium above 160",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    and include altered mental status, lethargy, coma, and seizures. In the most severe cases, such as salt poisoning, the rapid rise in sodium leads to acute brain shrinkage, resulting in vascular rupture with cerebral and subarachnoid hemorrhage, demyelination, and irreversible neurologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/14,19\">",
"     14,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the most common cause of pediatric hypernatremia is excessive fluid losses, patients may also have manifestations of hypovolemia, including tachycardia, orthostatic blood pressure changes or decreased blood pressure, dry mucous membranes, and decreased peripheral perfusion with a delay in capillary refill. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Clinical assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653430726\">",
"    <span class=\"h2\">",
"     Chronic hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears that patients with chronic hypernatremia (defined as hypernatremia that is present more than one day) are asymptomatic due to cerebral adaption, which occurs within one to three days. This process involves restoration of brain volume by water movement from the cerebrospinal fluid into the brain, and generation and uptake of intracellular solutes (osmolytes) that promote water movement into the brain cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H11#H11\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Cerebral adaptation to hypernatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, it may be difficult to appreciate nonspecific findings, as many of these patients have underlying neurologic conditions (midline brain abnormalities) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1304699243\">",
"     'Inadequate water intake'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536507107\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypernatremia is made by the detection of an elevated plasma or serum sodium level above 150",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"   </p>",
"   <p>",
"    Transient",
"    hypernatremia (in which the serum sodium concentration can rise by as much as 10 to 15",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    within a few minutes due to water loss into cells) can be induced by severe exercise or seizures. Sodium returns to normal within 5 to 15 minutes after the cessation of exercise or seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Water loss into cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, spuriously falsely elevated sodium values have been observed in ill neonates with hypoalbuminemia (plasma albumin &lt;30",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    in whom sodium is measured by indirect ion-selective electrodes, commonly utilized in main laboratory analyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/20\">",
"     20",
"    </a>",
"    ]. This artifact is circumvented by measurements using direct ion-selective electrodes found in point-of-care blood analyzers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699271\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation in pediatric hypernatremia is focused on determining the underlying etiology. However, evaluation should be delayed in the severely ill patient who requires fluid resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653430891\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying etiology of hypernatremia is usually evident from the history. Because pediatric hypernatremia is most often due to unreplaced hypotonic fluid losses, the history focuses on whether there are increased body fluid losses (eg, diarrhea) or inadequate fluid intake.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of excess gastrointestinal losses because of the presence of watery stools with documentation of the frequency and amount, or loss from nasogastric or colostomy drainage.",
"     </li>",
"     <li>",
"      History of impaired urinary concentration based on excessive urine output (polyuria) and dilute appearance. Urinary concentrating defect is suggested in infants who regularly and frequently soak through their diapers every few hours, and in older children with increased frequency of voiding, including nighttime voiding. In addition, questions about the appearance of the urine may be helpful, as a child with impaired concentration typically has urine that looks like water with little or no odor (dilute), and does not ever have a concentrated urine typically characterized by a yellow appearance, which may be accompanied by a strong ammonia odor.",
"     </li>",
"     <li>",
"      Neurologic impairment, particularly with midline brain defect, which is associated with impaired thirst mechanism, or inability to independently access free water.",
"     </li>",
"     <li>",
"      In breastfed infants, history of intake is assessed by whether there is successful latch-on, the frequency of feeding, mother&rsquo;s feeling of milk release, and whether the infant appears satiated following feeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=see_link\">",
"       \"Initiation of breastfeeding\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653430899\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies should preferably be obtained before significant fluid intervention has taken place, although fluid therapy should never be delayed in the severely ill patient.",
"   </p>",
"   <p>",
"    When the underlying diagnosis remains uncertain, comparing the urine with plasma osmolality may be helpful in establishing the underlying mechanism and diagnosis (",
"    <a class=\"graphic graphic_algorithm graphicRef88818 \" href=\"UTD.htm?36/7/36989\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine osmolality less than plasma osmolality is consistent with a urinary concentrating defect (ie, diabetes insipidus [DI]), which is usually due to a defect in either the release or response to antidiuretic hormone (ADH). Further evaluation to delineate between central and nephrogenic DI is based on the child&rsquo;s urinary response to water deprivation and the subsequent administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"       desmopressin",
"      </a>",
"      , which is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link&amp;anchor=H12#H12\">",
"       \"Diagnosis of polyuria and diabetes insipidus\", section on 'Infants and children'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urine osmolality greater than plasma osmolality demonstrates that the secretion and response to ADH is intact. In this setting, hypernatremia is typically caused by free water loss from the gastrointestinal tract or skin and inadequate water intake, and less frequently by osmotic diuresis or excess salt intake (ie, iatrogenic causes or salt poisoning).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other laboratory studies that may be included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum BUN and creatinine to determine renal function. Serum creatinine is also used to calculate the fractional excretion of sodium (FENa).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Serum/plasma",
"      </span>",
"      and urine measurements of sodium and creatinine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Urine sodium is typically low (&lt;25",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      in patients with hypernatremic hypovolemia, generally due to gastrointestinal losses.",
"     </li>",
"     <li>",
"      In contrast, urine sodium exceeds 200",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      in patients with salt poisoning [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fractional excretion of sodium (FENa) may be useful, as a FENa greater than 2 percent is strongly suggestive of salt poisoning, whereas a FENa less than 1 percent is suggestive of hypernatremia caused by water loss [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/1,17\">",
"       1,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=see_link&amp;anchor=H17605911#H17605911\">",
"       \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\", section on 'Fractional excretion of sodium'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1026424383\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653432175\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of hypernatremia requires both the administration of dilute fluids to correct the water deficit and, when appropriate, interventions to limit further water loss. Many pediatric patients also have a concurrent volume isotonic deficit usually due to gastrointestinal losses. Such patients with hypernatremia will require replacement of",
"    <strong>",
"     both",
"    </strong>",
"    water and electrolyte deficits. In these patients, it is important to assess the volume status as in the setting of significant hypovolemia, because in patients with moderate to severe hypovolemia, fluid resuscitation with isotonic fluid to restore intravascular volume and tissue perfusion takes precedence over correction of the hypernatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hypovolemia (dehydration) in children\", section on 'Emergent fluid phase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases where hypernatremia alone is the primary abnormality, therapy is aimed at correcting the plasma sodium by providing free water and determining a rate of desired correction. Issues that need to be addressed when treating pediatric hypernatremia are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the volume status of the patient? Is there an emergent need for fluid resuscitation to restore intravascular volume and tissue perfusion?",
"     </li>",
"     <li>",
"      What is the magnitude of the water deficit that needs to be restored?",
"     </li>",
"     <li>",
"      At what rate should the hypernatremia be corrected (as lowering the sodium concentration too rapidly may lead to neurologic injury)?",
"     </li>",
"     <li>",
"      Is there a concurrent ongoing fluid loss that needs to be addressed?",
"     </li>",
"     <li>",
"      What is the underlying cause of hypernatremia and are there specific interventions that need to be considered?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management also includes ongoing monitoring of the patient&rsquo;s fluid status with frequent clinical examinations and follow-up laboratory evaluation, including subsequent assessment of sodium levels. Based on these data, the initial fluid prescription may need to be revised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699285\">",
"    <span class=\"h2\">",
"     Volume status and emergent fluid resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In any child with significant volume depletion, first management steps should be directed toward ensuring cardiovascular stability. In patients with moderate to severe hypovolemia, emergent fluid resuscitation with isotonic fluid is administered to restore intravascular volume and tissue perfusion. However, overzealous fluid resuscitation needs to be avoided to prevent inadvertent volume overload, which may be associated with cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hypovolemia (dehydration) in children\", section on 'Emergent fluid phase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192147418\">",
"    <span class=\"h2\">",
"     Calculating the free water deficit",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the restoration of effective intra-arterial volume, or in cases where there is no need for urgent volume expansion, the focus turns to providing the fluid necessary to correct any existing hypovolemia, and enough free water to correct the hypernatremia.",
"   </p>",
"   <p>",
"    The volume of free water to be provided can be calculated using one of two common approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free water deficit in liters = Current total body water x ([current plasma",
"      <span class=\"nowrap\">",
"       Na/140]",
"      </span>",
"      - 1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For this equation, estimating total body water (TBW) as 60 percent of the child&rsquo;s weight in kilograms (0.6",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    is a reasonable starting point for the purposes of calculating fluid replacement. The exact proportion varies as a child progresses from infancy to adolescence, and is lower in obese individuals (",
"    <a class=\"graphic graphic_figure graphicRef56512 \" href=\"UTD.htm?32/46/33518\">",
"     figure 2",
"    </a>",
"    ). Thus, in a 6 kg infant with a plasma sodium of 160, the free water deficit is: (0.6",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    x (6 kg) x",
"    <span class=\"nowrap\">",
"     ([160/140]",
"    </span>",
"    &ndash; 1) = 0.51 liters or 510 mL.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free water deficit in liters = (4",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      x (weight in kg) x (desired change in plasma Na)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach uses the estimate that the provision of 4",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of free water will lower plasma sodium by approximately 1",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    For the 6 kg infant described above with plasma sodium elevated 20",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    above desired, his or her water deficit would be: (4",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    x (6 kg) x (20",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    change) = 480 mL.",
"   </p>",
"   <p>",
"    The variation in free water needed between the two calculations is generally clinically negligible and, in any case, the equations are used as estimates with follow-up laboratory results and clinical exams guiding ongoing changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733673763\">",
"    <span class=\"h3\">",
"     Prescribed fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free water calculations provide for an estimate of the amount of water without sodium needed to return plasma sodium to a normal concentration. However, in most clinical settings, the administered fluid typically contains sodium, but is hypotonic to the patient&rsquo;s plasma, thereby providing free water. As an example, the 500 mL free water deficit in the example above could be delivered with the administration of a liter of 0.45 percent saline. In addition, normal saline (0.9 percent saline) is isotonic in patients with normal plasma sodium; however, it is a hypotonic fluid for children with hypernatremia, and accordingly can be used as initial rehydration fluid for patients with hypernatremic hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/22\">",
"     22",
"    </a>",
"    ]. Enteral fluids including oral rehydration therapy are also typically hypotonic fluids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699299\">",
"    <span class=\"h2\">",
"     Rate of correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to determine the chronicity of hypernatremia when determining the rate of correction. As mentioned previously, in patients with chronic hypernatremia, cerebral adaption to hypernatremia takes place over the first few days with restoration of brain volume. In these patients, there is a risk of cerebral edema with rapid provision of free water. Even in cases where hypernatremia is known to have occurred acutely, similar rates of correction are generally used out of caution, especially with more pronounced aberrations in plasma sodium.",
"   </p>",
"   <p>",
"    For children with chronic hypernatremia (plasma sodium &ge;150",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    for greater than 24 hours) or those with acute severe hypernatremia (plasma sodium &gt;160",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    we and other experts recommend that a rate of correction does",
"    <strong>",
"     not",
"    </strong>",
"    exceed a fall of sodium greater than 0.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    per hour (ie, 10 to 12",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    per day). The following studies provide support for this recommendation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective case control study of 97 children with hypernatremia and dehydration with a mean baseline serum sodium of 165",
"      <span class=\"nowrap\">",
"       mEq/L,",
"      </span>",
"      patients who developed cerebral edema had a significantly faster rate of correction compared with those without complications following correction of hypernatremia (1.0 versus 0.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      per hour) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in another report in which the rate of reduction in serum sodium was 1.0",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      per hour in the nine infants who developed seizures compared with 0.6",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      per hour or less in 31 infants who did not develop seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5337/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699306\">",
"    <span class=\"h2\">",
"     Ongoing losses and maintenance needs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above calculations correct free water losses that have occurred up to the time of presentation. Children have ongoing normal maintenance needs and may also have excess free water losses not accounted for by calculations for maintenance fluids (eg, continuing diarrhea or persistent fever), and should receive replacement of these ongoing losses to prevent further electrolyte derangement. Since ongoing losses can fluctuate over time, it can be challenging to try to estimate them for inclusion in a fluid and electrolyte prescription that addresses current deficits as well. Accordingly, many clinicians will prescribe fluid orders to address current needs and desired rates of correction, and write separate orders to address ongoing losses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699313\">",
"    <span class=\"h2\">",
"     Treatment of specific etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation and management of hypernatremia usually occur concurrently. As noted above, obtaining additional laboratory studies for evaluation should not delay initiation of fluid therapy for the critically ill child. Although most young children develop hypernatremia related to acute illness or inability to take in fluid, in cases where a chronic condition is identified, such as nephrogenic or central diabetes insipidus, therapy directed to the underlying condition (eg, administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     desmopressin",
"    </a>",
"    ) should be initiated in addition to providing free water replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733673820\">",
"    <span class=\"h2\">",
"     Clinical example",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following case synthesizes the information presented above in an attempt to show how the principles are applied clinically. A 10 kg child (TBW 0.6 times body weight) is estimated to have a 10 percent hypovolemic loss (about 1 liter of fluid) and a",
"    <span class=\"nowrap\">",
"     serum/plasma",
"    </span>",
"    sodium concentration of 156",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"    The following calculations can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total fluid deficit: 10 percent of 10 kg = 1000 mL",
"     </li>",
"     <li>",
"      Free water deficit: 6 L",
"      <span class=\"nowrap\">",
"       [(156/140",
"      </span>",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      - 1] = 686 mL",
"     </li>",
"     <li>",
"      Isotonic loss: Total fluid deficit - water deficit = 314 mL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the emergent fluid phase, the patient received a 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    bolus of normal saline (200 mL), replacing all but 114 mL of the isotonic fluid loss. Subsequent therapy includes replacement of the free water deficit (686 mL) and remaining isotonic loss (114 mL), maintenance of usual daily sodium and fluid needs (1000",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    of one-quarter isotonic saline in this case), and any excess ongoing loss of fluid and electrolyte. The water deficit should be replaced over at least 36 hours so that the sodium is lowered at a rate below 0.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    per hour. This is often accomplished by replacing two-thirds of the free water deficit over the first 24 hours and the remainder over the next 12 or more hours.",
"   </p>",
"   <p>",
"    Over the first 24 hours, the fluid regimen, which does not include replacement of excess ongoing losses, would entail:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Free water deficit (two-thirds of total water deficit) = 460 mL",
"     </li>",
"     <li>",
"      Remaining isotonic deficit = 114 mL of water and 17 mEq of sodium",
"     </li>",
"     <li>",
"      Maintenance needs = 1000 mL of water and 30 mEq of sodium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this case, administration of one-quarter isotonic saline at 65",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    would provide adequate replacement of maintenance needs and remaining isotonic deficit, and would provide free water at a rate lower than the maximum threshold rate of 0.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    per hour. Enteral fluids can also be used to replace free water deficits and provide maintenance needs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304699363\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypernatremia is defined as a serum or plasma sodium greater than 150",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      and is an uncommon problem in children. Pediatric hypernatremia is most commonly seen in the newborn period due to inadequate intake in breastfeeding neonates. In older children, the most common cause of hypernatremia is excess water loss from gastroenteritis or systemic infection. (See",
"      <a class=\"local\" href=\"#H536507079\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypernatremia is due to imbalance of the body&rsquo;s handling of water resulting in an excess of plasma tonicity to total body water. In children, hypernatremia is usually caused by loss of body fluids with a sodium plus potassium concentration that is less than serum or plasma sodium. These losses are from the gastrointestinal tract, urine, or skin. Less frequently, pediatric hypernatremia can be caused by excess salt intake, including iatrogenic administration and salt poisoning. (See",
"      <a class=\"local\" href=\"#H536507266\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1304699208\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants and small children are more vulnerable to hypernatremia than older individuals because of greater insensible water losses and their inability to communicate their need for fluids and access fluids independently. (See",
"      <a class=\"local\" href=\"#H536507544\">",
"       'Infants and young children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical findings are generally manifested by neurological symptoms in patients with acute hypernatremia as water moves out of brain cells leading to cerebral contraction. The presence and severity of symptoms correlate with the degree of plasma or serum sodium elevation and its rate of rise, and range from nonspecific findings (eg, irritability, restlessness, weakness, vomiting, muscular twitching, fever, and, in infants, high-pitched cry and tachypnea) to severe neurologic findings of altered mental status, lethargy, coma, seizures, intracerebral and subarachnoid hemorrhage, and demyelination. Most patients with chronic hypernatremia (defined as hypernatremia that is present more than one day) are asymptomatic as cerebral adaption restores brain volume. (See",
"      <a class=\"local\" href=\"#H536507069\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of hypernatremia is made by the detection of an elevated plasma or serum sodium level above 150",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H536507107\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation of hypernatremia is focused on determining the underlying cause of hypernatremia. However, it should be delayed in the severely ill patient who requires fluid resuscitation. In most cases, the etiology of hypernatremia is evident from the history. When the underlying diagnosis remains uncertain, comparing the urine with plasma osmolality may be helpful in identifying children with urinary concentrating defects (ie, diabetes insipidus) from those with water losses from the skin or gastrointestinal tract. In addition, urinary sodium and fractional excretion of sodium may help differentiate between hypernatremia due to water loss and salt",
"      <span class=\"nowrap\">",
"       ingestion/poisoning",
"      </span>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef88818 \" href=\"UTD.htm?36/7/36989\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef88819 \" href=\"UTD.htm?33/25/34204\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1304699271\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of hypernatremia consists of correcting hypernatremia with both the administration of dilute fluids to correct the water deficit, and, when appropriate, interventions to limit further water loss. Management of pediatric hypernatremia includes determining the volume status of the patient, the magnitude of the water deficit, and the safe rate of sodium correction; and identifying maintenance fluid needs, excess ongoing losses not included in maintenance fluid calculation, and the etiology of hypernatremia. In addition, readjustment of therapy is based on data from ongoing monitoring of the patient&rsquo;s fluid status based on frequent clinical examinations and follow-up laboratory evaluation, including subsequent assessment of sodium levels. (See",
"      <a class=\"local\" href=\"#H1026424383\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend that the rate of correction in chronic pediatric hypernatremia or severe acute hypernatremia (sodium greater than 160",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      does",
"      <strong>",
"       not",
"      </strong>",
"      exceed a fall of 0.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      per hour (ie, 10 to 12",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      per day) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Faster rates of correction are associated with a higher risk of cerebral edema. (See",
"      <a class=\"local\" href=\"#H1304699299\">",
"       'Rate of correction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/1\">",
"      Forman S, Crofton P, Huang H, et al. The epidemiology of hypernatraemia in hospitalised children in Lothian: a 10-year study showing differences between dehydration, osmoregulatory dysfunction and salt poisoning. Arch Dis Child 2012; 97:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/2\">",
"      Moritz ML, Ayus JC. The changing pattern of hypernatremia in hospitalized children. Pediatrics 1999; 104:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/3\">",
"      Kaiser P, Borte M, Zimmer KP, Huppertz HI. Complications in hospitalized children with acute gastroenteritis caused by rotavirus: a retrospective analysis. Eur J Pediatr 2012; 171:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/4\">",
"      Namdar T, Stollwerck PL, Stang FH, et al. Transdermal fluid loss in severely burned patients. Ger Med Sci 2010; 8:Doc28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/5\">",
"      Cooper WO, Atherton HD, Kahana M, Kotagal UR. Increased incidence of severe breastfeeding malnutrition and hypernatremia in a metropolitan area. Pediatrics 1995; 96:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/6\">",
"      Moritz ML, Manole MD, Bogen DL, Ayus JC. Breastfeeding-associated hypernatremia: are we missing the diagnosis? Pediatrics 2005; 116:e343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/7\">",
"      Oddie S, Richmond S, Coulthard M. Hypernatraemic dehydration and breast feeding: a population study. Arch Dis Child 2001; 85:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/8\">",
"      Oddie SJ, Craven V, Deakin K, et al. Severe neonatal hypernatraemia: a population based study. Arch Dis Child Fetal Neonatal Ed 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/9\">",
"      Iyer NP, Srinivasan R, Evans K, et al. Impact of an early weighing policy on neonatal hypernatraemic dehydration and breast feeding. Arch Dis Child 2008; 93:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/10\">",
"      Schaff-Blass E, Robertson GL, Rosenfield RL. Chronic hypernatremia from a congenital defect in osmoregulation of thirst and vasopressin. J Pediatr 1983; 102:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/11\">",
"      K&ouml;nig R, Beeg T, Tariverdian G, et al. Holoprosencephaly, bilateral cleft lip and palate and ectrodactyly: another case and follow up. Clin Dysmorphol 2003; 12:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/12\">",
"      Hoorn EJ, Betjes MG, Weigel J, Zietse R. Hypernatraemia in critically ill patients: too little water and too much salt. Nephrol Dial Transplant 2008; 23:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/13\">",
"      Paut O, Andr&eacute; N, Fabre P, et al. The management of extreme hypernatraemia secondary to salt poisoning in an infant. Paediatr Anaesth 1999; 9:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/14\">",
"      Finberg L, Kiley J, Luttrell CN. Mass accidental salt poisoning in infancy. A study of a hospital disaster. JAMA 1963; 184:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/15\">",
"      Meadow R. Non-accidental salt poisoning. Arch Dis Child 1993; 68:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/16\">",
"      Dobato JL, Barriga FJ, Pareja JA, Vela L. [Extrapontine myelinolyses caused by iatrogenic hypernatremia following rupture of a hydatid cyst of the liver with an amnesic syndrome as sequela]. Rev Neurol 2000; 31:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/17\">",
"      Coulthard MG, Haycock GB. Distinguishing between salt poisoning and hypernatraemic dehydration in children. BMJ 2003; 326:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/18\">",
"      Finberg L. Hypernatremic (hypertonic) dehydration in infants. N Engl J Med 1973; 289:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/19\">",
"      FINBERG L. Pathogenesis of lesions in the nervous system in hypernatremic states. I. Clinical ovservations of infants. Pediatrics 1959; 23:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/20\">",
"      King RI, Mackay RJ, Florkowski CM, Lynn AM. Electrolytes in sick neonates - which sodium is the right answer? Arch Dis Child Fetal Neonatal Ed 2013; 98:F74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/21\">",
"      Fang C, Mao J, Dai Y, et al. Fluid management of hypernatraemic dehydration to prevent cerebral oedema: a retrospective case control study of 97 children in China. J Paediatr Child Health 2010; 46:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/22\">",
"      El-Bayoumi MA, Abdelkader AM, El-Assmy MM, et al. Normal saline is a safe initial rehydration fluid in children with diarrhea-related hypernatremia. Eur J Pediatr 2012; 171:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5337/abstract/23\">",
"      Kahn A, Brachet E, Blum D. Controlled fall in natremia and risk of seizures in hypertonic dehydration. Intensive Care Med 1979; 5:27.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14276 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-8FC26C7E2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5337=[""].join("\n");
var outline_f5_13_5337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1304699363\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699201\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H536507079\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H536507266\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699208\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699334\">",
"      Excess water losses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699215\">",
"      - Gastrointestinal loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192147411\">",
"      - Urinary water loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H536507457\">",
"      Urinary concentration defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H536509723\">",
"      Osmotic diuresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699229\">",
"      - Skin loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699243\">",
"      - Inadequate water intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H536507544\">",
"      Infants and young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H976490264\">",
"      Impaired thirst mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699250\">",
"      Excess salt intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699257\">",
"      - Iatrogenic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699264\">",
"      - Salt poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H536507069\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H653430718\">",
"      Acute hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H653430726\">",
"      Chronic hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H536507107\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699271\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H653430891\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H653430899\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1026424383\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H653432175\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699285\">",
"      Volume status and emergent fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192147418\">",
"      Calculating the free water deficit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H733673763\">",
"      - Prescribed fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699299\">",
"      Rate of correction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699306\">",
"      Ongoing losses and maintenance needs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699313\">",
"      Treatment of specific etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H733673820\">",
"      Clinical example",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304699363\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14276\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14276|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/7/36989\" title=\"algorithm 1\">",
"      Evaluation of pediatric hypernatremia - Uosm and Posm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14276|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 1\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/46/33518\" title=\"figure 2\">",
"      Total body water",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14276|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/25/34204\" title=\"table 1\">",
"      Ped causes of hypernatremia due to urine loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=related_link\">",
"      Hypokalemia-induced renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8217?source=related_link\">",
"      Initiation of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_13_5338="Approach to the patient with hypertension and hypokalemia";
var content_f5_13_5338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with hypertension and hypokalemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5338/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5338/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5338/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5338/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5338/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5338/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5338/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/13/5338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/13/5338/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/13/5338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsuppressible (primary) hypersecretion of aldosterone is an underdiagnosed cause of hypertension. The classic presenting signs of primary aldosteronism are hypertension and hypokalemia. The most common subtypes of primary aldosteronism are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aldosterone-producing adenomas",
"     </li>",
"     <li>",
"      Bilateral idiopathic hyperaldosteronism (bilateral adrenal hyperplasia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common forms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism) and type II (the familial occurrence of aldosterone-producing adenoma or bilateral idiopathic hyperplasia or both) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"       \"Familial hyperaldosteronism\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H27\">",
"       'Genetic testing'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Pure aldosterone-producing adrenocortical carcinomas",
"     </li>",
"     <li>",
"      Ectopic aldosterone-producing tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of primary aldosteronism will be reviewed here. The clinical manifestations and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VARIABLE PRESENTATION OF PRIMARY ALDOSTERONISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of primary mineralocorticoid excess (with aldosterone and, to a much lesser degree, deoxycorticosterone being the major endogenous mineralocorticoids) should be suspected in any patient with the triad of hypertension, unexplained hypokalemia, and metabolic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, there are patients with primary mineralocorticoid excess who are normokalemic and rarely some who are hypokalemic but normotensive.",
"   </p>",
"   <p>",
"    Normokalemia is more common than hypokalemia in patients diagnosed with primary aldosteronism. This was illustrated in a retrospective international report combining data from five centers (Italy, United States, Singapore, Chile, Australia) in which less than 50 percent of diagnosed cases were hypokalemic at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/4\">",
"     4",
"    </a>",
"    ]. In another series, hypokalemia was found in only 50 percent of patients with aldosterone-producing adenomas, and 17 percent of patients with bilateral hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features of primary aldosteronism\", section on 'Hypokalemia: an inconsistent finding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, normokalemia is the rule in patients with the rare genetic disorder glucocorticoid-remediable aldosteronism (GRA). There are, however, important physiologic differences between GRA and other forms of hyperaldosteronism that could account for the lesser likelihood of potassium wasting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few patients with primary aldosteronism have hypokalemia but a normal systemic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/6\">",
"     6",
"    </a>",
"    ]. Surreptitious vomiting or diuretic therapy or Bartter syndrome should be excluded; each of these disorders is associated with secondary hyperaldosteronism, as the plasma renin activity and plasma renin concentration are increased rather than suppressed, as in primary aldosteronism. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Plasma renin activity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=see_link&amp;anchor=H16729862#H16729862\">",
"     \"Clinical manifestations and evaluation of metabolic alkalosis\", section on 'Diagnostic approach in unexplained metabolic alkalosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OTHER CAUSES OF HYPERTENSION AND HYPOKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two other major causes of hypertension and hypokalemia are renovascular disease (in which hypersecretion of renin leads sequentially to increased angiotensin II and then aldosterone secretion) and diuretic therapy, which may be surreptitious. Less common causes include Cushing's syndrome, licorice ingestion, certain forms of congenital adrenal hyperplasia, Liddle's syndrome, and rare renin-secreting tumors.",
"   </p>",
"   <p>",
"    Cushing's syndrome may lead to hypokalemia, due in part to the overproduction of ACTH-dependent compounds such as deoxycorticosterone, corticosterone, and cortisol. However, the hypertension in this disorder is usually not related to mineralocorticoid excess or sodium retention, and is usually suspected from the classic cushingoid appearance, including central obesity, purple abdominal striae, proximal muscle weakness, and hirsutism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of ACTH and cortisol hypersecretion, and therefore the frequency of hypokalemia, is much higher in the ectopic ACTH syndrome than with a pituitary adenoma (50 versus 9 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with renin-secreting tumors are typically young (average age 22 years in one report) and have severe hypertension and hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/8\">",
"     8",
"    </a>",
"    ]. Contrast enhanced CT appears to be the diagnostic procedure of choice, since false negative results occur with arteriography or renal vein renin sampling. Surgical removal of the tumor cures the disease.",
"   </p>",
"   <p>",
"    Liddle's syndrome is a rare autosomal dominant condition in which there is a primary increase in sodium reabsorption in the collecting tubules and, in most cases, potassium secretion. The underlying defect is a gain-of-function mutation in the collecting tubule sodium channel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\", section on 'Liddle's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IS THERE A ROLE FOR ROUTINE SCREENING?",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has not been considered feasible to screen every hypertensive patient for primary aldosteronism. However, case detection testing has historically been recommended in hypertensive patients with one or more of the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/1,2,9\">",
"     1,2,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypokalemia, including patients treated with low-dose thiazide diuretics (",
"      <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe or resistant hypertension, which is suggestive of some form of secondary hypertension; the likelihood of detecting primary aldosteronism is highest in patients with resistant hypertension (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"       \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An adrenal incidentaloma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of the random plasma aldosterone concentration-to-plasma renin activity",
"    <span class=\"nowrap\">",
"     (PAC/PRA)",
"    </span>",
"    ratio described below has, in some centers, led to screening of many more hypertensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Part of the rationale for this approach is the observation, as noted above, that less than 50 percent of diagnosed cases are hypokalemic at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Plasma aldosterone to renin ratio'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Older studies suggested a prevalence of primary aldosteronism of less than 1 percent of hypertensive patients. However, newer studies suggest that the prevalence is considerably higher [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. In the retrospective, multicenter review cited above, more widespread use of the",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio as a screening test in hypertensive patients resulted in marked increases (1.3- to 6.3-fold) in the annual detection rate of primary aldosteronism, and in the proportion of hypertensive patients in whom primary aldosteronism was detected (1 to 2 percent before screening to 5 to 10 percent after screening) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endocrine Society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, The Endocrine Society published evidence-based guidelines for the diagnosis and treatment of primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/12\">",
"     12",
"    </a>",
"    ]. They recommend case detection and case confirmation in patient groups with a relatively high prevalence of primary aldosteronism. The approach outlined below is consistent with the guidelines. Recommendations for the treatment of primary aldosteronism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest case detection testing for primary aldosteronism in the following patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension and spontaneous or low dose diuretic-induced hypokalemia",
"     </li>",
"     <li>",
"      Severe hypertension (&gt;160 mmHg systolic or &gt;100 mmHg diastolic) or drug-resistant hypertension (defined as suboptimally-controlled hypertension on a three-drug program that includes an adrenergic inhibitor, vasodilator, and diuretic)",
"     </li>",
"     <li>",
"      Hypertension with adrenal incidentaloma",
"     </li>",
"     <li>",
"      Hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (&lt;40 years)",
"     </li>",
"     <li>",
"      All hypertensive first-degree relatives of patients with primary aldosteronism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    screening in elderly normokalemic patients with mild hypertension or in patients in whom the diagnosis would not change management (eg, the blood pressure is easily controlled with a single antihypertensive agent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of hypertension in adults\", section on 'Definitions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequential evaluation of a patient with otherwise unexplained hypertension and hypokalemia begins with measurement of the plasma renin activity or plasma renin concentration and aldosterone concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7736?source=see_link\">",
"     \"Assays of the renin-angiotensin-aldosterone system in adrenal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Plasma renin activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma renin activity (PRA) and plasma renin concentration (PRC) are typically very low (due in part to the associated mild volume expansion) in patients with primary mineralocorticoid excess, usually less than 1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    per hour (0.2778",
"    <span class=\"nowrap\">",
"     ng/L",
"    </span>",
"    per sec) for PRA and usually undetectable for PRC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/13\">",
"     13",
"    </a>",
"    ]. On the other hand, increased PRA or PRC in a hypokalemic hypertensive patient is most often due to diuretic therapy, renovascular or malignant hypertension, or rarely a renin-secreting tumor (",
"    <a class=\"graphic graphic_algorithm graphicRef75620 \" href=\"UTD.htm?42/43/43710\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7736?source=see_link\">",
"     \"Assays of the renin-angiotensin-aldosterone system in adrenal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Plasma aldosterone to renin ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated plasma aldosterone to renin ratio",
"    <span class=\"nowrap\">",
"     (PAC/PRA)",
"    </span>",
"    and an increased plasma aldosterone concentration (PAC) are both required for the diagnosis of primary aldosteronism.",
"   </p>",
"   <p>",
"    The 2008 Endocrine Society guidelines recommend that the",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio be used for case detection of primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following general principles apply in a hypertensive hypokalemic patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary aldosteronism should be suspected when PRA is suppressed (or PRC is undetectable) and PAC is increased as described below.",
"     </li>",
"     <li>",
"      Secondary hyperaldosteronism (eg, renovascular disease) should be considered when both the PRA (or PRC) and PAC are increased and the",
"      <span class=\"nowrap\">",
"       PAC/PRA",
"      </span>",
"      ratio is &lt;10 (eg, renovascular disease).",
"     </li>",
"     <li>",
"      An alternate source of mineralocorticoid receptor stimulation (eg, hypercortisolism, licorice root ingestion) should be considered when both the PRA (or PRC) and PAC are suppressed. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonaldosterone mineralocorticoid excess'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The indications for measurement of the",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio as a case detection test in patients who are not hypokalemic are described above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Is there a role for routine screening?'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The test is performed by measuring a morning (preferably 8 AM), ambulatory, paired, random plasma aldosterone concentration (PAC) and plasma renin activity (PRA) or plasma renin concentration (PRC) (",
"    <a class=\"graphic graphic_algorithm graphicRef75620 \" href=\"UTD.htm?42/43/43710\">",
"     algorithm 1",
"    </a>",
"    ). The definition of an abnormal",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio is laboratory dependent. In general, PRA and PRC are undetectable in patients with primary aldosteronism. Also, in most patients with primary aldosteronism, the PAC is &gt;15",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (416",
"    <span class=\"nowrap\">",
"     pmol/L);",
"    </span>",
"    the net effect is a",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio greater than 20 (depending upon the laboratory normals) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/14\">",
"     14",
"    </a>",
"    ]. Although we consider a",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio &gt;20 to be suggestive of primary aldosteronism, others use a cutoff criteria of 30 (",
"    <a class=\"graphic graphic_table graphicRef87570 \" href=\"UTD.htm?25/57/26524\">",
"     table 1",
"    </a>",
"    ). Cutoff values also depend upon whether hormone concentrations are expressed in conventional or SI units (",
"    <a class=\"graphic graphic_table graphicRef87570 \" href=\"UTD.htm?25/57/26524\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is important for the clinician to understand that most antihypertensive medications can be continued and posture stimulation is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. For example, although &beta;-adrenergic antagonists do lower PRA and PRC measurements and raise the",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/20\">",
"     20",
"    </a>",
"    ], the increased",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio is not clinically important in this setting because of the low PAC (&lt;15",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    in patients without primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, the clinician should consider the risks of modifying antihypertensive medication programs (eg, hypertensive crisis, severe hypokalemia, atrial fibrillation, heart failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/21\">",
"     21",
"    </a>",
"    ]. There are potentially clinically important issues with the following drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It may be difficult to interpret data obtained from patients treated with a mineralocorticoid receptor antagonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ). These drugs prevent aldosterone from activating the receptor, resulting sequentially in sodium loss, a decrease in plasma volume, and an elevation in PRA, which will reduce the utility of the",
"      <span class=\"nowrap\">",
"       PAC/PRA",
"      </span>",
"      ratio. For this reason, spironolactone and eplerenone should not be initiated until the evaluation is completed and the final decisions about treatment are made.",
"      <br/>",
"      <br/>",
"      However, there are rare exceptions to this rule. For example, if the patient is hypokalemic despite treatment with spironolactone or eplerenone, then the mineralocorticoid receptors are not fully blocked and PRA or PRC should be suppressed in such a patient with primary aldosteronism. In this unique circumstance, the evaluation for primary aldosteronism can proceed despite treatment with mineralocorticoid receptor antagonists. However, in most patients already receiving spironolactone, therapy should be discontinued for at least six weeks, although the time may be shorter if the PRA is suppressed. Other potassium-sparing diuretics, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"       triamterene",
"      </a>",
"      , usually do not interfere with testing unless the patient is on high doses.",
"     </li>",
"     <li>",
"      Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin inhibitors could potentially elevate PRC and have variable effects on PRA in patients with primary aldosteronism. Thus, in a patient treated with one of these drugs, a detectable PRA level or a low",
"      <span class=\"nowrap\">",
"       PAC/PRA",
"      </span>",
"      ratio does not exclude the diagnosis of primary aldosteronism. On the other hand, a strong predictor for primary aldosteronism is an undetectable PRA or PRC in a patient taking one of these drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mean value for the",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio in normal subjects and patients with essential hypertension is 4 to 10, compared with more than 30 to 50 in most patients with primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. PRA and PRC are low in a significant number of patients with essential hypertension, but a high PAC (typically &gt;15",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [416",
"    <span class=\"nowrap\">",
"     pmol/L])",
"    </span>",
"    and a truly abnormal ratio are uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36804?source=see_link\">",
"     \"Low-renin essential (primary) hypertension\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio is denominator-dependent. The lower limit of detection varies among the different PRA assays and can have a dramatic effect on the",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/22\">",
"     22",
"    </a>",
"    ]. As an example, a very different ratio is obtained if the lower limit of detection for PRA is 0.6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    per hour compared with 0.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    per hour; for a PAC of 16",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (444",
"    <span class=\"nowrap\">",
"     pmol/L),",
"    </span>",
"    the",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio would be 27 and 160, respectively. Thus, the cutoff for a \"high\"",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio is laboratory dependent and, more specifically, PRA assay dependent. It is for this reason that an increased PAC is part of the diagnostic requirement. Note that the conventional units for aldosterone are",
"    <span class=\"nowrap\">",
"     &ldquo;ng/dL&rdquo;",
"    </span>",
"    and SI units are",
"    <span class=\"nowrap\">",
"     &ldquo;pmol/L.&rdquo;",
"    </span>",
"    To convert",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    to SI units multiply by 27.74 (",
"    <a class=\"graphic graphic_table graphicRef87570 \" href=\"UTD.htm?25/57/26524\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio was illustrated in a study in which blood was drawn at 8 AM after two hours of ambulation in 62 patients with primary aldosteronism (48 adrenal adenoma, 14 adrenal hyperplasia), 263 with presumed essential hypertension, and 434 normotensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/13\">",
"     13",
"    </a>",
"    ]. The combination of a PAC above 20",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (555",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    and a",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio above 30 had a sensitivity and specificity of 90 percent for the diagnosis of aldosterone-producing adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/13\">",
"     13",
"    </a>",
"    ]. In a selected population in which the prevalence of primary aldosteronism was 20 percent, the positive and negative predictive values for these findings were 70 and 98 percent.",
"   </p>",
"   <p>",
"    Other studies have suggested that a ratio 50 or higher, or 40 or higher, rather than 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/14,18,23\">",
"     14,18,23",
"    </a>",
"    ], or measurement of the ratio 60 to 90 minutes after a single dose of 25 to 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/24\">",
"     24",
"    </a>",
"    ] or 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/23\">",
"     23",
"    </a>",
"    ] might give better diagnostic discrimination. The latter tests are not widely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nonaldosterone mineralocorticoid excess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of suppressed PRA or PRC and a LOW plasma or urinary aldosterone value in a patient with hypertension and hypokalemia indicates the presence of some nonaldosterone mineralocorticoid. This can occur in the following settings (",
"    <a class=\"graphic graphic_algorithm graphicRef75620 \" href=\"UTD.htm?42/43/43710\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some types of congenital adrenal hyperplasia or familial cortisol resistance, which has a similar presentation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"       \"Adrenal steroid biosynthesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link&amp;anchor=H32#H32\">",
"       \"Uncommon causes of congenital adrenal hyperplasia\", section on 'Familial glucocorticoid resistance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic licorice root ingestion, the rare genetic syndrome of apparent mineralocorticoid excess, and severe cases of Cushing's syndrome, in which cortisol acts as the primary mineralocorticoid. In the last setting, there may also be hypersecretion of other mineralocorticoids such as deoxycorticosterone and corticosterone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"       \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A deoxycorticosterone-producing adrenal tumor, which can usually be detected by CT or magnetic resonance imaging (MRI) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings in the absence of mineralocorticoid excess are seen in Liddle's syndrome, which is caused by gain of function mutations in the beta or gamma subunits of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    -sensitive collecting tubule sodium channel, resulting in increased sodium reabsorption, potassium wasting, hypertension, and hypokalemia. Clinical genetic testing is available (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ). Blocking the sodium channel with amiloride or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    can treat both the hypertension and hypokalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link\">",
"     \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     24-hour urine collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low serum potassium concentration induced by mineralocorticoid excess is a result of increased urinary potassium excretion. Thus, in the past, a 24-hour urine collection was typically obtained to document the presence of inappropriate potassium wasting. At present, we do NOT order a 24-hour urine collection unless the PRA is not suppressed, the PAC is not elevated, or there is a clinical suspicion of surreptitious vomiting or laxative abuse.",
"   </p>",
"   <p>",
"    When a 24-hour collection is obtained, inappropriate potassium wasting is defined as more than 30",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    in a patient with hypokalemia. An appropriately low rate of potassium excretion suggests either extrarenal losses (vomiting, diarrhea) or diuretic treatment with the urine being collected after the diuretic effect has worn off. Aldosterone excretion can also be measured, with high values (&gt;12",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [33",
"    <span class=\"nowrap\">",
"     nmol/day])",
"    </span>",
"    on a high sodium diet (urine sodium excretion &gt;200",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    being consistent with primary aldosteronism if the PRA is low. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interpretation of the rate of potassium excretion requires attention to the patient's volume status and rate of sodium excretion. The patient must not have a low-sodium intake or hypovolemia (as evidenced by less than 50 meq of sodium being excreted per day), since the associated decrease in sodium and water delivery to the distal potassium secretory site can diminish potassium excretion even in patients with hyperaldosteronism. On the other hand, the degree of potassium wasting, and therefore the diagnostic accuracy, can be increased by a high-sodium diet, because the combination of increased distal flow and hypersecretion of aldosterone will maximize potassium losses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high-sodium diet can also be given as a provocative test in patients with an initial serum potassium concentration in the normal or low-normal range. Sodium-induced hypokalemia is strongly suggestive of nonsuppressible hyperaldosteronism. Normal subjects do not waste potassium during sodium loading, because the increase in distal flow is offset by reduced secretion of aldosterone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONFIRMATION OF THE DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with hypertension and either otherwise unexplained hypokalemia or an elevated",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio in selected normokalemic patients as described above, the results may suggest either primary aldosteronism (high PAC, low PRA or PRC) or nonaldosterone mineralocorticoid excess (low PAC, low PRA or PRC). Each can be caused by a variety of disorders (",
"    <a class=\"graphic graphic_algorithm graphicRef75620 \" href=\"UTD.htm?42/43/43710\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Primary aldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, an elevated",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio alone does not establish the diagnosis of primary aldosteronism, which must be confirmed by demonstrating inappropriate aldosterone secretion with one of several tests. The exception to the requirement for confirmatory testing is the patient with spontaneous hypokalemia, undetectable PRA or PRC, and a PAC &gt;30",
"    <span class=\"nowrap\">",
"     ng/dL;",
"    </span>",
"    in this clinical setting, there is no other diagnosis except primary aldosteronism to explain these findings. However, aldosterone suppression testing is usually needed and it can be performed with orally administered sodium chloride and measurement of urine aldosterone excretion or with intravenous sodium chloride loading and measurement of PAC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/17,26\">",
"     17,26",
"    </a>",
"    ]. The 2008 Endocrine Society Guidelines suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    suppression or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    challenge tests as two additional alternative confirmatory tests [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Oral sodium loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many centers use oral sodium loading over three days. After hypertension and hypokalemia are controlled (hypokalemia suppresses aldosterone secretion), avoiding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    as described above, the patients should receive a high sodium diet for three days.",
"   </p>",
"   <p>",
"    Patients should be given guidance on the sodium content of the types of food they need to consume to achieve a 5000 mg sodium diet. In circumstances of high sodium dietary intolerance, patients can be given oral sodium chloride tablets (eg, two 1 g sodium chloride tablets taken three times daily with food will provide approximately 90 meq of sodium). The risk of increasing dietary sodium in patients with severe hypertension must be assessed in each case. In addition, since sodium loading typically increases kaliuresis and hypokalemia, serum potassium should be measured daily and vigorous replacement of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    should be prescribed as indicated.",
"   </p>",
"   <p>",
"    On the third day of the high sodium diet, serum electrolytes are measured and a 24-hour urine specimen is collected for measurement of aldosterone, sodium, and creatinine. The 24-hour urine sodium excretion should exceed 200 meq to document adequate sodium loading. Urine aldosterone excretion &gt;12",
"    <span class=\"nowrap\">",
"     mcg/24",
"    </span>",
"    hours (33",
"    <span class=\"nowrap\">",
"     nmol/day)",
"    </span>",
"    in this setting is consistent with hyperaldosteronism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Saline infusion test",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternate method to suppress endogenous aldosterone production is by the intravenous administration of two liters of isotonic saline over four hours (from 8 AM to noon) while the patient is recumbent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/26\">",
"     26",
"    </a>",
"    ]. The PAC will fall below 5",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (139",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    in normal subjects, whereas values above 10",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (277",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    are consistent with primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUBTYPE CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of primary aldosteronism has been established, a unilateral aldosterone-producing adenoma (APA) or, rarely, carcinoma, must be distinguished from bilateral hyperplasia (idiopathic hyperaldosteronism, IHA). This is important since the treatment options are different for the two disorders. We recommend using the algorithm developed at the Mayo Clinic that uses adrenal CT and adrenal vein sampling (AVS) (",
"    <a class=\"graphic graphic_algorithm graphicRef76673 \" href=\"UTD.htm?35/23/36222\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenomas account for approximately 35 percent of cases and should be considered for surgical removal. In some patients, (8 of 22 in one report) APA has been associated with somatic mutations in the gene encoding the potassium channel KCNJ5 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In general, APA patients have higher aldosterone secretion rates, resulting in more severe hypertension, more profound hypokalemia (&lt;3.2",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      higher plasma (&gt;25",
"      <span class=\"nowrap\">",
"       ng/dL)",
"      </span>",
"      and urinary (&gt;30",
"      <span class=\"nowrap\">",
"       mcg/24",
"      </span>",
"      hour) levels of aldosterone; these patients are also younger (&lt;50 years) than those with IHA [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/17\">",
"       17",
"      </a>",
"      ]. In one study, a",
"      <span class=\"nowrap\">",
"       PAC/PRA",
"      </span>",
"      ratio of &gt;32 had a sensitivity of 100 percent and specificity of 61 percent for an APA [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bilateral adrenal hyperplasia, which accounts for approximately 60 percent of cases, is generally a milder disease with less hypersecretion of aldosterone and less hypokalemia; it should be treated with an aldosterone receptor antagonist. The cause of primary aldosteronism due to bilateral adrenal hyperplasia has not yet been determined. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"       \"Treatment of primary aldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adrenal CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2008 Endocrine Society Guidelines that adrenal CT should be the initial study to determine subtype (adenoma versus hyperplasia) and exclude adrenal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/12\">",
"     12",
"    </a>",
"    ]. When imaging adrenal glands, CT has superior spatial resolution when compared with MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76679 graphicRef75144 \" href=\"UTD.htm?23/18/23846\">",
"     image 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of an adrenal carcinoma should be suspected when a unilateral large (&gt;4 cm) adrenal mass is found on CT (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79992 \" href=\"UTD.htm?21/7/21618\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/28-32\">",
"       28-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An abnormality in both glands suggests adrenal hyperplasia; however, patients with hyperplasia may also have normal appearing adrenal glands on CT (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76679 graphicRef75144 \" href=\"UTD.htm?23/18/23846\">",
"       image 1A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When a solitary hypodense unilateral macroadenoma (&gt;1 cm) and normal contralateral adrenal morphology (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50033 \" href=\"UTD.htm?38/52/39746\">",
"       image 3",
"      </a>",
"      ) are found in a young patient with primary aldosteronism, unilateral adrenalectomy is a reasonable therapeutic option. However, because of the age-dependent risk that a solitary unilateral adrenal macroadenoma may be a nonfunctioning cortical adenoma, AVS should be considered in patients over 40 years of age who want to pursue a surgical cure of hyperaldosteronism (",
"      <a class=\"graphic graphic_algorithm graphicRef76673 \" href=\"UTD.htm?35/23/36222\">",
"       algorithm 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators suggest that the findings of hypokalemia, nonsuppressible hyperaldosteronism, a",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio exceeding 50, and a unilateral mass on CT can be followed directly by surgery to remove a presumed adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/14\">",
"     14",
"    </a>",
"    ]. However, CT findings are frequently misleading, as many patients with biochemical evidence of nonsuppressible hyperaldosteronism and a unilateral adrenal mass turn out to have bilateral hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/30,32-35\">",
"     30,32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another problem is that the absence of a mass does not exclude an adenoma (since aldosterone-producing adenomas can be very small [eg, &lt;3 mm in diameter] and lesions less than 1 cm in diameter may be missed on CT), and bilateral lesions are not diagnostic of hyperplasia (because some patients with an aldosteronoma in one adrenal gland have a nonfunctioning adrenal nodule in the other) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limitations of adrenal CT were illustrated in a study of 203 patients with primary aldosteronism who were evaluated with both CT and AVS; CT was accurate in only 53 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"     34",
"    </a>",
"    ]. Based upon CT, 42 patients (22 percent) would have been incorrectly excluded as candidates for adrenalectomy and 48 (25 percent) might have had unnecessary or inappropriate surgery.",
"   </p>",
"   <p>",
"    In a subsequent systematic review of 38 studies in a total of 950 patients with primary aldosteronism (including the 203 patients described above), adrenal",
"    <span class=\"nowrap\">",
"     CT/MRI",
"    </span>",
"    results did not agree with AVS in 359 of 950 patients (37.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/35\">",
"     35",
"    </a>",
"    ]. If",
"    <span class=\"nowrap\">",
"     CT/MRI",
"    </span>",
"    alone had been used to determine subtype, the following inappropriate treatment would have been recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      139 patients (14.6 percent) would have inappropriately undergone unilateral adrenalectomy (unilateral mass on",
"      <span class=\"nowrap\">",
"       CT/MRI",
"      </span>",
"      but bilateral findings on AVS), which would not have been curative.",
"     </li>",
"     <li>",
"      181 patients (19.1 percent) would have been offered medical therapy instead of curative adrenalectomy (bilateral findings on",
"      <span class=\"nowrap\">",
"       CT/MRI",
"      </span>",
"      but unilateral secretion on AVS).",
"     </li>",
"     <li>",
"      37 patients (3.9 percent) would have undergone adrenalectomy on the wrong side (AVS showing unilateral secretion on the opposite side of",
"      <span class=\"nowrap\">",
"       CT/MRI",
"      </span>",
"      abnormalities).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations highlight the importance of performing AVS in most patients to distinguish between unilateral and bilateral adrenal aldosterone hypersecretion. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Adrenal vein sampling'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The role of CT and MRI in the evaluation of incidental adrenal masses is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link&amp;anchor=H8#H8\">",
"     \"The adrenal incidentaloma\", section on 'MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Adrenal vein sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of aldosterone in samples of adrenal venous blood, obtained by an experienced radiologist, is the criterion standard test to distinguish between unilateral adenoma and bilateral hyperplasia. Unilateral disease is associated with a marked (usually fourfold greater than contralateral adrenal) increase in PAC on the side of the tumor, whereas there is little difference between the two sides in patients with bilateral hyperplasia (",
"    <a class=\"graphic graphic_figure graphicRef71391 \" href=\"UTD.htm?39/40/40590\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34,36,37\">",
"     34,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Endocrine Society recommends AVS to confirm unilateral disease in all patients with primary aldosteronism who would like to pursue surgical management (unilateral adrenalectomy). Our approach is slightly different, as we recommend AVS in such patients when the CT scan is normal, shows bilateral abnormalities, or shows a unilateral abnormality, but the patient is over age 40. We do not suggest AVS in patients under age 40 who have a unilateral adrenal microadenoma (&gt;1 cm and &lt;2 cm) because they are unlikely to have a nonfunctioning adrenal adenoma that could be confused with an aldosterone-producing adenoma (",
"    <a class=\"graphic graphic_algorithm graphicRef76673 \" href=\"UTD.htm?35/23/36222\">",
"     algorithm 2",
"    </a>",
"    ). The development of adrenocortical nodularity is in part a function of age.",
"   </p>",
"   <p>",
"    Other factors to consider before recommending AVS include the presence of comorbid conditions that could increase surgical risk, and the probability of finding an APA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/38\">",
"     38",
"    </a>",
"    ]. APA is more likely in patients who have spontaneous hypokalemia and marked elevations in aldosterone in blood (eg, &gt;30",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    or 24-hour urine collection (eg, &gt;30 mcg).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some centers perform AVS without cosyntropin stimulation, but we suggest continuous cosyntropin infusion (50 mcg per hour started 30 minutes before sequential sampling of the adrenal veins and continued throughout the procedure) for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To minimize stress-induced fluctuations in aldosterone secretion during nonsimultaneous AVS, which could potentially confound the interpretation of lateralization data.",
"     </li>",
"     <li>",
"      To maximize the gradient in cortisol from adrenal vein to inferior vena cava (IVC) and thus confirm successful sampling of the adrenal vein.",
"     </li>",
"     <li>",
"      To maximize the secretion of aldosterone from an APA [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34,36\">",
"       34,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some investigators have suggested that when given as a bolus injection and when the adrenal veins are sampled simultaneously, cosyntropin administration does not improve the diagnostic accuracy of AVS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. However, confidence in successful cannulation of both adrenal veins is critical to patient care. If the clinician cannot be confident that both adrenal veins were successfully sampled, the AVS data are not clinically useful.",
"   </p>",
"   <p>",
"    Aldosterone and cortisol concentrations are measured in the blood from all three sites (right adrenal vein, left adrenal vein, and IVC). All of the blood samples should be assayed at 1:1, 1:10, and 1:50 dilutions; absolute values and accurate laboratory assays for cortisol and aldosterone are essential for successful interpretation of the AVS data. An AVS-specific report should be developed by the laboratory to prevent any confusion on data interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/17,34,40\">",
"     17,34,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Confirming successful catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cortisol concentrations from the adrenal veins and IVC are used to confirm successful cannulation of both adrenal veins. With cosyntropin infusion, the adrenal vein to IVC cortisol ratio is typically more than 10:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"     34",
"    </a>",
"    ]; a ratio of at least 5:1 is required to be confident that the adrenal veins were successfully catheterized.",
"   </p>",
"   <p>",
"    However, when cosyntropin infusion is not used, an adrenal vein to IVC cortisol gradient of more than 3:1 is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/41\">",
"     41",
"    </a>",
"    ]. Some centers require only a 10 percent gradient between an adrenal vein and the IVC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/37,39\">",
"     37,39",
"    </a>",
"    ], a change that can be seen in minute-to-minute adrenal cortisol secretion and a change that is within the coefficient of variation of some cortisol assays. Thus, as noted, we suggest cosyntropin infusion during AVS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cortisol-corrected ratios",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dividing the right and left adrenal vein plasma aldosterone concentrations (PAC) by their respective cortisol concentrations corrects for the dilutional effect of the inferior phrenic vein flow into the left adrenal vein; these are termed cortisol-corrected ratios.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At Mayo Clinic, where AVS is performed with cosyntropin infusion, the mean cortisol-corrected aldosterone ratio (APA-side",
"      <span class=\"nowrap\">",
"       PAC/cortisol",
"      </span>",
"      to normal adrenal",
"      <span class=\"nowrap\">",
"       PAC/cortisol)",
"      </span>",
"      in patients with confirmed APA is 18:1 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"       34",
"      </a>",
"      ]. We use a cutoff for the cortisol-corrected aldosterone ratio from high-side to low-side of more than 4:1 to indicate unilateral aldosterone excess [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with presumed IHA, the mean cortisol-corrected aldosterone ratio is 1.8:1 (high-side to low-side); a ratio less than 3:1 is suggestive of bilateral aldosterone hypersecretion [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, most patients with a unilateral source of aldosterone will have cortisol-corrected aldosterone lateralization ratios greater than 4.0; ratios greater than 3.0 but less than 4.0 represent a zone of overlap. A ratio less than 3.0 is consistent with bilateral aldosterone hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the contralateral aldosterone to cortisol ratio is less than the IVC aldosterone to cortisol ratio in 93 percent of patients with surgically confirmed APA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Centers that perform AVS without cosyntropin infusion use lower lateralization cutoff values [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. However, using the diagnostic cutoffs described above for cosyntropin-stimulated AVS, the sensitivity and specificity for detecting unilateral aldosterone hypersecretion were 95 and 100 percent, respectively. These test characteristics deteriorate when lower cutoffs are used to determine successful catheterization and lateralization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Results",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVS may be most useful when there is no adrenal abnormality on CT or when both adrenal glands are abnormal but asymmetric (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76679 graphicRef75144 \" href=\"UTD.htm?23/18/23846\">",
"     image 1A-B",
"    </a>",
"    ). In one report, for example, 24 of 58 patients (41 percent) with normal adrenal CT and 16 of 33 (49 percent) with bilateral micronodules on CT had a unilateral source of aldosterone by adrenal venous sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are isolated cases of primary aldosteronism due to an ectopic adrenal adenoma (as in the kidney) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/42\">",
"     42",
"    </a>",
"    ]. These patients have low serum aldosterone concentrations in adrenal vein samples and CT or MRI may identify the site of the tumor.",
"   </p>",
"   <p>",
"    One limitation to AVS is an inability to obtain good samples, as the right adrenal vein is small and sometimes difficult to locate. Success rates vary in part with local expertise. In two series, catheterization was successful in 43 of 49 patients (88 percent) and 194 of 203 patients (96 percent), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complication rate in published studies is 2.5 percent or less [",
"    <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/34,39-41,43\">",
"     34,39-41,43",
"    </a>",
"    ]. The most common complication is groin hematoma; adrenal hemorrhage and adrenal vein dissection are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that have been used in the past to distinguish unilateral aldosterone-producing adenomas from bilateral disease before the development of the adrenal CT and AVS approach have limited clinical utility. These tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posture stimulation test &mdash; The posture stimulation test was based upon the observation that patients with bilateral idiopathic hyperplasia have a characteristic rise in plasma aldosterone concentrations when going from the supine to standing position (thought to be due to an enhanced sensitivity of the adrenal zona glomerulosa to the small changes in angiotensin II that occur with standing) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/44\">",
"       44",
"      </a>",
"      ]. In contrast, no such changes would be expected in patients with an aldosterone-producing adenoma because their hypersecretion of aldosterone is autonomous and diurnal. The test is performed by measuring plasma renin activity and serum aldosterone at 8 AM (supine), followed by an upright sample at noon after four hours of ambulation.",
"      <br/>",
"      <br/>",
"      However, this test does not discriminate well between unilateral adenoma and bilateral hyperplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/1,28,45,46\">",
"       1,28,45,46",
"      </a>",
"      ]. As an example, in a study of 20 patients with primary aldosteronism (15 with a unilateral aldosterone-producing adenoma) undergoing a postural stimulation test, PAC increased after four hours of standing in all patients with hyperplasia, and in 8 of 15 patients with adenomas (based upon a 30 percent rise) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      18-OH corticosterone &mdash; Patients with an aldosterone-producing adenoma typically have elevated supine plasma18-OH-corticosterone levels at 8 AM (&gt;100",
"      <span class=\"nowrap\">",
"       ng/dL)",
"      </span>",
"      while patients with bilateral idiopathic hyperaldosteronism do not [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/12\">",
"       12",
"      </a>",
"      ]. However, the accuracy of the test is low, and it does not help with localization [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/12,46\">",
"       12,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iodocholesterol scintigraphy &mdash; Radionuclide scintigraphy with 131-I-iodocholesterol or an analog (NP-59) is no longer used in most centers. While it has the potential advantage of correlating function with anatomic findings, it is not useful for evaluating small adrenal nodules, as tracer uptake is poor in aldosterone-producing adenomas &lt;1.5 cm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/47\">",
"       47",
"      </a>",
"      ]. In addition, this imaging modality is no longer available in the US.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three other forms of primary aldosteronism associated with adrenal hyperplasia: familial hyperaldosteronism type I, type II, and type III. All three are rare disorders characterized by autosomal dominant inheritance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism), the excess aldosterone secretion is due to stimulation by ACTH, which does not normally play an important role in mineralocorticoid regulation.",
"      <br/>",
"      <br/>",
"      The 2008 Endocrine Society Guidelines recommend genetic testing for familial disease in patients with primary aldosteronism who are younger than age 20 years, or who have a family history of primary aldosteronism or stroke at a young age (&lt;40 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"       \"Familial hyperaldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In familial hyperaldosteronism type II, the hyperaldosteronism is not dependent upon ACTH and therefore is not suppressible by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      . Families with familial hyperaldosteronism type II can have an aldosterone-producing adenoma or idiopathic hyperaldosteronism, or both. The genetic defect appears to be different from that of type I disease and is unrelated to abnormalities of the CYP11B2 (aldosterone synthase) gene [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. Linkage to chromosome 7p22 was described in several families [",
"      <a class=\"abstract\" href=\"UTD.htm?5/13/5338/abstract/50,51\">",
"       50,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In familial hyperaldosteronism type III, there is a point mutation in and near the selectivity filter of the potassium channel KCNJ5. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"       \"Familial hyperaldosteronism\"",
"      </a>",
"      .) This KCNJ5 mutation produces increased sodium conductance and cell depolarization, triggering calcium entry into glomerulosa cells, the signal for aldosterone production and cell proliferation. Familial hyperaldosteronism type III is very rare and inherited as an autosomal dominant trait. Familial hyperaldosteronism type III should be suspected in children with primary aldosteronism and in patients with primary aldosteronism found to have massive adrenal hyperplasia. In the limited families described thus far, most have had severe and refractory primary aldosteronism. Commercially available testing for germline KCNJ5 mutations is not yet available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsuppressible (primary) hypersecretion of aldosterone is an underdiagnosed cause of hypertension. The classic presenting signs of primary aldosteronism are hypertension and hypokalemia. However, normokalemia may be more common than hypokalemia in patients diagnosed with primary aldosteronism.",
"     </li>",
"     <li>",
"      The most common causes of primary aldosteronism are aldosterone-producing adenomas and bilateral adrenal hyperplasia, and in rare cases, familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism), type II, or type III (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"       \"Familial hyperaldosteronism\"",
"      </a>",
"      ). Excessive secretion of aldosterone is associated with an increased risk of cardiovascular disease and morbidity, including left ventricular hypertrophy, myocardial infarction and stroke.",
"     </li>",
"     <li>",
"      Consistent with the 2008 Endocrine Society Guidelines, we recommend case detection testing for primary aldosteronism in patients with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypertension and hypokalemia",
"     </li>",
"     <li>",
"      Severe or resistant hypertension",
"     </li>",
"     <li>",
"      Hypertension and an adrenal incidentaloma",
"     </li>",
"     <li>",
"      Hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (&lt;40 years)",
"     </li>",
"     <li>",
"      Hypertension and first-degree relatives with documented primary aldosteronism (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Endocrine Society guidelines'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial evaluation should consist of documenting that the plasma renin activity (PRA) or plasma renin concentration (PRC) is reduced (typically undetectable), and the plasma aldosterone concentration (PAC) is inappropriately high for the PRA (typically &gt;15",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      [416",
"      <span class=\"nowrap\">",
"       pmol/L]);",
"      </span>",
"      the net effect is a",
"      <span class=\"nowrap\">",
"       PAC/PRA",
"      </span>",
"      ratio greater than 20 (depending upon the laboratory normals) (",
"      <a class=\"graphic graphic_table graphicRef87570 \" href=\"UTD.htm?25/57/26524\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Plasma aldosterone to renin ratio'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An elevated",
"      <span class=\"nowrap\">",
"       PAC/PRA",
"      </span>",
"      ratio alone is not diagnostic of primary aldosteronism. As a result, we recommend confirming the diagnosis by demonstrating inappropriate aldosterone secretion. Aldosterone suppression testing can be performed with orally administered sodium chloride and measurement of urinary aldosterone excretion or with intravenous sodium chloride loading and measurement of the plasma aldosterone concentration. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Confirmation of the diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest adrenal CT as the initial test to distinguish between aldosterone-secreting adenoma and bilateral hyperplasia. Adrenal CT will also exclude adrenocortical carcinoma. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Adrenal CT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the CT scan is normal, shows bilateral abnormalities, or shows a unilateral abnormality but the patient is over age 40, we recommend adrenal venous sampling to confirm unilateral disease if the patient would like to pursue surgical management of their primary aldosteronism. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Adrenal vein sampling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adrenal venous sampling should only be performed by an experienced radiologist. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Adrenal vein sampling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/1\">",
"      Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 344:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/2\">",
"      Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/3\">",
"      Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/4\">",
"      Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/5\">",
"      Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/6\">",
"      Kono T, Ikeda F, Oseko F, et al. Normotensive primary aldosteronism: report of a case. J Clin Endocrinol Metab 1981; 52:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/7\">",
"      Aron DC, Raff H, Findling JW. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/8\">",
"      Haab F, Duclos JM, Guyenne T, et al. Renin secreting tumors: diagnosis, conservative surgical approach and long-term results. J Urol 1995; 153:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/9\">",
"      Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004; 22:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/10\">",
"      Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/11\">",
"      Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/12\">",
"      Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/13\">",
"      Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 1993; 153:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/14\">",
"      Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/15\">",
"      McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/16\">",
"      Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/17\">",
"      Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/18\">",
"      Hirohara D, Nomura K, Okamoto T, et al. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 2001; 86:4292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/19\">",
"      Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/20\">",
"      Ahmed AH, Gordon RD, Taylor P, et al. Effect of atenolol on aldosterone/renin ratio calculated by both plasma Renin activity and direct Renin concentration in healthy male volunteers. J Clin Endocrinol Metab 2010; 95:3201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/21\">",
"      Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/22\">",
"      Montori VM, Schwartz GL, Chapman AB, et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/23\">",
"      Giacchetti G, Ronconi V, Lucarelli G, et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/24\">",
"      Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/25\">",
"      Young DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol 1988; 255:F811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/26\">",
"      Holland OB, Brown H, Kuhnert L, et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/27\">",
"      Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/28\">",
"      Sheaves R, Goldin J, Reznek RH, et al. Relative value of computed tomography scanning and venous sampling in establishing the cause of primary hyperaldosteronism. Eur J Endocrinol 1996; 134:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/29\">",
"      Gleason PE, Weinberger MH, Pratt JH, et al. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia. J Urol 1993; 150:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/30\">",
"      Radin DR, Manoogian C, Nadler JL. Diagnosis of primary hyperaldosteronism: importance of correlating CT findings with endocrinologic studies. AJR Am J Roentgenol 1992; 158:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/31\">",
"      Doppman JL, Gill JR Jr, Miller DL, et al. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: reliability of CT. Radiology 1992; 184:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/32\">",
"      Harper R, Ferrett CG, McKnight JA, et al. Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas. QJM 1999; 92:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/33\">",
"      Magill SB, Raff H, Shaker JL, et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001; 86:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/34\">",
"      Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/35\">",
"      Kempers MJ, Lenders JW, van Outheusden L, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009; 151:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/36\">",
"      Doppman JL, Gill JR Jr. Hyperaldosteronism: sampling the adrenal veins. Radiology 1996; 198:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/37\">",
"      Rossi GP, Sacchetto A, Chiesura-Corona M, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/38\">",
"      Young WF Jr. Primary aldosteronism--one picture is not worth a thousand words. Ann Intern Med 2009; 151:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/39\">",
"      Rossi GP, Pitter G, Bernante P, et al. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 2008; 26:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/40\">",
"      Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf) 2009; 70:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/41\">",
"      Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005; 25 Suppl 1:S143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/42\">",
"      Abdelhamid S, M&uuml;ller-Lobeck H, Pahl S, et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Intern Med 1996; 156:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/43\">",
"      Nwariaku FE, Miller BS, Auchus R, et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006; 141:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/44\">",
"      Biglieri EG. Spectrum of mineralocorticoid hypertension. Hypertension 1991; 17:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/45\">",
"      Phillips JL, Walther MM, Pezzullo JC, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85:4526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/46\">",
"      Young WF Jr, Klee GG. Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am 1988; 17:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/47\">",
"      Nomura K, Kusakabe K, Maki M, et al. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. J Clin Endocrinol Metab 1990; 71:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/48\">",
"      Torpy DJ, Gordon RD, Lin JP, et al. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 1998; 83:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/49\">",
"      Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. J Hypertens 2000; 18:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/50\">",
"      Lafferty AR, Torpy DJ, Stowasser M, et al. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 2000; 37:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/13/5338/abstract/51\">",
"      So A, Duffy DL, Gordon RD, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 2005; 23:1477.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 138 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5338=[""].join("\n");
var outline_f5_13_5338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VARIABLE PRESENTATION OF PRIMARY ALDOSTERONISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OTHER CAUSES OF HYPERTENSION AND HYPOKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IS THERE A ROLE FOR ROUTINE SCREENING?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endocrine Society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Plasma renin activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Plasma aldosterone to renin ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Test performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nonaldosterone mineralocorticoid excess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      24-hour urine collection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONFIRMATION OF THE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Oral sodium loading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Saline infusion test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUBTYPE CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adrenal CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Adrenal vein sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Confirming successful catheterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cortisol-corrected ratios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/138|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/43/43710\" title=\"algorithm 1\">",
"      Plasma aldosterone renin ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/23/36222\" title=\"algorithm 2\">",
"      Subtype eval primary aldo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/138|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/46/14049\" title=\"diagnostic image 1A\">",
"      Adrenal hyperplasia CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/8/9345\" title=\"diagnostic image 1B\">",
"      Adrenal hyperplasia MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/7/21618\" title=\"diagnostic image 2\">",
"      Aldo secreting carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/52/39746\" title=\"diagnostic image 3\">",
"      Adrenal mass in primary aldo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/138|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/49/38685\" title=\"figure 1\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/40/40590\" title=\"figure 2\">",
"      Adrenal vein sampling primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/138|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/57/26524\" title=\"table 1\">",
"      ARR cut-off values",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7736?source=related_link\">",
"      Assays of the renin-angiotensin-aldosterone system in adrenal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39479?source=related_link\">",
"      Clinical manifestations and evaluation of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36804?source=related_link\">",
"      Low-renin essential (primary) hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_13_5339="Sources contact stomatitis";
var content_f5_13_5339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sources of sensitization in contact and irritant stomatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Flavoring agents in toothpaste/mouthwashes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flavoring agents in candy, gums, fruits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Dental restoration materials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eugenol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Balsam of Peru",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Colophony",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Dental procedure exposures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Latex, antibiotics, anesthetics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acrylic resins",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5339=[""].join("\n");
var outline_f5_13_5339=null;
var title_f5_13_5340="Hemorrhagic cystitis treatment";
var content_f5_13_5340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of hemorrhagic cystitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mild hematuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Suprahydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Saline continuous bladder irrigation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Moderate and severe hematuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Alum irrigation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Formalin instillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Silver nitrate instillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Estrogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Pentosan polysufate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Phenol instillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Prostaglandin instillation or irrigation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Hyperbaric oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        9. Embolization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a. Autologous clot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. Gelfoam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        c. Occlusive coils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        d. Ethanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        e. Isobutyl-2-cyanoacrylate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        10. Surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a. Percutaneous nephrostomy tube placement &plusmn; ureteral occlusion balloons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. Hypogastric artery ligation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        c. Ileal loop diversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        d. Cutaneous ureterostomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        e. Ureterosigmoidostomy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5340=[""].join("\n");
var outline_f5_13_5340=null;
var title_f5_13_5341="Asthma adherence IV";
var content_f5_13_5341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible solutions to common problems with taking asthma medications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Problem",
"       </td>",
"       <td class=\"subtitle1\">",
"        Solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You were interrupted just before taking your medicine.",
"       </td>",
"       <td>",
"        If you put your medicine down you will be more likely to forget about",
"it. So keep the medicine in your hand until you've taken it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You made a planned change in your usual routine and forgot.",
"       </td>",
"       <td>",
"        Think through your day ahead of",
"time and plan when you will take your medicines. Take",
"your medicines with you. Attach a reminder to something you will",
"be using, such as your car keys.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Your usual routine was unexpectedly changed and you forgot.",
"       </td>",
"       <td>",
"        Keep a small emergency supply of your medicines in your purse or car.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You ran out of medicine.",
"       </td>",
"       <td>",
"        Use a calendar to remind you to",
"refill medicines. Get prescriptions refilled several days before your",
"are due to run out. Keep a small emergency supply of your medicines.",
"Ask your pharmacist to remind you to get a new prescription when you pick up your last refill.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You felt so well, you forgot or decided not to take your medicine.",
"       </td>",
"       <td>",
"        Remind yourself that you are feeling well because you have been taking",
"your medicines. Establish the habit of taking your maintenance",
"medicines with activities you do every day. Place your medicines where",
"you will see them easily and frequently. Have someone at home and work",
"remind you that you need to take the medicine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You are confused about what, when, or how much medicine to take.",
"       </td>",
"       <td>",
"        Repeat medicine-taking instructions to your doctor. Read the directions",
"on the prescription label. If you don't understand them, ask the",
"pharmacist to write up a schedule for you. Call your pharmacist or",
"doctor and ask questions. Write down the exact instructions for taking",
"each medicine. Keep the instructions with your medicines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You became absorbed in an activity and forgot.",
"       </td>",
"       <td>",
"        Plan to take your medicines with",
"activities you do every day. Take your medicines with you. Place your",
"medicines where you can easily see them. Have someone remind you to",
"take your medicines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You are worried that if you take the medicine too much you will develop a tolerance to it and it will no longer work as well.",
"       </td>",
"       <td>",
"        Ask your doctor or pharmacist if you can develop a tolerance to the",
"medicine. This cannot happen with most breathing medicines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sometimes you just forget.",
"       </td>",
"       <td>",
"        Use an alarm clock as a reminder",
"or wear a watch with an alarm. Use a",
"pill dispenser. Keep prescriptions filled. Take medicines when you eat,",
"brush your teeth or go to bed. Ask your doctor to make your medicine",
"plan more convenient. Keep your medicine schedule in a handy place as a",
"reminder both at home and at work.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The medicines are too expensive.",
"       </td>",
"       <td>",
"        Ask your doctor to prescribe generic medicines. Ask your doctor if he",
"can give you samples of your medicines. Compare costs from several",
"discount drug stores. Use your inhaler properly so that medicine is not",
"wasted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You believe the medicine is not working.",
"       </td>",
"       <td>",
"        Keep taking the medicine until you can discuss this with your doctor.",
"Remember, some medicines will not make you feel better immediately.",
"They require long, continuous treatment to begin working.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some side effects are bothering you.",
"       </td>",
"       <td>",
"        Tell your doctor about any side effects. Ask your doctor about trying",
"different brand names. If stomach upset is a problem, ask your",
"doctor if you can take your medicine with meals or milk.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You have difficulty taking medicines.",
"       </td>",
"       <td>",
"        Take pills with ice cream, juice, jello, or meals. Empty capsules into",
"a drink. Ask for liquid or sprinkle forms of medicines. (DO NOT",
"CRUSH THEOPHYLLINE PILLS). Ask about long-lasting drugs.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5341=[""].join("\n");
var outline_f5_13_5341=null;
var title_f5_13_5342="Events LQTS with beta blocker";
var content_f5_13_5342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Outcome with beta blocker in the long QT syndrome is good in asymptomatic patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 358px; background-image: url(data:image/gif;base64,R0lGODlh6wFmAeYAAP///4CAgAAAAICzmYCZ//+AgDMzM3d3d/8AAKqqqoiIiO7u7hEREQBmMwAz/2ZmZru7uyIiIv9QUFVVVURERN3d3f8zM8zMzJmZmf/MzP+goP/w8P8QEP8REf+QkP/Q0MDAwP/u7v+IiFBz/0BAQFWZd4i4oFV3/6q7/4ig/xFwQczg1lCWc3etkjOFXP9VVaCz//+qqneS/6rMuxBA/5Cm/9DZ/8zW//8iIhFB/6DGszNc/0Rp//9ERPD28/Dz/+718f93d+7x//+wsJC8pv/d3dDj2RBwQCJO//+7u5mt/0SPaSJ6Tv9AQGaF/93r5GajhbvJ//8gIJnCrXCpjbvWyd3k/8DZzf9mZiB5Tf/AwP9wcMDN///g4P+Zmf8wMHCN/6CDz2CMzJ9DjwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADrAWYBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI0ocSEGAIAgMBES4MLGjx1IPBFgEwEABgAMGPqpcuQmlAosXBCwAAGEky5s4HymIUAGDxZoXBVQgBCKA0aNHQeRc+jGCyKcxZwIlihQpiQBMs3r0KajkyZSNjGodG5ErzYwbHYkly5bt2rZw/5m+jUtXHYShNPGemlu3bzkDBwShTMXXr2FvEAwwiGBAMdi9WA9L9pbgqUgGGAhHnsxZ24IHChbMVFW4s+lpCxQcWG0SVenTsJ1VfPrY1OvYuJEtEGAggW8ImnMLbwa41e3hyIE9iLD6QGvIyaMXM2C5dqnj0rPfgqDAt+/g2sPzeikggYEH4MWrv8U4QoLBrjevnx9rt/kED6yTwk6/v6kI+R3AAHrx+WdgKz5dppdt8h3ooCkQOLcggw9WWMoBFABwgQGZFWjhh6B4BcAE+o3CH4goQmKfYCWKcmKKMDLSGAYYDJhejDhKkqAADEy4X4M5BtnIBRKSBqSQSB7yAP+Bq7yYZI4kGnfkk1QqwEBzz1FI5ZaEUEfbjVxSCYF3CQDnYZhcVpDAAmuCiSaS5JnHpJZvPtneey2G4mSdD9rXW35u8okjgIDZeKagQe7YY6CIwhihAj7+2CiSGBTJ6KQfhnQZR4diiuJuEyRQY4adegpibyxeaqqDD1CwGgWuZmnilKs66GV10NWK4phklpmrrsBCsmewwA5LbK3GHmtqssoml0Coqja7Xk0CUMDpdbRKOx+bzv2qLX2pYRntt9HNJlKeoDBLbme79fbbuOsOVxwr6sZ72KvMsQavvaftZtm5+/JrWq/vlipwcnddFKmL2R6M27zwNbJARrwNhZH/RtcuUq/DcSW2WGMMoJtIcV5FrHHDHHdWmWWYSbJABBhERZNNJ6cc3WehiSZJSBlOVdOCRVVl1FU2R2fll5JM8IDMUw0StNBEF41cBE4pNsEjGFwNgAFXlyzyIBtLPdZuL32m9ZBeGmAxWhkrErbYHS0siJ8HRGkw3G0ZQIGsXU5wgEhzYou3X5oyMIGZhyjAt6SD91XB0bx1OIiabI7mbeNtQbCcSFUTEud5AWO+EnUAcnRBlneaLLjocCnQYcKE+Inf1528zTpDEOtHqICBM367Vh4z5pghisqdLsq/e7TyUy0b8qjxxyc/Nmg6F0Kwr3dLT5a//9LOie3aE3TA/+PNdTvIahH4fQCAoYfPkJ+4xl6eYKRe7r5Ka/JaMCEhi9pY+/dTSPnEVQjyiERydArgR7gXv0JE6ACIs58CJ3K9CMYCfBNMDgYzuI/xqYaAs9ggB/EBP6QJooIAHOFA8kcmxDHQhAlU4UQqBalCoE997MueDBmiKR61bUUnqV8Md+gQUImKAULsSm8w8D8dEjEh7klVAS2DwNU90SGvchWGkniR1VjQildcyAsBZgjKtcmJYVwhwb74ud7NKo0PgRxvDJE6721ChHCEB9V4Y7hCyA5QaMwjQMgmkwecbRC7M5QEBUkQutmNEMVLISPxwbW/CcCNzzPSJBuiuEPADv92i9ykQGgYqdxJUpT06CEDMhY8kNlRE3hE5TmMOCpCLO8yVfSdLAcSxa/4kXrVC+Qu7ZHFLBpCjq/MRCyHGY4xzrEQe7TaKZnJDhTKr2yGnCY13YE9P5YHMI8c4jb3cQGKGcByg6gk4LQ5znRQ7QAP6CMiOsnOdpoDiKqDxTLt2Y30+e+QA9SXMPn5DgOuchDOTCYm9knQbWTSlr7pjnfq2VBxLEkRbaRoRcERTjoawD35fONG8WElEM7tm7PT6Ei7catnEiKRbmTYSu+hv24OIpIDnSk6SImIh+ZUp+VQZdsAcFF6IQ+o9xRAqGpZiI7+FKniQJUvC3glgYYSqun/aFUxs9RSOy5gNuc8C8bUclSsjqOlZLxICx9RAQqIJgIm8RpZzQqPmu5vbgmwhAEUwDSaua2sdG1HZdAJCQWkxGdCoYrQAhC1wOZjsJPIz0z6WoinVaWxjr0HZCFRAdANQq5hAWxmu2FGwgqiAoGJxI40Ita0hHa068joIIgEnPzkUpewNUcdCbGc1Dwlr0/NrTX+WBvQUcewhwSjcMkB0y4dYDcMmOpVl9sNnAoinhOo1ogUegmGUpcYPj0txdZ0JZV+NxnGI1JeIwQ9T3j3vMBoTA0LyN3viRa+0ughtM4nE1e8F7++6Al1avO3AS5OpgAGh+acolRCWLKB4kxw/zZI9wALFrh8B9bTfSXcDNch4m+mDS6Hk+FBDHsuJcE074h7UcK0CuICs6EAcFYz3RU/g4XeiWAFKPYUzdV3Ev+1cS0+uaAJYEY0NXIKFzUsZG2YMp2pFcxYI9zkZ7RyeOk8pFNFWmVq3JJHCHwJYFAigAxHr8vVwJloTNvDBqsYzbhApiHecwDgvhnOtoimPEO4YfpYAAEZ8EQGEGCBTAy60B4hpNkU0cQaw0UECIg0Al4QgkKEAAEduMSfA/2IDiCg0oo4tKEJDYBNt0LUzfxm3dDVaCrXBdJBAACsP2HqTn96Eai+RK5dsetvqPOSflzzAlqt3MPMOgaTvnQHev/w6Q5kOgN/RkAPilDqSSMgBoOAdKRxgO0/vyDSXgAAtCM97Wp/W9IIiLW2ESACceMA06QmxLqDsG5um/vaGXi3pwv97QwMWtLtzgCzIw1qcaO73d6+dsJjIHByUzsIkn6BpyON7XHQk7/du3NEZo0Fdl9a0iFwNgBw0IEQJIHU0b62ISDdg2pnIOSZJrnJUS7pGHi60rN+dxHe7e94CwLSL1i5tKtNcZ6Lut+DGHTMO8DpQyid6Aqvucy9gAAsIBvRBse6Oh4Mw2IbZt3sBoCyB+FsUX88BLUeRAwGTvNAe9rsBK/1zQFw7ppjOuuE+HbFAbB2SRfa1GM/OqCLUHf/QPucEIRHN9oBLQhT/9vvIWC7CHrNjYCaD6HCDjGXJzPrQYxdECKX+cn/znhCeDoJot70yXEw8pKP3uWgRwC1IY0F07v+8EAnOwJQ33bQ357fgP52u29O8qYPQvgAuHmta01yahcC2TgYNOu/kdBaBFkhnRfE55P/7GiXO+0/j/SfSb/tQI9b2tSutbbVje4MIJvQh5e1pOkt/t7zvf7A9/e+b95wgid9/5+2fKXXf5O2bhaAbee2d9xgTdc1VBqHZ7PwQVblL3sjJRA4DV1FCI/jFIbzRbh1gc2gPyJiPUbGG6HhaCCIDHqTCKlBHXb2gSmoDB8UEvpBZKAEgzGo/4JUZAhPhoLLtQEaUABCOIREWIRGeIRGqAW0oD9tc2Uh84D8NARNgAASgIRWeIVHqISzkAAU0BiedUL/0jw+mFkbIAEcoAEbgA085lJzA0xN0mdIBYQcIAFpmA0DsmaJExoUkFxel1tAKAEI0ARDwA0KQAE5RkcKkF1lBoWi9AEeAIgSgIbe0GbW4Sfn8WOUcH3J44hYaIRmOIeSSH28YVJdcWGYCGRwOEGc6IkcMIedWIQe8AHlQAExdV0iYR58uHlXBIRE+IlVaISxqA9G5oW9kxoYsAAH4IAI9kSOCIlEGIwEkYFltCZnNIa384etGIl1KEZ4eEy3+IWupj1SSP+F0HgTuyViYlOGZ7iNECGBl3dS9wFI1gg3ckiHHiGNLxUgihSOjfOHgTiIHyGCfGNd/JiOGgCJoYgTK+g8loKO69KMVJiQLDGDbHhdtYiDzcKLr+iLEqmQO9hUp2gJmvghEPmLnViOwOMdDlhSVlWQgrKKBcCR7DgZ5tEhTPSCgoCPLkklMOmLQ4iSp2Fk/MOHNeWBilAZg3AxrsUII0kXMPmKQ+iTQgiU8lJc+lFUkjAbn2USIXUITTkRGrmR2QiVsCiL86EYozEx+rFljjAVlPVauRGWMUmFZEmVQfIS+eIUfMOS79gIiBUUQLNYjJWKNyGXzjiEHbkqbbZkOun/lyPxlk4jmJjVFyVJhImpLA90WzSxVpDQNKDFlIQpEdgIijOJN3L2COaSGUqpjIbwlfpQknbZOHqWi8uYFaOpjeGjaNnkkAVhmORolvfjSCEZCa55Dr5pkgVwme7zaxf5CcU5Dv6InMopQxc3j/wQndMJX8/JDSWZnQC2ndTQk9nonRIGns9wmz8JnBBonswwjhIQm+OEIRrCIYyYDVuwjjolImzJZPrQBV/wBV0AVPg0nMISmuIwBBywBVg1IzXSnO5loN+gjgAJVQTZh+7giHNYmkB1AaDBmvz5DU8plhwgiI51mtapDM04lmRZAPCJVLNZn7SQonPYogmmm7T5/6HScJs0OmLCCaOsAJvqCYLM6aOncJvkCYHVuZO8AKQ5eAvsGQniSZpN+mHkQ4oY2QohWoRSyaJBOqXeZB4QZqGiIJdRqaJIuKNeaj0LUJREGp1HiKZpGgkMqKSVgJ0aGqefUH28uQjdead4Ggo3hD4OWjsQCgBRipt/ugr4tGS1OQnoOZVdKi034AAnsBT9w0QE+gjqogFT+J6ROhxWwAMO4AA8kAK6MKmVmhMGJACaiaOPoAFSIAVHihs74AA3AAAowAOnSqlM8UBG2aiMAKuy2h854ABOYKqCUKy3mgNIIAQOkAOimgO3qgRIMKo7AABKUKy8igIOsAPFqqsAkP8Co+oAyDoIMjCupsqtO1CrOyAEqBoFDoAEAACvqdoRWKlJr4oAHmAgSjCupAoA5yoD/ZoCzpoD4Uqpk9qugpCwBysD3FqpTkCu4ioDAFCtVjAIEwsAoooC3KqropoCqAoAtYoCERsFH7GfV1oIGoAAGvAgNyAD1RoFk4oEPJADQlCwuEqpGSsIGauuD9uwJ+CvDoACgxC0RBuwP3uuIMur4noCOXCtH8GXZuacR7WyLWsgQsADSiAItXqxQWusAICzD5uwQrCw3dqwP/ux4uoEh5CxG5u05BqyFTuqW/sRjZmygmC1DyIDotqtRJuzthq2z5qzlUqt1oqt2sq23Jr/uDzrr7dqrqOaA+nKq0ort+cqryrBpmiktzHSsZbws6CgtDfRjU7EuTGysZ/Lq6CQAza7EibqahtwhsJlAzVAALZ7u7ibu7q7u7nLBcPwojokARIQWD8AA7c7AjRAAyPAu8zbvLrru8Fgo5eCoH7KSLTrvLo7Ag6wvLZbAzaQVOaxaowSuxMqPcWLveiLvMqLvrgLAz/QDkN6N8L7O9dru9rLvezLvN4rEPL5Eq16ZoVAvXhTvwSgvvjrvkyhn5k6V4bQBFe7FOebvxI8wRRcwdhrwLe7v2wxoG6yAQhQvQtBwLh7vxZcwiZ8wtirwX7BoPtYbAdZDxGMwsebvPjb/77v6z4V+oGRKA+0S8IynMHf+0REMl+d4sEgDA4EbMAInKiCwBcvTAwx/MPZS8NAzMSt2SBC6AtR7MNSrLsqbMWJwBdZPAsifLzba8NgPD6vIMYFYAplnLsYrLtLDMbyE74WSAhj/Ahv7LxxzLtfXCdGQAQDMMiEXMiGfMiInMiKvMiM3MiGTAU6AAA6QAVX4AuL8TGNMaj2VQh5DAAwAAbM28fs+8cPEsiOfMqFzAJHcAQsgMqu/MqwDMtZkAUNQMm+IEcuplx5DAMOAMp+HMQFYcqxPMzEXMyHrMqsbMyJTARGcA1EEMnBAEya16hjzMswwA4+oAPKzMjI3Mrb/P/N4LzIzCweNnU5WWzNw5DNsKwDPqAIwmzILNAA3hzOhjzOO1RO5zLNjkAeYQWanFwA6DwI6kzPr8zOg/DOqSzPsBzP85zKq9zQhGzQ3gAEKtAASxAKJdAAM5AJK9AALiAILtAAK8AS74RdlhATHDEvNYPHY+AA1wwA2czQBP3KDN3NiCzRkjDQ9dzM6WACDfDTTwAKGb3RmNDRH50THFwJhiUIhQiXgxAGLh3T8ozTrpDN9iwRIR3SLSAILfDTDVACPl0CAODTJtDVS1DRUJDRKjDSWf3TM+DTP/3RXf3TJgAAZo3Waj3SGf3TS/AEFe3WGT3ScN0AWy0R/sREN9r/CE0NADuhWFDTIDAgBgxN1QbS0Uxg2QAwAx49CBStAkDABCpg1w1Q1xX9BFPQAFAAACG9An4d2kM91oQNAEug0V1N2g1g2qhNCBltAkYtCIEd1lHLPB7KCEvN2EJkWVYBJFdA2Q4CBV7t1kAw23QNABmd0Vtd2wBQ0UCg2WK92tndAEDw2q/d1S2A3drN3WPNBF7dAr1N3SL92gHZkJSA0lsTZX+FJBUt2BY9CJrNBADQ0UAt2ra93V+t2iJdBQ3g3xk9BbC91bM9A+YN3tzd0aHt0+yd4L4t0sB9Gvysz2BTqNHh00dN0aPt1S5A1CEt1gL+3QTe3Q1Q0Zf93xUt/9c/rQJ1HeEt7t4eHdt7PQOBDds/Xdji8aSnEdJV0AjefSxE3hkIftSMkOTEsuR0fAyDKZhWfuVYnuVavuVc3uVe/uVgHuZiPuZkXuZmfuZonuZKwQ7ITQJXkeaL5eZwDjVvPudHIed2bhV1nud4nueMted23ud+LuiBDuiBDuLX4F0MteiI7pWNXgiMrotUK+kPOg+K/uiEEOmUvsnASqh4212YnumhLg2Xvul3NOpNjOqa7qqT3umeLg+l7uqn/ukiqeq2TuuVEOvxoOsA3Ou+XumyDkuoDgCrzurtwOutbuyvruyzHuzCburNvuvDXuzJzuzP7uwLNe23Du3pgP/swG7t1w7u2c7tyrTt2H4OILDmopDuo8Du667uoeDu8Q7vnyDvoGDv907vnoDv9a7vU/7vAB/wAj/wBF/w6jAbmqwL8mkMG7JO4PUUjAoMFRABEd8LFWAZU0sOO7EAO4aTwSASFd8LlaIhAjDcvNDxxjBs2lUMF99e5uA3glCBxrDYulHyxxATLp8L59EqxnDxIpHY5iDztHgMNH8MrnIMemkMsEJUIe8L5ZTx4wDzACDzxVD0xDBsCa8LL/O/uuDzEJ8MVM8OG4/yM9/0u4ARXM8LoAEAOwb1u8DzVR8Y5fSr54Dwx2AZOX8LbZb1tIABDAb0vgD34MVg9m3whn//+Iif+Iq/+Izf+I7/+JAf+bcDXZrwN1nyElBv+ZBfEXLPI3nfCZSvCDHxNZo/CJjfCKXv+DtW8hXh9nnKI4sw+oyQ+oy9iLNv+4//EhkBFn7/8yT/FFypVFdSI5dhQ8B/EtWSEYcEXRWRFr3fYDz2LBC/IH9DARmBHqf/YK1hQKtRZpVxTjAG8hXA/DLxYIDfpF4CHLIfEpITE9H1YCGxKFMUGBXxHouYEddC+ZVhLXMECA8CGBcCBgCIiBMCCokAB4wABgIQCoyWBwAUAgmWE4mQBwwGCwARDAsYAg8LAq6cho6ys7S1tre4ubq7vL2+v8DBwsPExcbHxKqfAJav/wIHFYuvC5CNAIKuy4qcj8/VkgIXia0MAIUGza8H54gKEeqO34udjPPdB/aIkK4P5s6G5BAt2OTKGrKDCBMqXMiwocOHEHElELCMXaJFjRgIoBZpnMYKiTBp4vRtkjiBAsp5soioUAR/Kp/FY7Tg3QVLCkRuoqet2iQMphiARFnO0cSXEZMqXcq0qdOnCydqw/Cu4AWNBjRybFTIFQOD+rw2KhlunDMKpai+aiQtgbRJmUA5A4qzW0pr6Q5Uq8BA6AWCFAMye2UgAdTDiBMrXsy4sePHkCNLnky5suXLmDNr3sy5s+fPoEOLHk26tOnTqFOrXs26tevXsGPLnk27tkrt27hz697Nu7fv38CDCx9OvLjx48iTK1/OvLnz59CjS59Ovbr169iza9/Ovbv37+DDix9Pvrz58+jTq1/Pvr379/Djy59Pv77pQAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a five year follow-up of 869 patients with a long QT syndrome, the estimated cumulative probability of experiencing aborted cardiac arrest or death on beta blocker therapy was significantly reduced in those who were asymptomatic (0.97 versus 0.31 events per year on therapy in probands and 0.26 versus 0.15 events per year in affected family members). Recurrent events despite beta blocker therapy were significantly higher in those with a history of syncope (hazard ratio 3.1) or aborted sudden death (hazard ratio 12.9).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Moss AJ, Zareba W, Hall WJ, et al, Circulation 2000; 101:616.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5342=[""].join("\n");
var outline_f5_13_5342=null;
var title_f5_13_5343="Use of platelet transfusions";
var content_f5_13_5343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Indications for inpatient platelet transfusions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 275px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The total usage of platelet transfusions (random donor platelet concentrates, single donor apheresis units, and HLA-matched single donor apheresis units) was estimated for all inpatient admissions for the years 1993-1995 in the United States for each recipient's DRG classification. The individual DRG classifications were combined into ten general disease groupings and the relative use of all platelet products (measured in \"single donor apheresis unit equivalents\") in these groups calculated. A \"single donor apheresis unit equivalent\" is appoximately 3 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets; six random donor platelet concentrates equal one \"single donor apheresis unit equivalent.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kuter, DJ. The use of PEG-rhuMGDF in platelet apheresis. Stem cells 1998; 16 Suppl 2:231.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_13_5343=[""].join("\n");
var outline_f5_13_5343=null;
